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COPD is  major health problem and is set to become the third leading cause 
of death globally by 2030. To date we have no therapies which significantly 
alter the course of this debilitating disease. The lungs of COPD patients are 
characterised by chronic inflammation which results in airway narrowing and 
tissue destruction and persists even after smoking cessation.  
Patients with COPD experience defective innate immunity, characterized in 
part by macrophage dysfunction. In established disease, COPD 
macrophages have impaired phagocytosis of bacteria and apoptotic cells 
(efferocytosis). There is evidence that COPD macrophages have altered 
expression of a transcription factor, Nrf2, the master regulator of antioxidant 
defences. I hypothesised that impaired macrophage functions in COPD share 
common mechanistic defects. These defects may relate to cellular energetics 
and or antioxidant responses. 
To address if macrophage dysfunction in COPD was regulated by the lung 
microenvironment alone, I isolated macrophages from the airways [Alveolar 
macrophages (AM)], and from the peripherally circulating blood [Monocyte-
derived macrophages (MDM)], of COPD and Healthy donors . I found that in 
COPD both AM and MDM had impaired bacterial phagocytosis and 
efferocytosis. I also found that efferocytosis and phagocytosis rates were 
closely correlated , suggesting a shared underlying mechanistic defect. 
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Efferocytosis and phagocytosis rates also correlated with markers of disease 
severity in COPD.  
Dynamic metabolic profiling of macrophages, using Seahorse technology, 
revealed that AM and MDM from COPD patients have impaired energy 
reserves in both glycolysis and oxidative phosphorylation. Whilst 
experiencing reduced reserves in both of these central metabolic pathways , 
Seahorse evaluation also revealed an apparent over reliance on glycolysis in 
COPD macrophages . This was mirrored in LC-MS (liquid chromatography 
mass spectrometry) analysis of resting state macrophages. LC-MS revealed 
a global up regulation of the glycolytic intermediaries in resting state AM and 
MDM from COPD Donors. 
 In parallel with this work , I established that COPD AM display an impaired 
transcriptional response to infection with Streptococcus pneumoniae, which 
primarily related to failure to mount an adequate anti-oxidant response. 
Manipulation of the anti-oxidant pathway with highly specific activators of 
Nrf2, enhanced bacterial phagocytosis and efferocytosis in COPD AM and 
MDM. Moreover ,treatment with Nrf2 agonists increased TCA cycle 
intermediaries, and restored redox balance to the cell, as assessed by LC-
MS.  Using transcriptomics analysis we identified a number of key metabolic 
targets which differed at baseline between COPD AM and Healthy Donor 
AM, with key shifts in metabolism induced by Nrf2 activation in COPD AM.  
In summary I have established that there is a global defect in macrophage 
function in COPD, which is not singularly driven by tissue specific factors. I 
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have determined that both AM and MDM from COPD patients have an 
impaired bioenergetic profile and I suggest that this may be the common 
underlying mechanism driving the phenotype. I have demonstrated a failure 
in COPD AM to mount an anti-oxidant response. I have subsequently shown 
a reversal of impaired macrophage function in COPD using a highly specific 
Nrf2 activator .Lastly, I have evidence that the Nrf2 mediated restoration of 
macrophage function in COPD is due, in part, to metabolic reprogramming, 
with a skewing towards oxidative phosphorylation. This highlights both the 
therapeutic potential for metabolic reprogramming in COPD and the role of 







Chronic obstructive pulmonary disease (COPD) is a chronic lung condition 
which is estimated to become the third leading cause of death globally, by 
2030.  None of the currently available treatments prevent the condition from 
deteriorating. Typically, hospital admissions are caused by infections and 
patients who get frequent infections deteriorate more rapidly.  
Specialised cells in the body called macrophages should protect patients 
from infections. They also play a major role in “mopping up” dead cells and 
debris left over after an infection has been controlled. If these dying cells are 
not removed properly, they can leak the toxic substances they had to fight 
infection, into the surrounding tissues, causing damage. We have found that 
macrophages, both from the lung and from the circulating blood of COPD 
patients, are unable to effectively clear bacteria or to mop up dying cells, as 
they should. We think this is because their metabolism is different to “Healthy 
cells” and this renders them exhausted and unable to carry out their normal 
function. Activating antioxidant pathways helps the body to deal with 
stresses, such as infection. We activated these pathways in macrophages 
from COPD patients, using a new drug therapy. This partially restored normal 
function to the macrophages of COPD patients. We think this is because 
increasing antioxidant signals in these cells switches their metabolism back 
to normal. Importantly, we think this could be used as a new drug therapy in 
patients with COPD to help reduce recurrent infections and the damage that 
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Chapter 1: Introduction 1 
1 Introduction 
 
1.1 Macrophages in Innate Immunity 
The innate immune system is the first line of defence against invading 
pathogens. It has a dual role; to provide initial control of infection and to 
initiate an adaptive immune response. The innate immune system comprises 
physical barriers such as epithelial layers and mucus in the airways, soluble 
factors including antimicrobial peptides, and cells such as neutrophils, 
macrophages and dendritic cells. The lack of specificity of the mediators of 
the innate response means that a balance must be struck between effective 
immunity without excessive ‘self’ injury. As central orchestrators of innate 
immunity, successful fine tuning of macrophage function is critical for striking 
this balance. Disruption of homeostasis, for example in disease, subverts this 
equilibrium and can lead, not only to failure of first line defences, but also to 
progressive and irreversible destruction of surrounding tissue.  
1.1.1 Macrophage Ontogeny  
Monocytes and macrophages are key effectors of the innate immune 
response and by virtue of their ability to process and present antigen, they 
also form a link between adaptive and innate immunity. They represent a 
diverse population of cells which possess a high degree of plasticity and 
heterogeneity. There have been numerous attempts to classify macrophages 
into groups based on function etc., but no system to date has captured the 
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intricacy of a cell population whose phenotype and even origins, are 
constantly evolving based on microenvironmental cues. Broadly, 
macrophages can be divided into Monocyte-derived Macrophages (MDM) 
and Tissue (or Resident) Macrophages. Monocytes are released into 
circulation from reservoirs in the bone marrow, blood and spleen. They are 
recruited to sites of infection and inflammation and subject to the 
microenvironment encountered, can differentiate into activated macrophages 
with variable phenotypes. Tissue macrophages are a distinct and tissue 
specific population of cells with roles suited to their anatomical and 
physiological niche. They include Kupffer cells in the liver, microglial cells in 
the brain and Alveolar Macrophages (AM) in the lung1. It was originally 
believed that tissue macrophages were replenished by circulating blood-
monocytes originating from a bone marrow progenitor, which differentiated 
into macrophages on tissue infiltration2. In recent years, seminal murine fate 
mapping studies and advances in transcriptional profiling including single cell 
RNA-seq, have refuted this hypothesis and highlighted that macrophages 
have several origins during ontology, which persist into adult life3. The new 
paradigm is that tissue macrophages are seeded in waves during embryonic 
development, with studies suggesting that Alveolar Macrophages are 
predominantly seeded from Fetal liver monocytes, within the first week of 
life4,5. Moreover, this embryonically seeded macrophage population, is able 
to self-renew in the steady state. However, if homeostasis is disrupted, for 
example during infection, tissues recruit circulating monocytes which infiltrate 
and differentiate into macrophages 6. Interestingly, as inflammation resolves 
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following Acute Lung Injury, resident macrophages once again become the 
predominant population. Thus, it appears that MDM are rapidly recruited to 
tackle injury, then having served their purpose, they are swiftly removed via 
efferocytosis, restoring the lung to pre-injury homeostasis7. Importantly, 
infiltrating MDM take on some, but not all of the characteristics, of resident 
tissue macrophages, and remain transcriptionally and in some cases 
functionally distinct. This varies depending on the organ, but studies have 
suggested that local cues and tissue imprinting in the lung play a more 
significant role in developing and shaping the phenotype of macrophages 
than in other organs. Embryonic host-derived and postnatal donor-derived 
murine AM were found to be highly transcriptionally concordant, with less 
than 5% of total genes seemingly governed solely by origin. An example of 
one such gene was MARCO, a scavenger receptor which plays a major role 
in macrophage mediated host defence and was only expressed by host 
derived AM8. Impaired tissue imprinting, for example in the diseased state, 
could possibly render these populations more dissimilar. This has been 
proposed as one explanation for the finding that bone marrow derived 
Kupffer cells take on only 50% of the characteristics of resident cells, 
following damage to the organ during requisite irradiation9. It is important to 
note that fate mapping studies to date have been conducted singularly in 
animal models and that our understanding of the origin and lineage of human 
macrophages lags behind, for obvious technical reasons. Evidence is 
accumulating however, that macrophages in humans, and more specifically 
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lung macrophages, share a similar divide of “original tissue” macrophages 
and infiltrating MDM which are distinct cell populations 10,11.  
1.1.2 Macrophage phenotype and function 
Macrophages, and in particular MDM, are often classified on a binary 
polarisation division of pro-inflammatory, antimicrobial “M1”  macrophages or 
anti-inflammatory, “M2” macrophages, which participate in tissue 
remodelling. This is based on phenotypic changes induced by cytokine 
signalling, ligation of pattern recognition receptors, response to circulating 
mediators and the nature of the microenvironment, encompassing, for 
example substrate availability12. In reality, it is unlikely these exclusive roles 
are a realistic representation of the complex interplay which exists in vivo. 
Macrophages possess the highest degree of plasticity of any cell within the 
haemopoietic system. At any given time a macrophage may shift from a “pro 
inflammatory” polarisation state after exposure to a pathogen to a “pro-
resolution” state following cues from surrounding apoptosing cells. The 
polarisation phenotype seen in each tissue/and or disease state is likely a 
spectrum created by both the cell itself and the microenvironment in which it 
exists.  
This high degree of plasticity enables macrophages to carry out a diverse 
range of functions. In health, macrophages act as immune sentinels 
surveying for tissue injury and infection. They are essential for host defense 
through their capacity to phagocytose and subsequently kill bacteria. Alveolar 
macrophages can clear pathogens and debris from the alveoli, typically with 
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minimal inflammatory consequences, thus preventing excessive tissue 
damage13. However, if macrophage defenses become overwhelmed by 
invading pathogens, they trigger an inflammatory response by releasing an 
array of pro inflammatory cytokines and mediators, which guide infiltrating 
immune cells to the site of injury/infection. Release of this inflammatory 
milieu is necessary for amplifying the inflammatory response, but if the 
inflammatory cascade proceeds unchecked, it can have also have 
deleterious effects on the surrounding tissues. Thus, once the danger has 
passed, careful and rapid dismantling of the inflammatory response is 
required to prevent further host cell damage14. Once again, macrophages 
have a central role in co-ordinating this process. Inflammation resolution 
requires apoptosis of the large population of infiltrating neutrophils and 
macrophage efferocytosis of these cells safely removes them and their toxic 
granule contents from the site of injury. Furthermore, macrophage 
efferocytosis triggers release of anti-inflammatory IL-10 and TGFb which 
further polarise macrophages towards an anti-inflammatory state 15,16. IL-10 
release has also been shown to abrogate LPS mediated neutrophil survival17. 
Thus macrophages ensure that the inflammatory response is well controlled 
and disassembled once the “threat” has been removed.  
As mentioned, both internal and external stimuli induce phenotypic shifts in 
macrophages. What is now abundantly evident is that metabolic 
reprogramming is intrinsically linked to macrophage function and activation 
states. Quiescent macrophages have a large capacity for mitochondrial 
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metabolism and oxidative phosphorylation. However, pro-inflammatory 
stimuli such as LPS cause macrophages to undergo a phenotypic shift 
towards glycolysis as their main source of ATP18. This facilitates the rapid 
generation of ATP which is required for pro inflammatory function but renders 
the cells vulnerable to metabolic exhaustion. By products of glycolytic 
metabolism can in turn augment “M1” polarisation of macrophages. Similarly 
M2/anti-inflammatory macrophages possess a distinct and divergent 
metabolic signature. They are heavily reliant on mitochondrial metabolism - 
both oxidative phosphorylation and fatty acid oxidation. Disruption of these 
metabolic pathways, and subsequent  loss of their signalling metabolic 
intermediaries results in impairment of M2 phenotype19.   
As key effectors of the innate immune response, macrophages are well 
equipped with the machinery to combat pathogens, generate an inflammatory 
response and carefully orchestrate inflammation resolution. Their high 
degree of phenotypic plasticity is essential for their wide ranging function and 
is reliant on successful rewiring of cellular metabolism. The role of 
intracellular redox balance and effective metabolic reprogramming in 
governing macrophage function will be discussed in more depth throughout 
this thesis. 
1.2 COPD- a disease of Innate Immunity? 
1.2.1 Defective innate immunity in COPD 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity 
and mortality worldwide and is predicted to become the third leading cause of 
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death globally by 203020. In the U.K 1.2 million people have a diagnosis of 
COPD but it is estimated that a further 2 million people are currently 
undiagnosed. Existing therapies do not have a major disease-modifying 
impact and many patients have progressive airflow obstruction despite long-
term inhaled and oral treatments.  
Cigarette smoke is the major cause, with an ever increasing recognition of 
additional contribution from environmental pollutants21. However, while the 
triggers for COPD have been identified, the primary mechanisms driving 
disease pathogenesis are yet to discovered. As some smokers appear to be 
protected from COPD, there has always been much interest in elucidating a 
genetic predisposition. Unfortunately, while identifying several genetic loci 
associated with COPD, the GWAS COPD cohort, failed to unearth a unifying 
molecular mechanism or to attribute hereditability to the disease22. It is likely 
that a genomic approach to COPD is hindered by the prominent 
heterogeneity of the disease and a failure to identify markers by which to 
accurately group patients. Alpha-1 anti trypsin deficiency is evidently the 
exception to this, whereby a known inherited mutation in the protease 
inhibitor leads to development of pulmonary emphysema, and in some 
patients, liver cirrhosis.  
The histological hallmark of COPD is persistent inflammation of the airways, 
resulting in airflow limitation (measured by a decline in forced expiratory 
volume in 1 second (FEV1), chronic bronchitis and emphysema. This 
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inflammation persists in people with COPD, even following smoking 
cessation23. In established disease, severe chronic oxidant stress and 
defective innate immunity may down-regulate host-pathogen responses, 
resulting in inflammation that is damaging but also ineffective24. Inhaled 
toxins such as cigarette smoke, contain high levels of Reactive Oxygen 
species (ROS), which is likely the initial trigger for large quantities of 
inflammatory cells to gather in the lungs of these patients. It also triggers 
endogenous ROS production in these cells and additional ROS release, 
coupled with other inflammatory mediators, puts in place a cycle of chronic 
oxidant stress. While there is increased cellularity in the lungs of smokers, it 
is not currently known why the initial inflammatory reaction evoked by 
exposure to cigarette smoke, does not progress to disease pathology in all 
smokers25. By contrast, in COPD, there is evidence of widespread 
impairment of innate immunity with defective epithelial, dendritic cell, 
neutrophil and macrophage function all described in the context of the 
disease. In COPD, mucus secreting goblet cells in the epithelial lining 
undergo hyperplasia, further exacerbating airways obstruction and causing 
significant symptomatology in patients26. Increased permeability of the 
epithelial barrier has also been described27. Dendritic cells are reduced in 
numbers and activation states in COPD and there is evidence that they have 
impaired presentation of viral antigen28,29. In contrast, neutrophils, rather than 
exhibiting suppressed immunity, predominantly contribute to disease 
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pathology by persistent recruitment to and infiltration of lung tissue with 
release of highly destructive neutrophils derived proteases such as neutrophil 
elastase30. It has also been shown that while neutrophils in COPD display 
faster speed of chemotaxis, they have impaired directional accuracy to the 
potent chemokine fMLP 31. However, as the first line of defense in the innate 
immune system, macrophage dysfunction in COPD is perhaps the greatest 
contributor to disease pathology.   
1.2.2 The role of macrophages in the pathogenesis of COPD  
It has long been established that macrophages play a major role in the 
pathogenesis of COPD. Alveolar macrophages are present in high numbers 
in the airways and airway secretions of patients with COPD, In fact, their 
abundance correlates directly with disease severity32. Conversely, 
macrophage depletion in murine models, protects form Cigarette Smoke 
Exposure mediated pulmonary inflammation33.  
Clinical exacerbations of COPD, frequently associated with acute bacterial 
infection, accelerate decline in lung function and increase hospitalisation and 
mortality24. The presence of pathogenic bacteria in the lower airways, a 
feature of COPD, is strongly associated with exacerbation frequency and 
increased inflammation34. The increased numbers of airway macrophages in 
COPD, coupled with these high rates of infection and colonisation, indicate a 
major disconnect whereby excessive cellular inflammation results in 
ineffective immunity. This disconnect is now understood to be largely driven 
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by macrophage dysfunction. COPD macrophages have defective bacterial 
phagocytosis, leading to further recruitment of innate immune cells and 
ongoing release of damaging inflammatory mediators35. Macrophage 
phagocytosis of bacteria that colonise the lungs in COPD, such as non-
typeable Haemophilus influenzae and Streptococcus pneumoniae is greatly 
reduced in disease 36,37,38. In vitro analysis of AM function has confirmed 
reductions as high as 50% 37. Macrophage dysfunction also extends to 
impaired inflammation resolution. Failure to efferocytose apoptotic cells has 
been confirmed in COPD macrophages, with reductions between 20-40% 
demonstrated39. Failure to clear apoptotic cells enables them to undergo 
secondary necrosis, releasing large quantities of potentially toxic granules 
and further contributing to an already inflammatory environment. 
Interestingly, a number of studies have demonstrated normal uptake of 
polystyrene beads by COPD AM40. Initial studies suggested this was due a 
specific impairment of efferocytosis in COPD macrophages, but normal 
uptake of beads compared to uptake of bacteria, has been documented also 
36. It is possible that either the energy requirement for uptake, or the 
processes engaged in uptake of inert particles are distinct and unaffected in 
COPD. It also stresses the importance of using physiologically relevant 
targets. Reports of efferocytosis and phagocytosis rates in smokers with 
preserved lung function (NLFS) vary between studies. Normal AM 
phagocytosis and efferocytosis in NLFS compared to never smokers have 
been described 36,38. In contrast a study by Hodge et al reported reduced 
rates in current smokers, but importantly efferocytosis was reduced further 
  
 
Chapter 1: Introduction 11 
still in COPD patients and smoking cessation failed to restore macrophage 
function in COPD patients40,23.  
In conjunction with impaired macrophage internalisation rates, macrophages 
in COPD also upregulate several molecules known to induce pulmonary 
tissue damage. The release of MMP (matrix metalloproteinases) 9 and 12 is 
increased in AM from COPD patients 41,42. MMPs are known to degrade the 
alveolar wall matrix and have long been implicated in COPD pathogenesis. In 
fact, cigarette smoke exposed MME -/- mice (also known as MMP-12) are 
protected from developing emphysema. Production of NADPH oxidase, 
leading to increased levels of ROS and subsequent elevated oxidant stress, 
is also increased in COPD AM43. Thus, defective AM and MDM function in 
COPD leads to inflammation that is both ineffective and skews the balance 
towards “self-injury” in the lung.   
1.2.3 Advances in the treatment of macrophage dysfunction in 
COPD  
Once established as a key cause for disease pathogenesis and progression, 
there have been numerous attempts to understand and reverse the impaired 
phagocytic phenotype of COPD. Studies have predominantly focused on 
pharmalogical augmentation of COPD macrophage function, with several 
studies attempting to work backwards to the mechanistic level. The macrolide 
antibiotic, Azithromycin, possess both anti-bacterial and anti–inflammatory 
properties and has been shown to improve phagocytosis and efferocytosis 
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rates, though a mechanism was not investigated44. Moreover, utilization of 
this as a therapy is limited by the very justified concerns of antibiotic 
resistance. The use of glucocorticoids, a drug commonly employed to treat 
COPD, have been shown to improve efferocytosis rates but impair 
phagocytosis of bacteria. Treatment with fluticasone was found to reduce 
release of inflammatory cytokines such as TNFa and IL-12 , but also 
prevented  acidification of the phagolysosome, leading to reduced bacterial 
killing45. This may explain the increased rate of Community Acquired 
pneumonia seen in patients on inhaled-corticosteroids. The cholesterol 
lowering drug Lovastatin, was found to augment efferocytosis specifically in 
COPD macrophages, in a HMG-CoA reductase dependent manner. Inhibition 
of HMG-CoA reductase- the mechanism of action of statins-  decreases 
levels of the metabolic intermediary Mevalonate46. Mevalonate is known to 
regulate the process of geranylgeranylation- a form of post translational 
modification which provides a membrane anchor for proteins.  This is 
particularly relevant as the Rho GTPases, central regulators of efferocytosis, 
undergo geranylgeranylated-mediated lipid anchoring for optimal 
functioning47. More recently, the increasingly recognised role of specialised 
proresolving mediators (SPM’s) in inflammation resolution has led to the 
exploration of their potential role in enhancing efferocytosis in cigarette -
smoke-exposure exposed MDM48. Lastly, as chronic oxidant stress is a 
defining feature of COPD, efforts have focused on restoring redox balance in 
these patients. A cardinal study by Harvey et al found that by targeting redox 
balance in the cell they could augment COPD macrophage phagocytosis. 
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They treated cells with Sulforaphane, a phytochemical compound which 
increases the cytosolic pool of the master regulator of the antioxidant 
response element, Nrf2. Sulforaphane enhanced COPD macrophage 
phagocytosis in an apparently MARCO dependent fashion49. Altered redox 
balance in COPD is the focus of Chapter 5 of this thesis and is discussed in 
more detail there.   
1.3 Summary  
In summary, macrophages are the central mediators of innate immunity. 
Through key phenotypic shifts, they orchestrate both the inflammatory 
response to injury, and, critically, also regulate the highly co-ordinated 
process of inflammation resolution. Much of these shifts in phenotype are 
directed by the microenvironment but also require intact cell signalling and 
metabolic rewiring to take place. The role of macrophage dysfunction in 
COPD has been recognised for decades and individual studies have 
identified specific pathways which are altered in disease. However we still 
lack an overarching mechanism for COPD macrophage dysfunction, 
particularly outwith the direct noxious effect of cigarette smoke and 
environmental pollutants. The existence of impaired phagocytosis and 
efferocytosis rates in COPD suggests a potential shared mechanistic defect. 
As both phagocytosis and efferocytosis have high energy requirements 50, 
defective cellular energetics and or metabolism would have a major effect on 
these processes. A failure to undergo appropriate metabolic reprogramming 
  
 
Chapter 1: Introduction 14 
in response to various stimuli could also lead to impaired macrophage 
function and may account for the altered polarisation state seen in COPD 
macrophages51. Emerging evidence points towards a role for antioxidant 
responses - which are  known to be defective in COPD - in supporting 
metabolic reprogramming and macrophage activation. To date, no study has 
investigated metabolism in COPD macrophages nor evaluated the link 
between it and the antioxidant response.  
Thus, for this body of work our overall hypothesis was that impaired 
macrophage functions in COPD share common mechanistic defects and that 
these defects may relate to cellular energetics and antioxidant responses. 
Our aims were to define these functional defects in parallel with profiling the 
bioenergetics and antioxidant status of both COPD and healthy donor 
macrophages. Ultimately we wished to explore the possibility of restoring 
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2 Methods and Materials 
 
2.1 Patient Recruitment  
This study was approved by the South East Scotland Research Ethics 
Committee (REC Ref 15/SS/0095, CPMS ID 30704 , IRAS ID 181196). 
Patients were recruited through the Clinical Research Facility at the Royal 
Infirmary of Edinburgh, the Western General Hospital, and through existing 
NHS bronchoscopy lists in NHS Lothian. COPD donors had an FEV1/FVC 
ratio of <0.70 and GOLD Stage 1,2 and 3 patients were included, as were 
current smokers and ex-smokers. Healthy Bronchoscopy Donors had normal 
spirometry and were never, ex or current smokers. Patients with diabetes, 
renal failure, liver failure, cardiac failure, active malignancy or other major 
respiratory diagnosis eg asthma/bronchiectasis were excluded . Healthy 
Volunteers for blood donation were age matched +/- 5 years and were 
recruited through the Centre for Inflammation Research Blood Resource, 
Queens Medical Research Institute, Edinburgh. Peripheral venous blood was 
taken from healthy volunteers with written informed consent as approved by 
the Centre for Inflammation Research Blood Resource Management 
Committee. Study Title : The Role Of Inflammation in Human Immunity 
(AMREC 15-HV-013).  
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2.2 Peripheral Blood Mononuclear Cell, Neutrophil Isolation and 
generation of Autologous serum 
Peripheral blood mononuclear cells (PBMC) and neutrophils were isolated 
from blood using dextran sedimentation with discontinuous Percoll gradients. 
A 21 gauge needle was used to draw blood. 36ml of blood was decanted into 
tubes containing 4ml sterile 3.8% Sodium Citrate and mixed gently by 
inverting the tube. Cells were then centrifuged at 350g, acceleration (acc.) 5, 
deceleration (dec.) 5, for 20 minutes to separate the cell layer from the  
Platelet Rich Plasma (PRP) layer. The upper PRP layer was carefully 
aspirated and the cell layer beneath was mixed with 6ml of 37°C  6% Dextran 
stocks and topped up to 50ml with 37°C 0.9% Sodium Chloride (NaCl). The 
tubes were carefully inverted and bubbles were aspirated from the surface 
with a sterile Pasteur pipette to reduce potential activation. The tubes were 
then left for 25-30 minutes at 37°C to sediment. At this point, to generate 
autologous serum, 220µl of Calcium Chloride was added to 10ml of the PRP 
layer and placed in the water bath for approximately 30 mins to generate a 
platelet plug with surrounding platelet depleted plasma. After dextran 
sedimentation and separation, the cell-rich upper layer was aspirated and 
transferred to a Falcon tube, made up to 50ml with 37°C 0.9% NaCl and 
spun at  300g for 6 minutes, acc. 5 , dec. 5, to generate a leucocyte pellet. A 
Percoll gradient was then used to separate granulocytes from the whole 
leucocyte population. A stock solution of 90% Percoll (GE Healthcare) was 
made using 10% vol. of 10X PBS. 73%, 61% and 49% Percoll were made by 
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dilution of the 90% stock with 1X PBS as outlined in Appendix 1. Gradients 
were made up in 15ml polystyrene Falcon tubes. Using a sterile Pasteur 
pipette throughout, 3ml of 73% Percoll was pipetted into the bottom of the 
tube and 3ml of 61% Percoll was gently layered on top. The leucocyte pellet 
was then resuspended in 3ml of the 49% Percoll and carefully layered onto 
the 61% layer. The Percoll gradient was centrifuged at 720g for 20 minutes 
(acc. 1, dec. 0). Following cell layer separation on the gradient, the upper 
layer of Peripheral Blood Mononuclear Cells (PBMC) was aspirated carefully 
using a sterile Pasteur pipette and transferred to a clean 50ml Falcon tube. 
The lower layer of Polymorphonuclear Leukocytes (primarily neutrophils), 
was similarly removed and transferred to a clean Falcon tube. 20ml 1x PBS 
was added to the neutrophils and PBMCs and cell number was calculated 
using an Improved Neubauer haemocytometer. Cells were then divided 
based on requirement, centrifuged at 300g, acc. 5 , dec. 5, for a further 6 
minutes at 20°C and resuspended in media. Purity was determined via 
morphology on Cytospins.  
2.3 Cytocentrifuge slide preparation 
Cytocentrifuge slides (Cytospins) were utilised to assess cellular morphology 
throughout experiments. To generate Cytospins a glass slide, filter paper and 
cytospin chamber with a funnel for cells, were held together with a slide 
holder. 100µl-200µl of cell suspension (1x105-5x105 cells), was pipetted into 
the funnel and the cytospin was centrifuged at 300 revolutions per minute 
(rpm) for 3 minutes in a CytoSpin3 cytocentrifuge (Thermo Scientific). Slides 
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were fixed with 100% methanol and stained using the Shandon Kwik-Diff 
staining system (Thermo Scientific). Slides were first stained with Eosin 
(90seconds) and then with Methylene Blue (30seconds) to delineate nuclear 
structures. Slides were mounted using DPX mountant (Sigma-Aldrich) and a 
glass cover slide was added.  
2.4 Monocyte Derived Macrophage Culture 
Based on intended experiments, cells were cultured via Method A or Method 
B. Method A was used for functional assays (bacterial internalisation, 
bacterial killing and efferocytosis assays). For assays that required removal 
of cultured macrophages for transplantation into an assay specific plate (i.e. 
Seahorse assays), cells were cultured via Method B. 
Method A: PBMC were re suspended in RPMI 1640 (Sigma-Aldrich R8758) 
without serum at a dilution of 4 x 106 /ml. 500µl of this solution was pipetted 
into 24-well cell culture plates (Costar). Plates were then incubated for one 
hour at 37C, 5% CO2. Following this the media was aspirated and replaced 
with complete media (RPMI containing 10% Heat Inactivated Fetal Calf 
Serum (FCS, Gibco, 10500-064), 1ml per well, for the duration of their culture 
period. The media was changed again the following day and there after every 
3-4 days. Cells were cultured for a total of 12-14 days prior to use. No 
antibiotics were used in the media throughout culture.  
Method B: After isolation of the PBMC layer , monocytes were isolated via 
the Miltenyi Biotec Pan Monocyte Isolation kit (130-096-537) and Miltenyi 
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Monocyte Isolation Columns (130042401), following manufacturer’s 
instructions. Isolated monocytes were counted via an Improved Neubauer 
haemocytometer. 4 x 106 monocytes were then plated into Corning Low 
Adherence Flasks (CLS3815-24EA) in 5 ml of complete media as above. An 
additional 5ml of complete media was added on Day 4 of culture. Cells were 
cultured for 8-9 days prior to removal. To remove, flasks were left on ice for 
30mins, then flasks were tapped vigorously on both sides and cells were 
removed by washing with a 5ml stripette. Flasks were then given a final wash 
with cold PBS and examined under the microscope to ensure sufficient 
removal. Cells were counted following staining with 0.4% Trypan Blue, to 
exclude non-viable cells, and plated as required into assay specific plates. 
Recovered yield of viable cells ranges from 40%-60% 38. 
2.5 Alveolar Macrophage Isolation and Culture 
Bronchoalveolar Fluid (BAL) was collected from COPD and Healthy donors 
as per ethics protocol. After inspection of the airways during bronchoscopy, 
the scope was wedged into the Right Middle Lobe (RML). 2-4 ml of lidocaine 
was then instilled via the scope into the RML, prior to injecting a total of 
240ml of saline in 40ml aliquots. The first 40ml of return was discarded/sent 
for routine culture and sensitivity, due to the high content of epithelial cells. If 
the RML was deemed inappropriate to wash, the Right Upper lobe was used. 
Following bronchoscopy, samples were kept on ice in 50ml Falcon tubes and 
transported to the lab immediately. Whole BAL fluid was sieved into a 50ml 
Falcon tube through a sterile 100µm cell strainer and spun at 400g, 
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acceleration 5, deceleration 5, for 10 min, at 4°C. Supernatant was removed, 
flash frozen on dry ice and stored at -80°C. The cell pellet was vortexed as 
soon as possible to avoid clumping of cells and re-suspended in up to 10ml 
of Antibiotic Media  (RPMI 1640 [Sigma] with 10% heat inactivated FCS 
[Gibco], 1% Penicillin [Lonza DE17-603E] and Amphotericin [fungizone 
GIBCO 15290-026 0.5μg/mL]). Viable cells were counted using a 
haemocytometer and 0.4% Trypan Blue. An aliquot was prepared for 
Cytospin to assess purity. Rarely, if there were significant quantities of Red 
Blood cells macroscopically or on the counting chamber, 10ml of cell 
suspension was spun on a 12.5mL Ficoll (Sigma-Aldrich) gradient, washed 
x1 in 20ml of PBS and re-suspended in media for recount. Alternatively 
RBCs were lysed by adding 400µl of deionized sterile H20 to the cell pellet for 
30 seconds before adding 30 ml of  PBS, then spun as above and recounted. 
Following counting, cells were washed at 400g, for 10 mins at 4°C and  
resuspended at 400,000 trypan negative cells per 1ml of media. 500µl of cell 
suspension was then pipetted per well of a 24-well TC plate (Costar) and 
incubated in a humidified chamber at 370C and 5% CO2. After 60 mins, this 
was removed and 1ml of fresh Antibiotic Media was added to each well. D+1- 
Media was changed the following day for complete media that did not contain 
antibiotics ( RPMI 1640 with 10% HI FCS) if cells were to be used for a 
bacterial internalisation assay, otherwise, old media was replaced with fresh 
antibiotic media (as detailed above). D+2 -Wells were washed gently with 
media and fresh basic media was added in preparation for assays. Cytospins 
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were prepared on D0 and D3 . Cells were 93% -97% Alveolar macrophages 
as assessed by Cytospin morphology 38. 
2.6 Macrophage Protein Lysis Protocol  
Monocyte derived macrophages (MDM) were cultured as above or Alveolar 
Macrophages (AM) for a period of 3 days, prior to lysis for protein in 24 well 
plates (Costar). Tissue culture plates were put on ice with 200ul of "Scraping 
Buffer" for 10-30 mins. Scraping buffer = 5ml PBS, 200µl EDTA (2.5mM), 
500ul of BSA ( 1%). Proteinase Inhibitors were included in the scraping buffer 
(Protease inhibitor cocktail 4:100 [Roche], EDTA-Free Protease inhibitor 
cocktail 3 1:100 [Merck Millipore] and phenylmethanesulfonylfluoride (PMSF) 
1:100 [Sigma-Aldrich]). Cells were then removed in scraping buffer with a cell 
scraper (Sarstedt), 3 wells were combined per lysate. The suspension was 
first pelleted (5mins at 300G at 4 degrees) in a 1.5ml eppendorf. Supernatant 
was discarded and the pellet was resuspended in 25µl of RIPA buffer 
(Thermoscientific, 889900). Again, the above ratios of proteinase inhibitors 
were added to the RIPA buffer. The eppendorf was placed on ice for 20-
30min and vortexed every 5-10 min. It was then frozen on dry ice and stored 
in -800C overnight or for longer. For use, it was defrosted on ice, vortexed & 
spun at 400g 4°C for 10min – the supernatant was then removed and 
pipetted into a newly labelled eppendorf. Supernatants were heated on a hot 
plate at 100°C for 10 minutes to denature proteins. A Pierce BCA assay 
(Thermo Scientific) was used to calculate protein concentration in the 
supernatant (RIPA buffer alone was used as the blank for the samples). To 
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generate samples,20µg of protein was mixed thoroughly with 20µl of 2xSDS 
lysis buffer and the sample was topped up, if required to 45µl using dH2O. 
Samples were stored at  -80°C  and boiled for 5 minutes at 99°C, prior to 
use. 40µl of sample was loaded into each well for western blotting.  
2.7 Western Blotting 
Macrophage protein lysates were analysed for protein expression by western 
blot. Details of the gels and buffers used are in Appendix 2. Proteins were 
separated by SDS-PAGE using the BioRad mini-protean system prior to wet 
transfer onto PVDF membrane (Merck Millipore). Membranes were blocked 
using 5% skimmed milk powder for a minimum of 2 hours. Primary antibodies 
were made up in 5% skimmed milk in 1X TBS-Tween (TBST, 0.05% Tween) 
and membranes were incubated at 4°C overnight on a rolling platform. 
Antibodies used were against Heme-oxygenase-1 (HO- 1) (Santa Cruz, sc-
10789, rabbit polyclonal ,1:1000) or Tubulin (Sigma, T5168, mouse 
monoclonal ,1:1000). The following morning, membranes underwent three 
10-minute washes in 1X TBST prior to incubation with Donkey Anti-Rabbit 
secondary antibody (Life Technologies, SA1-200 ,1:400) for 1 hour at room 
temperature. The membrane then again underwent three 10-minute washes 
in 1X TBST prior to developing in enhanced chemiluminescent (ECL) 
detection reagent (GE Healthcare). Protein detection was then carried out 
using a Konica SRX-101A table top processor, 1 minute exposure was 
optimal for HO-1. Protein quantification was normalised to a loading control 
as follows: The membrane was stripped using Restore Western Blot stripping 
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buffer (Thermo Scientific), washed with dH2O and then re-probed for the 
loading control protein b-Actin (Sigma, T5168, mouse monoclonal 1:1000) on 
a rolling platform, with primary and secondary antibodies as above. The 
membrane was then developed, and protein content was normalised using 
ImageJ densitometry detection.  
2.8 Maintaining Bacterial Stock  
As Streptococcus pneumoniae (S. pneumoniae) is a Class II pathogen, all 
experiments were carried out in a Cat 2 laboratory, in a laminar flow hood, 
following all Cat 2 lab standard operating procedures. On day 1 
Streptococcus pneumoniae Serotype 14 master stock (NCTC11902- kindly 
gifted by Professor David Dockrell) was thawed on the bench. After mixing 
the sample, one drop was streaked out onto a blood agar plate (Colombia 
Blood Agar Oxoid, VWR Int) via a sterilized loop and then incubated 
overnight at 37oC 5%CO2. On day 2, 50ml broth of brain/heart infusion + 20% 
FCS (Gibco) was made up. Approximately 10 colonies of S. pneumoniae 
from the blood agar plate was removed via a sterilized loop and mixed into 
25ml of broth. Three aliquots were prepared as such. A further aliquot of 
broth, without S. pneumoniae, was kept as a blank.  The aliquots and the 
“broth only” blank, were incubated on a continuous mixer plate for 
approximately 4.5 hours. The OD of 1ml from each Falcon was measured in 
a spectrophotometer at 600nm. The blank broth was used to zero the 
spectrophotometer. This was repeated every 30mins until the OD 
approached 0.6 – the cuvette was then kept in the reader until the OD 
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reached 0.6 exactly. The broth was then immediately removed from the 
incubator, aliquoted into 1ml eppendorfs and frozen at  -80°C. The following 
day two aliquots were thawed, spun at 9000g for 3 minutes and washed x3 in 
PBS. Three 10µl drops from each of the 8 dilutions (of Miles Misra , see 
below) were then plated onto blood agar plates and cultured overnight in 37 
oC. Stock concentration was calculated as total colonies per 3 x 10µl, divided 
by 30, multiplied by 1000 and the average of both thawed aliquots was used 
to determine final stock concentration.  
2.9 Miles-Misra Dilution 
To determine bacterial concentration eight 1.5 ml eppendorfs with 900µL of 
sterile PBS each, were placed in a rack and labelled ‘1’ to ‘8’. 100µL of 
bacterial suspension was added to vial ‘1’, generating a 1 in 10 dilution. 
Eppendorf “1” was then vortexed and using a new tip, 100µL from this vial 
was added to vial ‘2’ –to generate a 1:100 dilution. This was repeated for 
each subsequent vial until a 1:108 dilution was achieved . Finally, three x 
10µL drops of each vial were placed into a quadrant of a blood agar plates 
(VWR Int.), in order of eppendorf “8” down to “1”. Plates were then incubated 
overnight at 37oC, 5%CO2 . Cfu/ml was calculated by (Number of colonies in 
quadrant / 30) = CFU per µL. This was multiplied by 1000 to give CFU per 
mL and then by 10quadrant number to factor in dilution e.g. 14 colonies in 
Quadrant 6. Bacterial count = (14/30) x 1000 x 106 = 4.7 x 108 CFU per mL. 
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2.10  Opsonising Streptococcus pneumoniae 
S. pneumoniae immune serum was generated by pooling serum from a 
group of inoculated healthy volunteers who had received the polysaccharide 
pneumococcal vaccine. Blood was drawn using a 21 gauge needle. 36ml of 
blood was decanted into tubes containing 4ml sterile 3.8% Sodium Citrate 
and mixed gently by inverting the tube. Cells were then centrifuged at 350g, 
acceleration 5, deceleration 5, for 20 minutes to separate the cell layer from 
Platelet Rich Plasma (PRP) layer. The upper PRP layer was carefully 
aspirated and 220µl of Calcium Chloride was added to each 10ml of the PRP 
layer and placed in the water bath for approximately 30 mins to generate a 
platelet plug with surrounding platelet depleted plasma. Plasma was then 
aliquoted and stored at -80°C. A vial of bacteria was thawed and washed as 
above x 3 in PBS. After the third spin, the pellet was resuspended in 500ul 
RPMI (Sigma) containing 10% of S. pneumoniae immune serum. The vial 
was then incubated on a shaking platform at 37 oC for 30 minutes before 
being spun down and washed as before x 2 in PBS. The pellet was finally 
resuspended 1ml RPMI (Sigma) 38. 
2.11 Assessment of Bacterial Internalisation at 4 hours post-
infection  
Cells (MDM or AM) were cultured in in 24-well plates, with approximately 
200,000 cells per well for Monocyte-Derived Macrophages (MDM) and 
Alveolar Macrophages (AM). All conditions were carried out in a minimum of 
duplicates and with a 2 x MOI of zero (ie no bacteria added) as a control for 
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cross contamination of S. pneumoniae. Wells were washed with PBS x2 
before adding 1ml of fresh, antibiotic free, complete media per well. 
Opsonised Streptococcus pneumoniae was added directly to the well at a 
multiplicity of infection of 10:1 (MOI 10:1). The tissue culture (TC) plate was 
then placed on ice for 1 hour, to optimise bacterial binding, before being 
moved to a 37°C, 5% CO2,  incubator for 3 hours. After 4 hours total co-
incubation with S. pneumoniae, cells were washed x3 in PBS. For each wash 
the well was filled completely with PBS to remove any potential adherent 
bacteria. 1ml of RPMI containing 40 units of benzylpenicillin (Sigma, P3032) 
and 20 μg/ml of gentamycin (Sigma G4918) was then added to each well to 
kill extracellular bacteria and the TC plate was returned to the incubator for 
30 min. After 30min, cells were washed x3 with PBS. Again, each well was 
filled to the top to remove any residual antibiotics which could alter the 
viability readout. A Miles-Misra dilution was carried out on the last 
supernatant/PBS wash removed to provide a pre-lysis bacterial count. Cells 
were then lysed in 250μl 2% Saponin (Sigma-Aldrich) for 12 minutes exactly 
at 37oC, 5% CO2. At twelve minutes exactly, using a pipette tip, wells were 
scraped thoroughly followed by rapid, vigorous pipetting to ensure all cells 
were broken open. 750µl of PBS was then added to the well immediately and 
a second Miles-Misra was conducted to determine lysed viable count. The 
quantity of bacteria internalised was calculated by deducting the first Miles 
Misra count from the second ( i.e. [viable bacteria following lysis] minus 
[viable bacteria in the pre lysis wash]). The pre-lysis count, if the assay is 
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performed correctly, should only contain 1-2 colonies.  
For bacterial killing at later time points: After cells were incubated with 
40u benzylpenicillin and 20 μg/ml gentamycin for 30 min at 37°C, they were 
washed 3X PBS, and incubated with 0.75μg/ml vancomycin (Sigma). At the 
designated time, eg 4-8 hours, vancomycin was washed off x3 with PBS and 
the pre-lysis wash was plated as above. Cells were then lysed in 250μl 2% 
Saponin for 12 minutes, as before and the supernatant plated out.  
To measure bacterial internalisation in hypoxia, cell were cultured for 12 
days prior to the assay in a hypoxic chamber at 1% O2 (Ruskin INVIO2). On 
the day of the assay, complete media and PBS were equilibrated for four 
hours in the hypoxic chamber. All steps outlined above were conducted in the 
hypoxic chamber (ie no transfer to incubator). Blood agar plates were then 
grown overnight in a standard 37oC, 5% CO2 incubator.  
To measure bacterial internalisation in a glucose deprived environment, 
standard complete media was replaced with a Glucose deplete media 
(Gibco, 11879-020) and supplemented with dialysed FCS 10% (Dialysed by 
tangential flow filtration using 10,000 MW cut off filters), Life Technologies, 
26400044) for 16 hours prior to conducting the experiment. Both an MOI of 0, 
and wells with standard glucose replete media, were used as a control 52. 
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2.12  Neutrophil Staining with PKH26 and Flow Efferocytosis 
assay 
Neutrophils were stained with a PKH26 labelling kit (PKH26GL, Sigma-
Aldrich). PKH26 is a yellow-orange fluorescent dye with long aliphatic tails 
that insert into the lipid regions of the cell membrane. Neutrophils were 
freshly isolated from a Percoll prep as described in 2.2. Prior to staining , 
approximately 1 million cells were removed for an “unstained sample” for flow 
settings and resuspended in serum free media at 5 x106 cells/ml. 20 million 
cells were then washed in serum free media at 400g for 5mins. 1ml of 
Diluent B was added to the pellet followed by 1ml dye (4µl dye + 996µl of 
Diluent B). After 2-5 mins staining was stopped by addition of 2ml of 
FCS/Autologous serum. Staining was noticeable better with autologous 
serum. Cells were then washed x 3 in complete media  (400g, 5min) and re -
suspended  at 5 x106 cells/ml and plated in a 96 well plate (Costar 2595)  at 
150ul per well. Cells were cultured for 20h resulting in 70-80% apoptotic 
cells, and less than 5% necrotic cells by trypan blue exclusion - verified by 
Annexin V-Topro3 staining*(BD Biosciences).The apoptotic neutrophils were 
added to the macrophages at an MOI 5:1, including an MOI of 0 for 
macrophage gating. On a separate TC plate, apoptotic neutrophils were 
added to macrophages but kept on ice from the beginning of incubation to act 
as an internalisation control. After 90 minutes, cells were vigorously washed 
x 2, with warm PBS via a Pasteur, and a final wash with ice cold PBS to aid 
removal of macrophages. Cells were then scraped in 250µl of PBS ,or 
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alternatively 250 µl of Trypsin (Gibco) was added to each well and incubated 
at 37oC, for 8 minutes prior to removal with cell scraper (Sarstedt). 
Efferocytosis was then assessed on a BD FACS Calibur flow cytometer 
(Becton Dickinson) through excitation with a 488nm laser filtered through a 
585nm dichroic bandpass filter (FL2). 
For Annexin-Topro staining approx. 750,000 neutrophils were pelleted at 
2000rpm for 3 minutes in an Eppendorf Minispin (Z606235) then 
resuspended in 95µl of Annexin binding buffer (BD Biosciences). 5µl of 
Annexin was then added to the suspension and incubated for 20 minutes on 
ice. In the mean time 1ml of Annexin binding buffer was added to 9mls of 
distilled H2O. 5mls of this mix was then added to 1µl of Topro= 1:5000. Topro 
was added to the above Annexin stained neutrophils immediately prior to 
analysis on flow cytometry 71.  
To assess efferocytosis in a hypoxic environment, cells were cultured for 
12 days prior to the assay in a hypoxic chamber (as above-1% O2). Apoptotic 
neutrophils (not cultured in hypoxia) were then co incubated with hypoxic 
macrophages and the assay was performed as outlined above.  
To assess efferocytosis in a glucose deprived environment, cells were 
cultured as normal but complete media was replaced with Glucose deplete 
media (Gibco, 11879-020) and supplemented with dialysed FCS 10% (Life 
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Figure 2.1: Optimisation of Efferocytosis assay.  
(A)Annexin/Topro staining of 20hr apoptotic neutrophils showing 69% 
apoptotic, <1% necrotic neutrophils. (B) Freshly isolated neutrophils were 
stained with PKH26 membrane dye, integrity of dye maintained at 20hrs. (C) 
Adherent non internalised neutrophils were successfully washed off after 90 
mins incubation, as evidenced by the Ice Control (blue) compared to the 
Macrophage only (pink) condition on the histogram. (D) 90 mins incubation is 
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2.13  Nrf2 activation via pharmacological compounds  
Where used, cells were pre-treated with Nrf2 activating compounds for 16 
hours prior to performing assays. Compounds A,B,C and 7 were supplied by 
GSK under an existing MTA via COPD MAP and Sulforaphane was 
purchased from Sigma (S6317). Compounds were resuspended in DMSO , 
which was used as a vehicle control in non Nrf2 treated wells. Doses for 
sulforaphane were based on previous work by our group and published 
literature. Dose ranging for the GSK compounds were supplied by GSK 
based on the EC50 for previous assays. I then generated dose response 
curves for specific assays . Final doses used were Sulforaphane=10µM, 
Compound A, B and C = 10nM, Compound 7 =0.065µM. 
2.14  Seahorse Assays 
For MDM Seahorse Assays, cells were cultured using Method B, outlined 
above. AM were seeded into Seahorse Assay Plates immediately following 
isolation. 24 hours prior to performing the assay, both MDM and AM were 
seeded into Xe24 seahorse assay plate (MDM=V8,100882-004, AM= V7-
PS,1000777-004 Agilent), at a density of 250,000 in 300µl and 210,000 in 
300µl per well, respectively, for 45 mins at room temperature, before an 
additional 200µl of complete media was added to each well. This ensured an 
even distribution of cells throughout the well. 4 wells per plate, minimum, 
were kept cell free to calculate background during the assay. A Seahorse 
Xe24 Cartridge plate was hydrated using Seahorse calibration media 
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(Agilent) for at least 8 hours prior to the assay at 37oC, in a sealed bag. All 
cells were subjected to either/both a glycolytic and mitochondrial stress test.  
For the Glycolytic Stress Test , 30ml of media was made using 29.7ml of 
Seahorse Media (Agilent 103575) with 300µl of L-Glutamine (Gibco, 
25030081) giving a final concentration of 2mM. Media was warmed to 37oC 
before the pH was adjusted to pH 7.4 by addition of NaOH. Media was then 
filter sterilised through a 0.2µM filter. All wells were then washed x 2 with 
warm PBS and 500µl of Seahorse Glycolytic Stress Test media was added to 
each well before incubating the plate at 37oC, with NO CO2 for 45 min. 
Glucose, Oligomycin and 2DG compounds were prepared and added to the 
Seahorse Cartridge plate as per Appendix 3. Following the injection of each 
compound, three readings were taken 8 minutes apart totalling 3 cycles x 24 
mins each. Glycolysis, Maximal Glycolytic Rate and Glycolytic Reserve were 
calculated during the assay and exported to Excel for analysis via the 
Glycolytic Stress Report Generator on Wave software.  
For the Mitochondrial Stress Test, 30ml of media was made using 29.7ml 
of Seahorse Media with 300µl(2mM )of L-Glutamine, 300µl(1mM) of sodium 
pyruvate (Sigma 5836)  and 0.054g(10mM) dextrose (Sigma, G7021). Again 
media was warmed, pH adjusted, filter sterilized and incubated with cells for 
45 mins, as above, at 37oC,NO CO2 . Oligomycin, FCCP and Antimycin& 
Rotenone A compounds were prepared and added to the Seahorse Cartridge 
plate as per Appendix 3 and the assay was run as above (3 x 24 min cycles). 
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Basal Oxygen Consumption, Maximal Respiratory Capacity, Spare 
Respiratory Capacity and Proton Leak were calculated during the assay and 
exported to Excel for analysis via the Mitochondrial Stress Report Generator 
on Wave software. A Cell Energy Phenotyping report was also exported for 
analysis 53.  
Following either assays, lysates for protein quantification were made by 
adding 80ul of RIPA to each well and scraping thoroughly for a count of 60 
seconds. Samples were then boiled at 100 oC for five minutes and a Pierce 
BCA assay (Thermo Scientific) was used to calculate protein concentration in 
the supernatant. ECAR/OCR readings were then normalised to µg protein/ml.  
Seahorse and Co-incubation with Apoptotic neutrophils: When used 
macrophages were co incubated with 20hr apoptotic neutrophils (generated 
as outlined above in 2.12) for 90min prior to vigorous washing for removal of 
any non-internalised neutrophils. Standard complete media was then 
replaced with the relevant Seahorse Media as above for 45 minutes prior to 
performing the assay. For Healthy Donor macrophages a standard MOI 10:2 
was used, for COPD macrophages the MOI was increased to 15:2 to adjust 
for differential internalisation rates.  
Seahorse and Polarisation of Alveolar Macrophages: To determine if 
polarisation influenced macrophage metabolism as detected by Seahorse, 
AM were pre-treated with 20ng/ml IL-4 (68-8780-63, eBioscience) and 
20ng/ml IL-13 (571102, BioLegend) or 20ng/ml IL-10 (217-IL, R&D) for 16hrs 
  
 
Chapter 2: Materials and Methods 34 
prior to performing the assay. Wells were then washed and assay performed 
as before.  
2.15  Measuring Glucose uptake via a 2NBDG Assay 
Uptake of 2NBDG was measured as a surrogate for glucose uptake using a 
2NBDG kit ( Cayman Chemical 600470). Cells were incubated in glucose 
free media (Gibco, 11879-020) for 90min. 250µl of 240µM proprietary 
glucose was added to each well for 60 mins before adding the Cell Based 
assay buffer and incubation on ice for 10 min. Supernatant was aspirated 
and 100µl of 1:100 Infra-Red Fixed viability (Biolegend, 423195) stain was 
added, incubated for 10mins, light protected on a shaking platform. 200µl of 
cell Based Assay buffer was then added and the TC plate was incubated on 
ice for 10min prior to scraping and analysis on a Attune NXT flow cytometer. 
Wells were pre-treated for 24hours with Apigenin ( included in the kit)  to 
inhibit 2NBDG, as a control.  
2.16  Measuring Intracellular Glycogen Stores  
Glycogen stores were measured in both Monocyte-Derived Macrophages 
(MDM) and Alveolar Macrophages (AM), cultured  as outlined above. Three 
wells of approximately 200,000 cells per well ,were combined per condition . 
Wells were rapidly washed with cold PBS on ice x 3 to remove any media. 
Cells were then scraped in 200µl H20 per well and lysates were transferred to 
cooled eppendorfs (3 wells per eppendorf) and boiled at 100°C for 10 min. 
Samples were spun at 13,000g for 5 mins at 4°C, the supernatant was 
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transferred to fresh eppendorfs and the cells pellet was stored for protein 
quantification via a Pierce BCA assay (Thermo Scientific). Glycogen levels 
were determined via a fluorometric plate based assay (Sigma Aldrich 
MAK016-1KT), the supernatant was used at a 1:2 dilution and the assay run 
as per the manufacturer’s protocol 54 .  
2.17  Measuring BAL nutrient levels 
Aliquots of Bronchoalveolar Lavage Fluid ( BALF), generated as described in 
2.5, were thawed on ice. All nutrient concentrations were determined using 
fluorometric/colorimetric plate based assays, as per the manufacturer’s 
protocol and the optimal dilution of samples was ascertained for each 
different analyte. The optimised dilutions and incubations were as follows: 
Glucose (Biovision 
K606-100) 
1 in 2 dilution 10 min incubation  
Glutamine (Abcam 
197011) 
1 in 2 dilution 60 min incubation 
Lactate ( Abcam 
65330) 
1 in 2 dilution 30 min incubation 
 
2.18  HPLC-MS analysis of metabolite abundance  
Samples were generated from MDM (method A) and AM cultured as outlined 
in 2.5. 3 wells were combined for each condition (approximately 600,000 
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cells total). All samples were kept on ice during the experiment. NaCl, 
eppendorfs and Methanol ( 80% Methanol, 20% dH2O) were kept on dry ice. 
Cells were washed x 3 with cold NaCl. 300µl of Methanol was added to the 
first well, thoroughly scraped then rapidly transferred to the next well and 
scraped, for all 3 wells before the 300µl was transferred to the cooled 
eppendorfs. Samples were stored for at least 24 hours in -80°C before being 
thawed on ice and spun at 10,000g for 10 mins at 4°C. Supernatant was 
carefully removed and cell pellet was stored for protein count. The total 
volume of sample was recorded at this stage to adjust for any discrepancies 
due to evaporation, if required.  
For normalisation to protein content, 200µl of 200 mM NaOH solution was 
added to each pellet. Samples were then boiled at 95°C for 20min, cooled on 
ice and spun down for 10min at 400g. Protein content was measured using a 
Pierce BCA assay (Thermo Scientific).  
Samples were analysed using Dionex UltiMate 3000 LC System (Thermo 
Scientific) coupled to a Q Exactive Orbitrap mass spectrometer (Thermo 
Scientific) operated in negative mode, by our collaborators ,Dr Bart 
Ghesquière and Wesley Vermaelen at the VIB Center for Cancer Biology in 
Leuven. Data collection was performed using Xcalibur software (Thermo 
Scientific). As there have been issues with the computer generated 
interpretation of metabolite peaks in the past, each peak for each metabolite 
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was manually measured by me, to ensure quality control.  All data values 
were subsequently corrected for protein content based on the BCA assay.  
2.19  RNA Sample generation and extraction 
For MDM and AM , 3 wells were pooled per condition (approximately 
600,000) cells). Cells were centrifuged at 300G for 5 minutes at 4°C, 
supernatant was discarded and cells were washed in PBS. This was 
repeated x 2. Following the final spin, supernatant was removed and cells 
were lysed in 600μl mirVANA lysis/binding buffer (Invitrogen) pipetting up 
and down 5 times to aid lysis before being stored in the -80°C. Before RNA 
extraction, samples were thawed on ice and 40μl of miRNA Homogenate 
Additive was added before vortexing for 30 seconds. Samples 
were incubated on ice for 10 minutes. 600μl of Acid-Phenol:Chloroform 
was added to the sample before vortexing for 30 seconds to mix, and the 
mixture centrifuged for 5 minutes at 10,000g at room temperature. 
The aqueous phase was removed from the sample and put in a sterile 
RNAse-free tube. A volume of 100% ethanol 1.25 times that of the extracted 
aqueous phase was then added. Lysates was added to a filter cartridge over 
a clean collection tube and centrifuged for 15 seconds at 10,000g. Flow-
through was discarded and 700μl miRNA Wash Solution 1 was added to 
the filter and centrifuged for 30 seconds at 10,000g. Flow-through was then 
discarded and 500μl Wash Solution 2/3 was added to the filter and 
centrifuged for 15 seconds at 10,000g. Flow through was discarded and a 
second wash was repeated using 500μl Wash Solution 2/3. Following the 
  
 
Chapter 2: Materials and Methods 38 
second wash, the filter and collection tube were centrifuged for 1 minute at 
10,000g to remove residual fluid from the filter. The filter cartridge was 
transferred to a fresh collection tube and 40μl of pre-heated (95 C) RNAse-
free H20 added to the filter, and the assembly centrifuged for 30 seconds at 
13,000G to recover RNA. Flow-through was run through the filter again for 30 
seconds at 13,000G to ensure maximum recovery. RNA purity and 
abundance was measured using a NanoDrop Spectrophotometer 
(ThermoFisher Scientific). DNA and protein contamination was ascertained 
through ratio of absorbance at 260nm/280nm and 260nm/230nm, 
respectively. Samples were treated with 1μl TURBO DNAse (Invitrogen) and 
incubated at 37 C in the heat block for 30 minutes. 2μl of DNAse inactivation 
reagent (Invitrogen) was added and sample centrifuged at 10,000g for 90 
seconds at 4C to pellet inactivation beads. Samples were then reanalysed 
with the NanoDrop for final RNA concentration 54.  
2.20 Transcriptomics Data and Analysis 
Transcriptomics Data Set A: Total RNA sequencing data set with COPD +/- 
Compound 7 vs Healthy AM +/- Compound 7. RNA samples were generated 
as above. RNA was quantified again via Qubit at the Western CRF, and Total 
RNA sequencing was run by the Edinburgh Clinical Research Facility 
Genetics Core as detailed in the report in Appendix 4. 
Bioinformatic analysis was carried out by Dr John Thompson of 
Thomson Bioinformatics, Edinburgh UK.  In brief raw sequencing FastQ files 
were mapped to the reference genome (UCSC hg19) using the STAR 
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alignment tool (STAR 2.6.1a) with filters applied to allow no more than 5 
mismatches per read, read QC scores above a defined normalised threshold 
score of 0.66 and multimapping alignment scores no greater than 1. 
Following mapping overall metrics were analysed to assess the quality of 
each run (i.e. % reads passing QC thresholds following removal of abundant 
RNA reads, median coverage uniformity statistics and comparative genomic 
alignment distribution analyses). Transcripts Per Million (TPM) scores were 
then calculated for each gene across all samples. Differentially expressed 
genes were defined as genes displaying greater than Log2 1.5 fold change 
and with P-values <0.05 between two sample cohorts.   
Transcriptomics Data Set B: COPD AM +/- D39 Streptococcus 
Pneumoniae vs Healthy AM +/- D39 Streptococcus Pneumoniae Affymetrix 
Array. . *** I did not generate this affymetrix data myself. I acquired it through 
a collaboration with Professor David Dockrell. I then analysed it myself , 
focusing on the cellular stress response and metabolism. Therefore the 
below information was supplied to me by Drs Joby Cole/ Martin Bewley who 
originally processed the samples.  
 RNA was extracted and hybridized onto the Affymetrix HG-U133 plus 2.0 
Array. Data were analysed in R using affyPML and Limma. Enrichment 
analysis of Gene Ontology (GO) terms using a hypergeometric model 
(BiNGO App) in Cytoscape 3.0 was performed for differentially expressed 
genes. False discovery rates (FDR) were corrected with the Benjamini-
Hochberg procedure.  
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2.21 Taqman analysis of Gene expression 
The quantity of RNA used to generate cDNA was dependent on the nature of 
the samples and was usually in the region of 250ng. *For samples which 
were used to complete a data set with Transcriptomics Data set A , RNA QC 
and quantification was carried out by the Edinburgh Clinical Research Facility 
Genomics Core, to ensure consistency.  
Samples for direct comparison were always normalised to generate the same 
quantity of cDNA and were made up to 12.4μl in RNase-free water. cDNA 
was made using AMV reverse transcriptase and random primers (Promega), 
details of the master mix used are in Appendix 5. Samples were run on a 
Techne Thermal cycler as follows:  
• 23°C for 5 minutes  
• 42°C for 2 hours  
• 99°C for 2 minutes (to heat inactivate AMV RT)  
Samples were stored at -20°C until use. 
Gene expression was analysed using predesigned qPCR primer/probe 
assays (detailed in Appendix 5) and Prime Time Gene Expression Mastermix 
(IDT, Leuven). For all assays, samples were run in duplicate and the gene of 
interest expressed relative to expression of a housekeeping gene (beta-
actin). Assays were run on a 7900HT Fast real-time PCR system (Applied 
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Biosystems) with the following negative controls: no RNA, no RT and no 
cDNA. Data was analysed using SDS 2.0 software (Thermo Scientific)
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In health alveolar macrophages (AM) play a critical role in maintaining 
homeostasis in the lung, an organ which directly interfaces with the external 
environment. Macrophage phagocytosis of pathogens, particulate matter and 
apoptotic cellular debris, results in key alterations in gene transcription, 
metabolic programming, antigen presentation and cytokine release and as 
such macrophage phagocytosis plays a critical role in triggering the innate 
and adaptive immune response55,56,57. 
Macrophages are highly responsive to the extracellular environment and are 
characterised by high degree of phenotypic plasticity. Traditional dogma 
dictated a strict M1 (pro inflammatory) M2 ( anti-inflammatory) divide in 
macrophage phenotype, driven mostly by cytokine stimulation. In reality, in 
vivo macrophage activation is likely an ever evolving continuum of this  
polarisation spectrum, constantly changing and reacting to external stimuli.  
Macrophage exposure to, and subsequent phagocytosis of bacteria induces 
a proinflammatory programme, with release of inflammatory cytokines such 
as TNFa and IL-1 and a switch from oxidative phosphorylation to glycolysis. 
Knock down of HIF1a abrogates this inflammatory programme in 
macrophages 58,59. Efferocytosis by macrophages protects local tissue from 
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the deleterious effects of necrotic cellular debris but it also initiates 
inflammation resolution by secreting  IL-10 and TGFb. “M2” stimuli such as 
apoptotic cells have been shown to reprogramme macrophages towards fatty 
acid oxidation and oxidative phosphorylation60.  
Fate-mapping studies in murine models indicate that alveolar macrophages 
can self-renew in the homeostatic state. However, during infection for 
example, peripherally circulating monocytes are recruited to the injured lung 
where they undergo differentiation into macrophages, taking on some, but 
not all, of the characteristics of the tissue resident macrophage3. A recent 
study was the first to tackle this concept in human lungs by utilizing a multi 
parameter approach to classify mononuclear phagocyte subsets in the non-
diseased lung. This revealed the presence of diverse myeloid populations, 
even in the health. In addition to Alveolar Macrophages, there were four 
distinct populations, including a seemingly monocyte derived population of 
airway macrophages10. It is likely that the relative contributions of each 
subset may change during a chronic inflammatory state, such as COPD. 
This is one possible explanation for the major dichotomy which exists in 
COPD lungs. Whilst the numbers of almost all immune cells are increased in 
the lungs of patients with COPD, macrophage numbers are upwards of five 
times the amount found in the non-diseased lung. In fact, macrophage 
abundance, unlike other innate immune cells, directly correlates with disease 
severity61. This represents a major disconnect in innate immunity as despite 
increased numbers of macrophages in the airways of these patients, there is 
  
 
Chapter 3 : Macrophages from COPD Donors have defective function 
  44 
 
pathogen persistence coupled with chronic inflammation. One hypothesis is 
that due to the chronic distribution of homeostasis in COPD, a higher 
proportion of macrophages in COPD airways are recruited from peripherally 
circulating monocytes, with differing functional capacity to the resident cells. 
However a study by Ravi et al showed that COPD monocytes have 
decreased migratory ability and suggested that increased macrophage 
numbers in COPD lungs may be due to delayed apoptosis62. This would 
mirror recent findings that alveolar macrophage apoptosis is required for late 
stage killing of streptococcus, but does not occur in COPD lungs38. Thus, the 
origin of airway macrophages in COPD still remains unclear. However, it is 
extremely likely that a combination of differential macrophage origins, 
coupled with the combative inflammatory microenvironment of the COPD 
lung, is likely driving the profound macrophage dysfunction seen in COPD. 
To date changes across a catalogue of macrophage functions have been 
described in COPD. Exposure of macrophages to cigarette smoke leads to 
upregulation of several molecules known to induce tissue damage in COPD, 
such as MMP-9,MMP-12 – long implicated in lung parenchymal destruction -
and NADPH oxidase, leading to increased levels of ROS and subsequent 
elevated oxidant stress43. Increased chemokine release further exacerbates 
a highly cellular and inflammatory environment, with amplified release of IL-8 
and TNFa ( potent neutrophil chemokines) and CCL2 ( monocyte 
chemoattractant protein 1)63. However, arguably the most crucial defect in 
  
 
Chapter 3 : Macrophages from COPD Donors have defective function 
  45 
 
COPD macrophages is their impaired bacterial phagocytosis and 
efferocytosis (phagocytosis of apoptotic cells).  
A number of in vitro studies have shown that in COPD, AM phagocytosis of 
bacteria which colonise the lungs of these patients, such as non-typeable 
Haemophilus influenzae (ntHi) and Streptococcus pneumoniae (Spn), is 
greatly reduced. A similar defect has been described for efferocytosis of 
apoptotic cells 36,37,40. Whilst reduced phagocytosis and efferocytosis has 
been described in the macrophages of smokers with preserved spirometry, 
this defect is significantly more pronounced in COPD patients, regardless of 
their smoking status, with reductions as high as 20-50% described across 
both processes 37,60. This phenotype is not confined to the lung and has been 
demonstrated in circulating COPD Monocyte-Derived Macrophages, though 
study findings have conflicted between groups. A study by Taylor et al and 
more recently work published in conjunction with our collaborator Professor 
David Dockrell, confirmed a bacterial phagocytic defect in monocyte-derived 
macrophages from COPD patients38,36. This finding challenges the long held 
concept that macrophage dysfunction in COPD is caused by the direct insult 
of cigarette smoke and the inflammation perpetuated by it. If COPD 
monocyte-derived macrophages display impaired function prior to migrating 
to the lung, it is unlikely that this phenotype could be rescued via tissue 
imprinting by a diseased organ. Once again, this speaks to the concept that  
an increased presence of monocyte-derived macrophages in the COPD lung, 
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leads to an increased overall macrophage presence with poor macrophage 
mediated immunity.  
The discovery of impaired bacterial phagocytosis in a group of patients where 
colonisation, a major risk factor for exacerbation, morbidity and mortality, can 
be as high as 50%, has resulted in many studies aimed at determining the 
specific cause for impaired internalisation rates in COPD34. Bacterial 
phagocytosis involves recognition of the invading pathogen by pathogen- 
recognition receptors and a subsequent complex co-ordination of pathways 
relating to transcription, metabolism, protein modification etc, eventually 
culminating in pathogen internalisation and its destruction within the 
phagolysosome. Thus, many groups have interrogated macrophage surface 
marker expression as a possible source for impaired pathogen uptake. A 
number of these markers such as HLADR, CD80, CD163, and TLR3 have 
been identified as differentially expressed between COPD and Healthy 
macrophages64,65. However, there is a lack of consensus across studies and 
this, coupled with phagocytic defects found across a wide range of 
pathogens and apoptotic bodies, suggests that discrepancies in cell surface 
marker expression is unlikely to be the main driver of the phenotype. 
Interestingly, one study did find that COPD AM displayed a higher number of 
both M1 and M2 markers, with dual polarisation progressing with disease 
severity, suggesting that COPD AM do have a unique disease-specific 
phenotype66. Detailed transcriptional analysis of airways macrophages by 
Shaykhiev et al also found a distinct phenotypic pattern. Though now 
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recognised to be an overly rigid view of macrophage function, they compared 
COPD airway macrophages to known polarised macrophage modules and 
found that COPD AM possess a distinct transcriptional phenotype at 
baseline, with partial M1 downregulation and partial M2 upregulation51. 
Similarly, a study in which the transcriptional profile of COPD AM was 
compared to a generated library of 299 macrophage activation 
transcriptomes, revealed an unexpected loss of inflammatory signatures in 
the COPD cohort67 . Whilst very informative  studies, they do emphasise the 
need to couple transcriptional profiling with functional assays as to date  
these have revealed a highly inflammatory response in COPD AM, with 
impaired “M2” functions ie efferocytosis. 
Thus, defective macrophage function is a major driver of persistent 
inflammation, the histological hallmark of COPD. There exists a major 
disconnect in immune responses as despite increased numbers of 
macrophages in the airways of these patients, there is pathogen persistence 
coupled with chronic inflammation. It is currently non known if this is due to a 
different cohort of macrophages populating the lung in COPD or primarily due 
by local environmental factors. Whilst many immune responses are altered in 
COPD, in vitro studies suggest that impaired macrophage bacterial 
phagocytosis and efferocytosis may be a major driver of disease. There is 
evidence for an impaired transcriptional programme at baseline in COPD AM 
50, and certain surface marker expression has been found to be altered, 
albeit with some variability, but the specific driver of impaired macrophage 
  
 
Chapter 3 : Macrophages from COPD Donors have defective function 
  48 
 
function has yet to be elucidated. It is currently unknown if cigarette smoke 
exposure triggers an inherent macrophage defect in susceptible individuals,  
or whether a defect already exists which is propagated by cigarette smoke 
exposure and the causal relationship leading to altered function in MDM 
merits particular attention. 
Regardless of the cause , impaired macrophage phagocytosis and 
efferocytosis further perpetuates inflammation by leading to ongoing 
recruitment of immune cells with excess levels of pro inflammatory cytokines, 
chemokines and ROS generation, leading to severe tissue damage. Thus, 
defective AM and MDM function in COPD leads to persistent inflammation 
that is both highly damaging and ineffective.  
We hypothesized that both bacterial phagocytosis and efferocytosis would be 
reduced in COPD macrophages. Crucially, we wished to separate 
macrophage dysfunction driven by local tissue specific factors from a 
systemic defect arising in the bone marrow, by profiling both AM and MDM 
from COPD patients and Healthy Controls. We sought to gain insight into the 
mechanisms driving macrophage dysfunction and to understand the 
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Results:  
3.2 Demographic data of recruited patients 
 
To characterise macrophage dysfunction in COPD, donors were recruited for 
either bronchoscopy, venepuncture or both procedures (Chapter 2.1).  
Donors with COPD, free from exacerbation, were age matched to Healthy 
Control donors ± 7 years (mean age). COPD and Healthy Non-smokers had 
a female:male  distribution of 52%:48% and 60%:40% respectively. Healthy 
smokers were all male. Forced expiratory Volume in one second (FEV1) was 
significantly lower in COPD donors as expected, p=<0.0001, unpaired t-test.  
Our COPD cohort included mild (25%) moderate (52%), severe (21%) and 
very severe disease (2%), as per the GOLD classification system (Appendix 
6). 25 of 42 patients with COPD (52%) had a history of frequent 
exacerbations (>2/yr). There was no significant difference in pack-years of 
cigarette exposure between COPD donors and Healthy Smokers (p=0.11, 
unpaired t-test). 45% of our COPD donors continued to smoke. The COPD 
Assessment test (CAT) is a validated health-related quality-of-life questionnaire 
(Appendix 7) and was used to measure symptoms, with a higher score 
indicating worse symptomology. 82 % or 39/48 COPD donors had CAT 
scores >10, standardly used as a cut off to stratify patients with more severe 
symptoms (GOLD guidelines 2019). Approximately 50% of our cohort were 
not prescribed an inhaled steroid at the time of recruitment.  
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Figure 3.2: Demographic data. 
Patients were recruited via the RIE Clinical Research Facility and existing 
NHS bronchoscopy lists. Not all patients underwent both bronchoscopy and 
venepuncture. Values are presented as mean ± SD or range. FEV1= Forced 
Expiratory Volume in 1 second, Gold Stage classification of COPD severity, 
(Appendix 6). CAT score = COPD symptom Assessment Test (Appendix 7).  
Pack year = 20 cigarettes per day for 1 year. ICS= Inhaled corticosteroid, 
LABA= Long acting Beta Agonist, LAMA= Long Acting Anti Muscarinic, 
SABA= Short Acting Beta Agonist. 
 
  
Healthy Non smokers Healthy Smokers Subjects with COPD
No of Subjects 20 5 48
Age (yr) 53 (31-70) 50 (36-68) 60 (39-77)
Sex female/male 12/8 0/5 25/23
FEV1 (L) 3.1 ± 0.7 3.5 ± 0.3 1.7 ± 0.5
FEV1 (% predicted) 105 ± 12.9 98 ± 4.1 64 ± 17.30
Gold Stage N/A N/A 12   Stage 1 
25   Stage 2
10   Stage 3 
1    Stage 4
Exacerbation per year
0/ >1/>2 / ≥3 N/A N/A 14/9/18/7
Smoking status
Current/Ex/Never 0/0/20 5/0/0 22/26/0
Pack years n/a 30 ± 10 36 ± 14
CAT score (Max 40) N/A N/A 16 ± 8
Inhaled Medication:
ICS+LABA / LAMA / SABA N/A N/A 25/32/31
  
 
Chapter 3 : Macrophages from COPD Donors have defective function 
  51 
 
3.3 Alveolar and Monocyte-derived macrophages from COPD 
donors have impaired bacterial phagocytosis and 
efferocytosis 
 
To establish if COPD macrophage dysfunction was a result of tissue specific 
factors, airway macrophages and peripherally circulating monocyte-derived  
macrophages from COPD donors were compared to Healthy controls. Alveolar 
Macrophages (AM) were isolated from bronchoalveolar lavage fluid . As 
discussed BAL fluid macrophages likely represent a heterogenous macrophage 
population consisting of tissue resident macrophages and infiltrating peripherally 
derived Monocyte-derived macrophages (MDM) . The relative contribution of 
macrophages from each source likely differs between Healthy and COPD 
donors. Blood MDM were isolated from peripheral blood and both AM and MDM 
were purified via the adherence method, as outlined in Chapter 2.3.  
Macrophages were co-incubated with live opsonised S14 S.pneumoniae 
(Figure 3.3 A+B) and PKH26 labelled apoptotic neutrophils (Figure 3.3 C+D) 
to establish internalisation rates. COPD AM bacterial phagocytosis was 
significantly reduced compared to Healthy Controls (n= 8 and 6, mean 
bacterial count recovered 2.36 vs 3.2 cfu/ml). Efferocytosis rates were also 
significantly reduced in COPD AM compared to Healthy Donors ( n=11 and 
8, mean 34% vs 13%).  
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We then performed these assays in monocyte-derived macrophages (MDM) 
to delineate the effect of the inflammatory niche on macrophage function, 
from the systemic effects of COPD. Strikingly, MDM exhibited the same 
defect in phagocytosis and efferocytosis as COPD AM (Figure 3 B+D). 
COPD mean MDM bacterial phagocytosis was significantly reduced 
compared to Healthy MDM ( n= 8, mean bacterial count recovered 2.99 vs 
3.51 cfu/ml). Similarly, efferocytosis was significantly lower in COPD donors 
(n=10, 14% vs 33%). While internalisation rates were reduced in both MDM 
and AM, COPD AM displayed a greater percentage reduction in function 
compared to Healthy donor , in both phagocytosis and efferocytosis (= 27% 
vs 15% and 62%vs 58% respectively).   
Rates were lowest in current smokers across both processes, as previously 
described68, but macrophage dysfunction did not recover in COPD patients 
who were no longer active smokers.  
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Figure 3.3: COPD donors have impaired phagocytosis and efferocytosis 
compared to Healthy Volunteers. 
(A-D) Alveolar and Monocyte-Derived Macrophages from Healthy Controls 
and COPD Donors were challenged with (A,B) opsonised serotype 14 S. 
pneumoniae, 4h post challenge, numbers of viable bacteria were measured 
or (C,D), co-incubated with PKH26 labelled 20h apoptotic neutrophils and 
efferocytosis rates were measured by flow cytometry.     = current smokers. P 
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3.4 COPD macrophages have preserved early bacterial killing 
 
To establish if the high rates of colonisation which characterize COPD airways 
were due to a combination of both impaired phagocytosis and impaired bacterial 
killing, we compared early (up to 10 hrs) bacterial killing in COPD donors. Late 
stage killing is mediated via macrophage apoptosis and has previously been 
shown to be defective in COPD69.  
S. pneumoniae was opsonised with serum from vaccinated donors (as per 
2.10). Cells were then co-incubated with opsonised and non opsonised S14 S. 
pneumoniae and after the addition of antibiotics at four hours, were lysed at 
sequential time points. While internalisation rates were lower in COPD, as 
described, the slope of recovered cfu/ml was comparable between COPD and 
Healthy donors, confirming that they do not have a defect in early Streptococcus 
pneumoniae killing (Figure 3.4 A-D). These assays were performed by Dr Martin 
Bewley , a post-doctoral researcher in the lab of our collaborator on this project, 
Professor David Dockrell and have been published 38.  
It is important to note the prominent defect in opsonic bacteria phagocytosis in 
the COPD donors. Reduced availability of opsonin could potentially lead to 
downregulation of opsonin mediated phagocytosis and a greater defect in this 
pathway. Consequently, we interrogated bronchoalveolar lavage (BAL)  fluid 
from donors and confirmed that unconcentrated BAL samples from COPD 
donors had comparable levels of pneumococcal antibodies to Healthy donors 
(Figure 3.4 E).  
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Figure 3.4: COPD Macrophages show no defect in early phase bacterial 
killing and COPD donors maintain their ability to produce opsonins. 
AM or MDM were collected from patients with COPD (A and C) or Healthy 
Donors (B and D) and were challenged with non-opsonised or opsonised 
serotype 14 S. pneumoniae for 4h, before extracellular bacteria were killed 
by the addition of antibiotics. At the designated time post antibiotics, viable 
bacteria in duplicate wells were measured, n=3. No significant differences 
were seen in any groups.(E) Pneumococcal antibodies were detectable by 
multiplex immunoassay in bronchoalveolar fluid from COPD (n=16) and 
Healthy (n=13) donors.  
¨Experiments in Figures A-D were performed by Dr Martin Bewley  
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3.5 Decreased opsonic bacterial phagocytosis in COPD 
correlates with markers of disease severity, but not with age 
 
To establish if there was a direct clinical read out of impaired bacterial 
phagocytosis in COPD,  correlation analysis of opsonized phagocytosis of S. 
pneumoniae against FEV1 was performed. FEV1 is an objective marker of 
airway inflammation and narrowing and is the central component of COPD 
severity stratification. We found a significant relationship between FEV1 % 
predicted (Actual Donor FEV1 as a % of their predicted FEV1 based on height 
and age) and macrophage bacterial phagocytosis (Figure 3.5 A). Similarly we 
found a negative correlation between impaired opsonic bacterial phagocytosis 
and scores representative of increased symptom severity (high CAT scores- 
Appendix 7) (Figure 3.5 B). Unlike age related findings in other innate immune 
cells30, macrophage opsonic bacterial phagocytosis did not correlate with donor 
age (Figure 3.5 C). 
Figures 3.5 A + B were compiled in conjunction with data produced by Dr Martin 
Bewley, a post-doctoral researcher in the lab of our collaborator on this project 
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Figure 3.5: Opsonised macrophage bacterial phagocytosis correlates 
with markers of disease severity but not with age.  
Opsonised bacterial phagocytosis correlates with FEV1% predicted (A) and 
symptom severity as measured by the CAT score (B). There was no 
significant correlation between opsonised bacterial phagocytosis and age 
(C). Pearson’s correlation coefficient (r) and p values shown. 
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3.6 Efferocytosis by COPD macrophages correlates with markers 
of disease severity, but not with age 
 
To determine the clinical impact of impaired efferocytosis, macrophage 
efferocytosis was correlated with makers of disease severity. AM 
Efferocytosis from COPD donors was highly correlated with objective 
measures of airflow limitation ( FEV1% predicted) (Figure 3.6 A). In contrast, 
no significant correlation was seen between peripherally circulating MDM and 
FEV1% (Figure 3.6 B). COPD macrophage efferocytosis rates were 
negatively correlated with self-reported markers of disease severity, as 
measured by the CAT questionnaire(Appendix 7) (Figure 3.6 C). 
Corresponding to our findings in bacterial phagocytosis, neither COPD nor 
Healthy donor macrophage efferocytosis rates correlated with age- shown as 
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Figure 3.6: Efferocytosis by COPD AM only, correlates with markers of 
disease severity age. Macrophage efferocytosis does not correlate with 
age. 
 (A) COPD AM display a high correlation with FEV1% ,whilst (B) MDM 
efferocytosis does not. Overall COPD macrophage efferocytosis negatively 
correlates with symptoms of disease severity as measured by the CAT score. 
All donor macrophage efferocytosis does not correlate with age. Pearson’s 
correlation coefficient (r) and P values shown. 
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3.7 Phagocytosis rates correlate with efferocytosis rates 
suggesting a common underlying mechansim 
 
We questioned if a shared mechanistic defect was driving macrophage 
dysfunction in COPD. To investigate this we correlated bacterial 
phagocytosis with efferocytosis in each donor and found a high degree of 
correlation in both AM and MDM, providing compelling evidence for a shared 
underlying defect causing impaired phagocytosis and efferocytosis in COPD 
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Figure 3.7: Correlation of phagocytosis rates with efferocytosis rates in 
AM and MDM from both COPD and Healthy Donors.  
Efferocytosis of PKH26 labelled apoptotic neutrophils was correlated with 
phagocytosis of S. pneumoniae S14 in both Alveolar (A) and Monocyte-
Derived Macrophages (B) from COPD and Healthy donors.     = COPD 
donors.    = Healthy donors. Pearson’s correlation coefficient (r) and P values 
shown. 
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3.8 COPD macrophages display a globally reduced 
transcriptional response to infection with S. pneumoniae  
 
To gain mechanistic insight into the defects driving macrophage dysfunction 
in COPD, we compared the transcriptional response of COPD and Healthy 
AM to opsonized S. pneumoniae. This specific experimental scenario was 
chosen over ingestion of apoptotic neutrophils, as we would be unable to 
entirely delineate the macrophage transcriptional signal from that of the 
apoptotic neutrophils, following ingestion. In addition, as phagocytosis closely 
correlated with efferocytosis, we hypothesised that findings related to broader 
cellular function would be applicable to both processes. 
AM from non-smoking COPD and Healthy donors were co-incubated with 
opsonised D39  S. pneumoniae for 4h at a multiplicity of infection (MOI) of 
10:1, and the transcriptional response was assessed via an Affymetrix array 
(Figure 3.8.1 A). There were significantly fewer differentially expressed 
genes, both up and down-regulated, in COPD AM in response to infection 
than in Healthy AM (Figure 3.8.1 B). 
Interrogation of phagocytic pathways, such as surface marker expression 
and actin rearrangement, revealed a divergent transcriptional response to 
infection between COPD and Healthy AM (Figure 3.8.2). Remarkably, at four 
hours, only complement receptors were upregulated in Healthy AM, with no 
change in transcription seen in COPD AM. However, MARCO, a key 
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scavenger receptor for bacterial phagocytosis, was upregulated in COPD AM 
but not in Healthy AM. This is in contrast to previous findings that MARCO 
expression is lower in COPD cells and is particularly interesting in light of the 
potential role of MARCO in delineating AM from infiltrating MDM 8,49. 
Pathogen exposure triggers a pro inflammatory response from AM, but as 
AM also play a critical role in orchestrating inflammation resolution, we 
queried if efferocytosis pathways may be upregulated in anticipation of this,  
following co-incubation with S. pneumoniae. At a four hour time point 
transcription of these pathways remained largely unaltered in both COPD 
and Healthy control AM (Figure 3.8.3). Interestingly, at this time point, only 
the efferocytosis receptor, MERTK, ligation of which supresses inflammatory 
cytokine release, was altered. It was downregulated in Healthy AM, but 
remained transcriptionally unaltered in COPD AM. Transcription of Protein S, 
a bridging molecule involved in ligation of efferocytosis receptors, including 
MERTK, was also downregulated in Healthy AM only70.  
The engulfment of foreign particles involves the careful and complex 
rearrangement of the actin cytoskeleton. We examined the transcriptional 
response to infection across core elements of actin organisation. Small Rho 
GTP-ases (eg RhoA, Rac1 Rac2, Cdc-42) bind to varied effectors such as 
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The Arp2/3 complex nucleates branched actin and ,in conjunction with 
members of the Wiskott-Aldrich syndrome family protein (WAVE 2, 
WIP/WASP), orchestrates critical actin remodelling during phagocytosis71. 
Failure to downregulate the Rho-GTPase activating protein, ARGHAP25, has 
been shown to prevent closure of the phagocytotic cup72. We found that 
these co-ordinators of actin organisation were appropriately upregulated in 
Healthy AM, but with the exception of RhoA, no transcriptional change was 
induced in COPD AM following infection. 
Differential transcription responses between Healthy and COPD AM, were 
not limited to phagocytotic mechanisms. Pathways relating to fundamental 
cellular processes such as metabolism and anti-oxidant responses were also 
differentially regulated (data not shown here, discussed in Chapters 4+5).  
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Figure 3.8.1: Affymetrix array reveals a reduced transcriptional 
response to S. pneumoniae in COPD Alveolar Macrophages. 
AM from COPD and Healthy Control donors were exposed to D39 S. 
pneumoniae, MOI 10:1, for 4 hours, before total cellular RNA was collected 
for transcriptional analysis. (A) Schematic representation of experimental 
conditions. (B) Venn diagram illustrating the number of genes upregulated or 
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Figure 3.8.2: Transcription of phagocytic receptors is minimally 
changed in COPD Alveolar Macrophages following infection with 
S.pneumoniae. 
In response to infection with S. pneumoniae, Healthy Controls alter 
transcription of phagocytic receptors, in particular upregulating transcription 
of complement receptors. Transcription of the scavenger receptor, MARCO, 
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Figure 3.8.3: Transcription of the efferocytosis pathway is largely 
unaltered in Alveolar Macrophages at 4hours post initial incubation 
with S.pneumoniae. 
With the exception of MERTK, receptors which specifically mediate 
efferocytosis were transcriptionally unaltered in both COPD and Healthy 
Control AM after 4 hours of co-incubation with S.pneumoniae. Transcription 
of the bridging molecule protein S was downregulated in Healthy AM but was 
unchanged in COPD AM. Log2 fold change in gene expression listed in 
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Figure 3.8.4: Co-incubation with S. pneumoniae induces differential 
transcriptional programmes in actin cytoskeletal organisation, in 
Healthy and COPD AM.  
Healthy AM alter transcription of key components of the actin cytoskeleton 
required for successful phagocytosis, following co-incubation with S. 
pneumoniae. COPD AM alter some but not all of these components and 
uniquely upregulate RhoA, in response to infection. Log2 fold change in gene 
expression listed in brackets where genes are altered in the same direction in 
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Figure 3.8.5: Schematic of key elements of cytoskeleton re arrangement 
required for phagocytosis.  
Key alterations in the actin cytoskeleton during phagocytosis are 
transcriptionally altered in Healthy but not COPD AM in response to co-
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The data in this chapter outlines the main phenotype of macrophage 
dysfunction in COPD. Crucially by recruiting patients for both bronchoscopy 
and venepuncture, we have been able to define this phenotype both in 
alveolar macrophages, directly influenced by the lung microenvironment, and 
in peripherally derived monocyte-derived macrophages, existing in an oxygen 
and nutrient rich environment.  
In keeping with previous findings, AM from COPD donors had reduced bacterial 
phagocytosis of S pneumoniae and efferocytosis of apoptotic neutrophils.37,40. 
Interestingly , in our hands, COPD MDM also displayed dysregulated phagocytic 
capacity suggesting macrophage dysfunction in COPD is not solely governed 
by lung specific factors. There has been much debate over conflicting findings 
in functional assays of COPD MDM, with some studies finding a similar defect to 
that found in AM and others finding the defect in AM alone37. It has been 
hypothesised that this discrepancy was due to the use of certain cytokines eg 
GM-CSF, driving the cell towards a more “ tissue like “ phenotype during 
culture36. Differentiation using cytokines introduces a major element of variability 
as there is potentially an altered response to cytokine stimulation in a diseased 
state. Instead our MDM were differentiated using the well-established 
adherence method, without use of cytokines to “drive a polarisation state”, thus 
removing this variable38. It is consequently all the more striking to observe the 
phenotype in MDM, which have been cultured for ³12 days in a substrate 
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replete environment. This suggests that the mechanism for macrophage 
dysfunction is hard wired in this population and not corrected by excess 
substrate availability. There is now a major focus on the potential epigenetic 
nature of COPD as a disease entity and this data provides evidence that a 
global defect rather than tissue specific modulation is altering macrophage 
function in COPD. This in turn invites discussion as to why this defect is so 
predominantly manifest in the lung? This may be due, in part, to the direct 
interface between the external environment/pathogens and immune cells of 
the lung. There may be aberrant tissue imprinting on infiltrating cells due to 
existing damage from cigarette smoke. Alternatively baseline dysfunction in 
the infiltrating MDM population may be contributing a larger proportion to the 
airway macrophages in COPD, leading to compromised immunity and 
recurrent infection.  
We observed a selective defect in AM opsonic bacterial phagocytosis, which 
was not driven by an opsonin scarcity in the airways, and as established by 
previous studies, not driven by AM Fc receptor expression 38 49. Despite 
producing appropriate quantities of opsonin, impaired opsonic phagocytosis 
will likely influence the efficacy of pneumococcal vaccination in these patients 
in whom S. pneumoniae is the leading cause of community acquired 
pneumonia.  
Impaired bacterial phagocytosis is one obvious cause for colonisation in the 
airways of COPD patients, which can be as high as 50%. Colonisation with 
pathogens such as Haemophilus influenzae, Streptococcus pneumoniae and 
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Pseudomonas aeruginosa is major risk factor for the exacerbations which are 
the lead cause of mortality in COPD patients 34. In light of these high 
colonisation rates, we were surprised to observe no defect in the early bacterial 
killing of Streptococcus in COPD macrophages.  It would thus appear that the 
initial inability to maintain homeostasis by quiescent clearing of pathogens, is 
due to a selective impairment of phagocytosis rather than a universal failure in 
macrophage function eg phagolysosomal acidification, though dedicated studies 
are required to verify this. 
 To establish the physiological significance of impaired macrophage 
phagocytosis and efferocytosis, we examined their relationship with clinical 
measures of disease severity. Spirometry (which measures FEV1) is both the 
gold standard for diagnosing and for classifying disease severity in COPD. 
Airway narrowing and loss of elasticity due to inflammation leads to a reduction 
in FEV1. Thus, we were interested to observe an inverse correlation between 
FEV1 and bacterial phagocytosis, suggesting that ongoing inflammation due to 
impaired pathogen clearance affects airway functionality. It was particularly 
interesting to see that only AM efferocytosis correlated with FEV1, not MDM, in 
contrast to the correlation in both populations with bacterial phagocytosis. The 
greatest discrepancy across both process was in AM efferocytosis, where rates 
in Healthy AM were >6 times that of COPD AM. It is unclear why this process, in 
this cell, would appear to be more sensitive to the deleterious environment of 
COPD but one possibility is direct impairment of efferocytosis by altered 
extracellular matrix proteins following cigarette smoke exposure 73. Alternatively, 
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a correlation between AM efferocytosis only and FEV1 ,may be due to tissue 
resident AM playing a greater role in efferocytosis in the lung, than infiltrating 
MDM.  
The COPD assessment test (Appendix 7) is a well validated questionnaire 
exploring symptom severity such as mucus production and breathlessness. 
FEV1 has previously been found to correlate poorly with patient 
symptomology74. It was therefore particularly significant to find a correlation 
between both bacterial phagocytosis and efferocytosis and high CAT scores . As 
mucus production, cough and wheeze are included in the CAT score, this 
suggests that the physiological processes leading to these symptoms may be 
driven by macrophage dysfunction.   
Another key finding was the high correlation between donor phagocytosis and 
efferocytosis, providing convincing evidence for a shared underlying 
mechanism. Phagocytosis and efferocytosis involve the ligation and 
downstream signalling of some over lapping but many distinct cell surface 
receptors and so this correlation suggests a broader underlying defect is driving 
macrophage dysfunction in COPD. It is tempting to implicate points of 
convergence of both signalling pathways eg Rho activation and 
Phosphoinositide 3-kinase as the cause. However previous studies carried out 
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The dramatically reduced transcriptional response to S. pneumoniae in COPD 
AM provides insights into the mechanisms driving impaired bacterial 
phagocytosis. As discussed, there is existing data showing a distinct 
transcriptional phenotype at baseline in COPD, but we were unsure how this 
would affect the induced response following infection. It was surprising to see 
that only complement receptors were induced in Healthy AM at 4 hours following 
co-incubation with S. pneumoniae. This may be because basal transcription of 
these receptors is lower than other pattern recognition receptors- which possess 
a broader functionality. A failure to upregulate these in COPD AM may account 
for the greater defect in opsonised phagocytosis compared to non opsonised 
(Figure 3.4). Upregulation of MARCO was an unexpected finding in COPD AM, 
as low levels of MARCO expression have previously been demonstrated in 
COPD macrophages76 . Upregulation of MARCO expression has been 
proposed as the mechanism for reversal of impaired bacterial phagocytosis by 
sulforaphane, an antioxidant drug, which will be discussed later. Importantly, our 
data provides us with transcriptional information only as we did not interrogate 
MARCO cell surface receptor via flow cytometry in these cells.  
As 4hrs of exposure to Streptococcus represents the early response to 
pathogens in macrophages, it was not too surprising to see minimal change in 
transcription of efferocytotic pathways in either Healthy or COPD AM.   
However, in COPD AM, there was a striking failure to regulate modules 
required for actin polymerization, its localization to the phagocytic cup and 
closure of the cup following engulfment. It is important to note the 
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upregulation of RhoA in COPD AM following infection. Successful 
internalisation of particles requires care fine tuning of small-GTPases and 
actin arrangement modules with time critical upregulation and subsequent 
downregulation of core elements, required for success. Previous work by our 
group demonstrated an improvement in efferocytosis but not bacterial 
phagocytosis using a small molecule inhibitor of Rho kinase75. It is unclear 
why this did not work in bacterial phagocytosis considering our findings, but 
may relate to the timing of upregulation of RhoA.  
Interestingly actin remodeling has been linked to MARCO cell surface 
expression77. A failure to upregulate actin remodeling programmes in COPD AM 
may account for our observed increase in MARCO transcripts, despite previous 
description of reduced MARCO cell surface expression in these cells.  
The transcriptional response to infection in COPD AM was also altered in 
pathways relating to broader cellular function including metabolism and 
oxidative stress, which will be discussed in later chapters. 
It is worth noting that the altered response across all pathways interrogated is 
does not merely represent a quiescent transcriptional response in COPD AM. In 
some instances, transcription of entirely different genes takes place in COPD 
AM compared to Healthy AM. This is all the more striking considering how few 
genes are comparatively induced or downregulated in COPD AM in response to 
infection. It is unclear if this suppression of transcription is driven by lack of 
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availability of required nucleotides, an inability to sense the microenvironment or 
an inability to react to it . 
In summary, we observed impaired bacterial phagocytosis with preserved early 
bacterial killing in both alveolar macrophage and monocyte-derived 
macrophages from COPD patients. Efferocytosis of apoptotic neutrophils was 
likewise reduced in both COPD AM and MDM. Identifying the same phenotype 
in both AM and MDM highlighted the critical importance of interrogating cells 
within the inflammatory niche in conjunction with peripherally circulating cells, to 
provide mechanistic insight into macrophage dysfunction in COPD.  
Impaired bacterial phagocytosis and efferocytosis correlate with both objective 
(FEV1) and subjective (CAT scores) markers of disease severity, indicating 
impaired macrophage function has a significant physiological impact in this 
population. Macrophage efferocytosis and phagocytosis are highly correlated. 
This suggests that despite the ligation of different cell surface receptors and 
activation of different down-stream signalling pathways, these processes are 
linked on a fundamental level. The global transcriptional response to infection 
with S. pneumoniae is significantly suppressed in COPD AM. There was 
differential transcription of key pathways including phagocytic surface marker 
expression and actin remodeling. Transcriptional differences in oxidant 
responses and metabolism will be discussed in later chapters but taken together 
these differences provide crucial mechanistic clues for macrophage dysfunction 
in COPD.  
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4 COPD macrophages display an altered 
metabolic profile  
 
4.1 Introduction 
There is a growing body of evidence that metabolic reprogramming in 
macrophages is inextricably linked to function and activation states. As key 
effectors of the innate immune response, macrophages are required to 
rapidly switch from relatively quiescent cells to highly active immune 
effectors. Fuelling high energy requiring processes such as efferocytosis and 
phagocytosis, requires increased levels of ATP to be rapidly generated and 
maintained. To facilitate this, macrophages are equipped with the necessary 
machinery to generate ATP via multiple metabolic pathways, namely 
glycolysis, oxidative phosphorylation and fatty acid oxidation. Metabolic 
plasticity is a crucial feature of macrophage adaptability. How macrophages 
utilize metabolic pathways in order to generate adequate energy is critical not 
only for effector function but also facilitates key phenotypic shifts.  
It is widely assumed that cells possess a “reserve metabolic capacity” which 
they can draw on to supply increased energy when required for maintenance 
of cellular function, instigation and resolution of the inflammatory response 
and detoxification of reactive species. Evidence for the necessity of this 
“bioenergetic reserve”, has been confirmed in a number of cell types, where 
loss of energy reserves result in death on exposure to oxidative stress 78,79. 
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While all metabolic pathways are linked in the cell via the relative flux of 
metabolic intermediaries, redistribution of these intermediaries can ensure 
that one metabolic pathway dominates. This can depend on the polarisation 
state of the cell, the speed ATP needs to be generated at or substrate 
availability, including oxygen. Glycolysis can be performed in anaerobic 
conditions and leads to the rapid generation of ATP. When oxygen is readily 
available, oxidative phosphorylation can occur.  Pyruvate generated by 
glycolysis is shuttled through the tricarboxylic acid (TCA) cycle, generating 
reducing equivalents for the Electron Transport Chain, which utilizes them to 
generate ATP. Glycolysis produces a net ATP yield of 2 units, Oxidative 
Phosphorylation yields 30-36 units and Fatty Acid Oxidation -where b-
oxidation of fatty acids generates Acetyl Co-A for the TCA cycle- yields 14 
units of ATP (Figure 4.1). However, ATP generation via oxidative metabolism 
is far slower than glycolysis. It requires intact mitochondria for electron chain 
transport and for a high volume of ATP generation, a degree of mitochondrial 
biogenesis. Hence, despite the higher yields generated via oxidative 
metabolism, a rapid surge in energy requirements can drive immune cells to 
utilize aerobic glycolysis. This preferential use of glycolysis, even in the 
presence of sufficient oxygen, is termed the Warburg effect and was first 
observed in cancer cells - though it is now known to be a “normal 
phenomenon”  in many immune cells. Preferential flux through certain 
metabolic pathways can have far reaching consequences, not only for energy 
production for also for driving macrophage phenotypes 
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Figure 4.1: Macrophages can engage different metabolic pathways to 
drive energy production. 
Green= Glycolysis, Blue= Oxidative phosphorylation, Purple= Fatty Acid 
oxidation.  
In addition to their role in fuelling essential macrophage function, it has 
become increasingly clear that metabolic enzymes and intermediaries play 
key roles in modulating the macrophage immune response. Quiescent 
macrophages have a large capacity for mitochondrial metabolism and 
oxidative phosphorylation. However, activation of macrophages with pro-
inflammatory/“M1” stimuli causes them to under-go a shift towards glycolysis 
as their main source of ATP, regardless of oxygen availability18. Treatment 
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with the proinflammatory stimulus, LPS, leads to increased glucose uptake, 
and similarly, over expression of GLUT-1 leads to a pro inflammatory 
macrophage phenotype80. Furthermore, two key breaks in the TCA cycle in 
pro-inflammatory/“M1”macrophages prime the cell for effective immune 
responses. A seminal study by Jha et al, identified an accumulation of Citrate 
and Succinate in LPS activated macrophages19. Excess Citrate was used to 
generate a key anti-microbial peptide, itaconate. More recently, it was 
discovered that itaconate induces the anti-inflammatory transcription factor 
Nrf2, following LPS stimulation81. Accumulation of Succinate leads to 
induction of pro-inflammatory IL-1b, via HIF1a stabilisation82. Increased flux 
through the Pentose Phosphate Pathway is also recognised as a feature of 
pro inflammatory macrophages, providing NADPH for use as a reducing 
equivalent and to generate Reactive Oxygen Species for microbial killing83. 
Critically, it is not just metabolic intermediaries which can exert 
immunomodulatory effects. Glycolytic enzymes induced by the switch to 
glycolysis serve a dual purpose by also acting as inflammatory signals. The 
glycolytic enzyme pyruvate kinase M2 (PKM2), which catalyses the final step 
in glycolysis, also induces IL-1b expression through HIF1a signalling. 
GADPH  (Glyceraldehyde 3-phosphate dehydrogenase) another glycolytic 
pathway enzyme, can regulate expression of the inflammatory signal TNFa . 
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The central role of metabolism in governing macrophage function is evident 
in the contrasting metabolic profile of anti-inflammatory/M2 macrophages. In 
vitro treatment of macrophages with cytokines such as IL-10, IL-4 and IL-13 
can induce phenotypic changes in transcription, cellular function, cell surface 
markers and metabolism, which ultimately propel macrophages in to an 
“inflammation resolution” programme, or a so called M2 phenotype12. While 
M1 macrophages are heavily reliant on glycolysis to execute their 
inflammatory activity, M2 activation of macrophages leads to increased rates 
of oxidative phosphorylation and fatty acid oxidation (FAO). Disruption of 
these process leads to an impaired anti-inflammatory response. This has 
been particularly well characterised using IL-4 activation of macrophages. IL-
4 activation leads to enhanced FAO and mitochondrial biogenesis with 
suppression of inflammatory cytokines, by inducing expression of STAT6 and 
PGC-1b respectively. Inhibition of oxidative metabolism or of PGC-1b (which 
governs mitochondrial biogenesis) abrogates this effect84. Similarly, over 
expression of CPT1 ( a key mitochondrial transporter of Fatty Acids) 
attenuates inflammatory responses in adipose tissue85. Profiling of metabolic 
flux in M2 (IL-4 and IL-13 treated) macrophages revealed an unbroken TCA 
cycle, in contrast to M1 macrophages. There was increased dependence on 
glutamine metabolism for the TCA cycle and increased generation of amino-
sugar and nucleotide sugar metabolites -characterized by high amounts of 
UDP-N-acetyl-alpha-D-glucosamine (UDP-GlcNAc). Disruption of these 
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Recent evidence has demonstrated that the dichotomy of glycolysis 
supporting acute inflammatory responses and oxidative metabolism fuelling 
sustained energy production, is as an over simplification of macrophage 
bioenergetics. Key studies have revealed that crosstalk between both 
metabolic pathways is indispensable for phenotype induction. LPS activation 
of macrophages induces glycolysis, but it also requires flux through the 
mitochondria. This is not to produce ATP but rather to increase mROS 
production, which in turn induces an inflammatory gene programme86. FAO , 
though recognised to drive macrophages towards an anti-inflammatory 
phenotype, was recently discovered to be dispensable for IL-4 mediated 
macrophage polarisation, however glycolysis was not87. Moreover, FAO was 
found to induce the inflammasome, conferring the pathway with both pro and 
anti-inflammatory roles88. A recent study examining metabolic 
reprogramming in human macrophages identified that mitochondrial health 
and activity was essential for metabolic plasticity89. While this area of interest 
is in its earlier stages of characterisation, it would appear that for effective 
metabolic and phenotypic reprogramming, the cross talk between metabolic 
pathways and the machinery required for this interplay, needs to be intact, 
particularly in human cells.  
Substrate availability adds an additional layer of complexity to metabolic 
regulation. LPS activation increases glucose uptake to maintain high levels of 
glycolysis90. Similarly IL-4 mediated activation of macrophages increases 
expression of the scavenger receptor CD36 and consequent increased fatty 
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acid uptake91. As mentioned, M2 polarised macrophages facilitate TCA cycle 
anaplerosis by shuttling increased amounts of glutamine into the TCA 
cycle19. Evidently, polarisation states can influence substrate uptake to fuel 
their requisite metabolic pathways. It is then a natural conclusion that 
substrate availability can, in turn, regulate a cell’s capacity to undergo 
polarisation. A study by Covarrubias et al was the first to provide a definite 
example of this by showing that Akt-mTORC1, a central axis for sensing intra 
and extracellular nutrient level, can couple nutrient availability with activation 
states. By limiting the supply of amino acids, they demonstrated impaired 
Akt-mTORC1 mediated induction of IL-4 macrophage activation genes92. 
Lastly , Hypoxia and activation of HIF (Hypoxia Inducible Factor) forces 
macrophages to shift to anaerobic metabolism and thus can exert a 
significant phenotypic effect. A seminal paper examining the role of hypoxia 
in macrophage function showed that HIF activation regulated macrophage 
glycolytic capacity and that knock down of HIF-1α  resulted in profound 
impairment of myeloid function59. In keeping with this ,HIF-1α over 
expression in murine macrophages results in increased glycolysis and a 
hyper inflammatory state58.  
Our understanding of the relationship between macrophage function and 
immunometabolism is constantly expanding, with additional layers of 
complexity emerging all the time. What is abundantly clear however, is that 
macrophage phenotype is a composition of both external stimuli and internal 
signalling, the later strongly dictated by successful metabolic reprogramming.  
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No study to date has examined the specific metabolic profile of macrophages 
in COPD, however, there is evidence for altered metabolism in COPD. Gene 
expression profiling of whole lung tissue from COPD and Healthy donors 
revealed that oxidative phosphorylation and protein catabolism were the most 
differentially regulated pathways. Both modules were comparatively 
downregulated in COPD lung tissue93. Similarly, airway smooth muscle cells 
(ASM) isolated from COPD donors display impaired energy balance with 
increased accumulation of glycolytic products- lactate and alanine- compared 
to Healthy controls94. A study dating as far back as 1985, evaluated the 
metabolic profile of Vastus lateralis tissue biopsies in COPD patients 
compared to Healthy Controls. Here too, they identified reduced levels of 
ATP and increased abundance of glycolytic intermediaries in the COPD 
donors95. 
Perhaps the most investigated area relating to metabolism in COPD, is 
mitochondrial dysfunction. At low levels Mitochondrial ROS (mROS) are 
considered a physiological by product of cellular metabolism. Increased 
mROS levels, which have been described in COPD AM, can indicate 
mitochondrial damage and progressive leak through the electron transport 
chain 69. Electron microscopy of bronchial epithelial cells from COPD donors 
revealed elongated and swollen mitochondria with increased fragmentation 
and cristae depletion. This was coupled with altered RNA regulation of key 
mitochondrial genes such as PINK1. These mitochondrial alterations 
mimicked some but not all of  the features of cigarette smoke exposed (CSE) 
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BEAS2b cells96. Mitochondrial profiling of ASM from COPD patients showed 
a reduced mitochondrial membrane potential, reduced ATP levels and 
reduced mitochondrial reserve capacity, as measured by Seahorse 
technology. Once again, mROS levels were increased. It was suggested this 
was driven by oxidative stress, as some findings were replicated in Healthy 
cells exposed to hydrogen peroxide and in an ozone-exposed mouse 
model97. Correspondingly, cigarette smoke exposure, which induces high 
levels of oxidative stress, has been shown to reduce mitophagy with 
consequent mitochondrial dysfunction. This finding was also observed in 
smooth airway epithelial cells from COPD patients98. AM isolated from 
smokers with preserved spirometry i.e “Healthy Smokers”, were found to 
have reduced spare respiratory capacity, a measure of mitochondrial 
reserve, as measured by Seahorse technology99.   
Lastly, as discussed ,microenvironmental regulation via substrate availability 
can have a profound effect on cellular metabolism. Glucose concentrations in 
the lower respiratory tract are approximately 12.5 times lower than plasma 
concentrations, suggesting changes in glucose concentrations have the 
potential to exert a significant effect100. There have been conflicting findings 
relating to glucose content in bronchoalveolar (BAL) fluid of COPD patients. 
In one study, BAL glucose concentrations in COPD patients were found to be 
elevated, compared to Healthy controls and interestingly, this was in the 
context of comparable albumin and urea levels101. A similarly designed study 
found equal BAL glucose concentrations but increased sputum glucose 
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levels in COPD patients, which rose further during experimentally induced 
and naturally occurring exacerbations102.  
In summary ,metabolic plasticity is essential for effective macrophage 
function. Macrophage phenotypes are regulated by external influences such 
as cytokine stimulation and substrate availability, but also extensively by 
internal metabolic reprogramming. This requires intact metabolic machinery 
and finely tuned signalling between the metabolic pathways. Although there 
are no dedicated studies defining the metabolic profile of macrophages in 
COPD patients , studies of other tissues and cells in COPD suggest that they 
are highly glycolytic with downregulated oxidative metabolism and 
mitochondrial dysfunction - which is likely to have far reaching consequences 
for cellular bioenergetics. Moreover, failure to undergo appropriate metabolic 
reprogramming in response to various stimuli could lead to impaired 
macrophage function and may account for the altered polarisation state seen 
in COPD macrophages51.  
We hypothesised that COPD macrophages have an altered metabolic profile 
and that defective cellular energetics may be driving our observed phenotype 
of macrophage dysfunction. To investigate, this we sought to define the 
metabolic status of COPD macrophages on a transcriptional level, both at 
baseline and in response to stimuli. We aimed to couple this with dynamic 
profiling to further understand COPD macrophage energetics, particularly in 
the context of impaired phagocytosis and efferocytosis. Lastly, we sought to 
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establish if differential substrate availability may be influencing COPD 
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Results: 
4.2 AM from COPD and Healthy Donors differ in their baseline 
transcriptional profile 
 
Following identification of a differential transcriptional response to co-
incubation with S. pneumoniae in COPD AM ( Figure 3.8), we generated a 
new dataset to establish if alterations existed at baseline or only in evoked 
transcriptional responses. Healthy AM and COPD AM were isolated from 
donors via bronchoalveolar lavage and then cultured in RPMI for 16 hours 
prior to isolating and analysing total cellular RNA ( n=3). Baseline Total RNA-
Sequencing was then performed to compare Healthy AM with COPD AM.  
Initial heat mapping revealed clear transcriptional differences between the 
two groups confirming that, at baseline, COPD AM are intrinsically different to 
Healthy AM. A total of 287 genes were significantly differentially expressed 
(DE) between resting state COPD and Healthy AM (significance was defined 
as P value £0.05,Fold Change > log21.5) (Figure 4.2.1). Of the 287 DE 
genes,  134 genes were more highly expressed in Healthy AM>COPD AM 
and 154 genes were more highly expressed in COPD AM>Heathy AM.  
Gene Ontology grouping of the genes more highly expressed in Healthy AM , 
revealed that metabolic processing was the second most differentially 
regulated biological process ,at baseline (Figure 4.2.2). Interrogation of 
individual metabolism-related genes upregulated in Healthy AM revealed 
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changes in solute transporters and AMPK regulation (a central mechanism 
for sensing energy status). A key finding was that ME1( Malic Enzyme 1) was 
also comparatively upregulated in Healthy AM. ME1 encodes a cytosolic, 
NADP-dependent enzyme which generates NADPH and, via oxidative 
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Figure 4.2.1: RNA-seq profiling reveals differences in baseline 
transcription between COPD and Healthy AM. 
AM were isolated from COPD and Healthy donors via bronchoalveolar lavage 
and cultured for 16 hours prior to collecting RNA for Total RNA-seq. (A) 
Heatmap of column normalized Z-scores for each gene identified as 
significantly altered between COPD and Healthy AM. Green indicates high 
expression, red indicates low expression. (B) Volcano plots displaying the 
log2 fold change between COPD and Healthy Controls. Log10 P values are 
plotted on the y-axis. Red dots (n = 287) are genes that are both highly 
altered as well as contain a significant P value = FC > log21.5 and P value  
£0.05. Orange dots contain genes which are FC >log21.5 but P value > 0.05. 
N=3 both groups. fc= Fold Change, DE = Differentially Expressed. 
A
B
DE Genes Healthy AM vs COPD AM
Healthy AM COPD AM
  
 
Chapter 4 : COPD Macrophages display an altered metabolic profile 




Figure 4.2.2: Transcriptional regulation of  metabolism differs between 
COPD and Healthy AM at baseline.  
(A) The top four Gene Ontology (GO) terms upregulated in Healthy AM , at 
baseline, compared to COPD AM. (B) Table illustrating key metabolic genes 
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4.3 AM from COPD have an altered metabolic response to 
Streptococcus pneumoniae.  
 
As transcriptional analysis revealed differences in metabolic regulation 
between COPD and Healthy AM at baseline, we investigated our existing 
transcriptomics data (outlined in figure 3.8) for a differential metabolic 
signature, in response to infection. COPD and Healthy AM were co-incubated 
with Streptococcus pneumoniae for four hours prior to generating RNA for 
transcriptional analysis. Once again, there was a clear difference in the 
metabolic transcriptional response between COPD and Healthy AM. After 
four hours co incubation with S. pneumoniae, Healthy AM had primarily 
upregulated genes related to oxidative phosphorylation, and to a lesser 
degree genes regulating glycolysis (no. of genes= 81 vs 16). This was in 
stark contrast to COPD AM, where only genes relating to glycolysis had been 
transcriptionally altered following infectious stimulus (n=40) (Figure 4.3 B). As 
discussed COPD AM have a globally reduced transcriptional response to 
infection, compared to Healthy AM ( Figure 4.3A). Consequently, the 
upregulation of glycolytic genes represented over 6% of total transcriptional 
change following exposure to S pneumoniae in COPD AM.   
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Figure 4.3: Affymetrix array reveals abnormal metabolic responses to 
infection in COPD AM. 
COPD and Healthy Donor AM were co-incubated with opsonised D39 
Streptococcus pneumoniae, MOI 10:1, for four hours prior to lysis and 
sequencing of total RNA via affymetrix array. (A) Venn diagram illustrating 
the number of genes upregulated or downregulated in Alveolar Macrophages 
in response to infection with S. pneumoniae D39. (B) COPD AM mount a 
distinctive metabolic response to infection, which differs from that of Healthy 
AM. Upregulation of glycolytic genes in COPD AM, represents 6% of the total 
genes upregulated in response to infection.  
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4.4 Metabolically profiling COPD macrophages in real time 
 
Once we established that COPD AM possess an altered metabolic 
transcriptional programme, both at baseline and following infectious stimulus, 
we undertook dynamic profiling of COPD macrophages to establish if these 
transcriptional differences resulted in impaired cellular energetics 
Seahorse technology provides a platform to metabolically profile cells in real 
time. The platform simultaneously measures changes in oxygen consumption 
(OCR -Oxygen Consumption Rate) to measure cellular respiration/oxidative 
metabolism and changes in pH (ECAR- Extracellular Acidification Rate), an 
indirect measure of glycolysis. These readings are taken at baseline and 
following injection of stressors compounds, enabling calculation of the 
reserve energy capacity of cells (Spare Respiratory Capacity and Glycolytic 
Reserve).  
In the Mitochondrial Stress Test, cells are incubated in Seahorse media 
supplemented with Glucose and Glutamine for 45 minutes prior to 
commencing the test. Basal rates are recorded before sequential injection of 
mitochondrial metabolism stressors, enabling calculation of Spare 
Respiratory Capacity. The injected compounds are Oligomycin – which shuts 
down ATP-synthase; FCCP - a potent ionophore which uncouples oxidative 
phosphorylation in the mitochondria; and Antimycin A&Rotenone - which 
respectively shut down complex 3 & 1 in the electron transport chain.(Figure 
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4.4 A). For the Glycolytic Stress Test, cells are incubated in Seahorse media 
supplemented with Glutamine only for 45 minutes prior to beginning the test. 
Basal glycolytic rates are recorded following injection of Glucose. 
Subsequent injection of Oligomycin and 2DG (which shuts down glycolysis ) 
enables calculation of Glycolytic reserve (Figure 4.4 B). Both protocols are 
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Figure 4.4: Seahorse profiling of cellular energetics. 
(A)The Mitochondrial Stress test which determines the maximal oxidative 
metabolism of the cell, while also recording glycolytic metabolism (via 
changes in pH). (B) The Glycolysis Stress test which determines glycolytic 
parameters by measuring pH change. 
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4.5 COPD AM display impaired bioenergetics compared to 
Healthy Donors 
Metabolic profiling of COPD AM revealed highly significantly reduced energy 
reserves in both oxidative metabolism and glycolysis, compared to Healthy 
donor AM. Spare Respiratory Capacity was significantly reduced in COPD 
AM (8.5±0.4 vs 4.2± 0.4, a 51% reduction) (Figure 4.5.1 A). This was 
regardless of current smoking status (unpaired t-test, p value = 0.103). 
Similarly, Glycolytic Reserves were significantly reduced in COPD AM, 
irrelevant of smoking status (0.84±0.04 vs 0.17±0.04, an 80% reduction, 
smoking status p value= 0.15) (Figure 4.5.1 B). The metabolic potential of 
COPD AM - the ability to increase metabolic rates above basal rates in 
response to increased energy demand- was significantly reduced in COPD 
AM (254% vs 190% in Healthy AM).  
Crucially, the loss of energetic reserves in both oxidative metabolism and 
glycolysis occurred in the context of reduced or equivalent basal metabolic 
rates. Basal OCR rates were, in fact, significantly lower in COPD AM with 
near equivalent basal rates in ECAR . While there was no significant 
difference between basal OCR rates in current and ex smoking COPD 
donors, a definite trend towards lower basal ECAR rates was observed in 
current smokers (Smoker vs Ex-smoker, OCR P value= 0.41, ECAR P 
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Figure 4.5.1: COPD Alveolar Macrophages display altered metabolic 
profiles with reduced energy reserves.  
Mitochondrial Stress (A + C) and Glycolytic (B) stress testing was performed 
in COPD and Healthy Donor AM. Reserves in both Oxidative metabolism (A) 
and Glycolysis (B) were significantly reduced in COPD AM. (C) Metabolic 
potential was significantly reduced in COPD AM. Green circles/squares 
indicate current smokers. COPD Smoker vs Ex-smoker, Spare Respiratory 
Capacity P value= 0.103, Glycolytic Reserve P value=0.158. All P values 
calculated by unpaired t-test, ** P£0.01, *** P£0.001, **** P£0.0001. Data 
represents individual values and mean ± SEM. ECAR= Extracellular 
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Figure 4.5.2: Basal OCR rates are reduced in COPD AM.  
Mitochondrial Stress (A) and Glycolytic (B) stress testing was performed in 
COPD and Healthy Donor AM. (A) Basal OCR rates were significantly lower 
in COPD AM than in Healthy Donor AM. (B) Basal ECAR rates were 
comparable between the two donor groups. Green circles/squares indicate 
current smokers. COPD Smoker vs Ex-smoker, OCR P value= 0.41, ECAR P 
value=0.06. P values calculated by unpaired t-test, *P£0.05, ns= not 
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4.6 COPD AM primarily upregulate glycolysis to meet increased 
energy demand 
 
In health, metabolic plasticity is a key feature of macrophage function. It enables 
a highly adaptable bioenergetic profile but also mediates key phenotypic 
switches. To evaluate the ability of COPD AM to engage different metabolic 
pathways we interrogated the energy response across both oxidative 
metabolism and glycolysis in COPD AM, using Seahorse.  
Compared to Healthy AM, COPD AM had a significantly reduced OCR/ECAR 
ratio. This preponderance for glycolysis over oxidative phosphorylation was 
mirrored in the ATP-linked-OCR ratios. ATP-linked-OCR is calculated as the 
reduction in oxygen consummation following shut down of ATP 
synthase/Complex 5 with Oligomycin (Figure 4.4 A). In COPD AM, absolute 
ATP-linked-OCR was reduced at baseline. It represented a similar percentage 
of Basal OCR but, critically,  a significantly higher percentage of the Maximal 
Respiratory Capacity in COPD AM ( Figure 4.6.1 A–D). This suggests that 
COPD AM are operating closer to their maximal respiratory capacity at all times 
and are unable either to recruit additional mitochondria or to increase ATP 
production in existing mitochondria .  
This apparent defect in mitochondrial function was particularly evident during 
energy phenotyping of COPD AM. To phenotype the energy response in the cell, 
absolute change in ECAR was plotted against absolute change in OCR 
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following injection of stressor compounds, to evaluate how the cell differentially 
employed either metabolic pathway to meet increased energy demand (Figure 
4.6.2).   
In response to injection of the stressor compounds ,Healthy AM increased both 
ECAR and OCR  rates. In contrast, COPD AM increased ECAR rates , albeit not 
to the level of Healthy AM, but only displayed a modest increase in OCR 
compared to Healthy donors. ( Figure 4.6.2 A) This was more apparent still 
when we co incubated the macrophages with an additional stimulus, mirroring 
our functional assays. AM were co incubated for 90 mins with 20 hr apoptotic 
neutrophils. Following co-incubation with neutrophils, there was a further 
exaggeration of the dominant glycolytic energy response in COPD AM 
compared to Healthy AM. Once more, Healthy AM employed both metabolic 
pathways , in contrast to COPD AM ,which displayed a persistent drive to meet 




Chapter 4 : COPD Macrophages display an altered metabolic profile 




Figure 4.6.1: Mitochondrial stress testing suggests a redundancy in 
mitochondrial units in Healthy AM , which is not present in COPD AM. 
(A) Healthy AM display a significantly higher OCR/ECAR ratio than COPD 
AM. (B) OCR consumption linked to ATP generation, as calculated by the 
reduction in OCR following injection of Oligomycin, was significantly higher in 
Healthy AM. (C) ATP-linked-OCR was an equivalent percentage of Basal 
OCR consumption in Healthy and COPD AM. (D) However it  presented a 
significantly higher percentage of Maximal OCR Consumption in COPD AM. 
All figures n=9/10 (Healthy/COPD). P values calculated by unpaired t-test, 
P£0.05 used to determine significance. Data represents individual values and 
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Figure 4.6.2: COPD AM have an over reliance on glycolysis to meet 
increased energy demand. 
Mitochondrial stress testing was performed to phenotype the energy 
response in both COPD and Healthy donor AM after injection of the standard 
Seahorse stressor compounds. (A) Absolute change in ECAR was plotted 
against absolute change in OCR following injection of stressor compounds. 
(B) Cells were co-incubated with 20hr apoptotic neutrophils for 90 mins prior 
to conducting energy phenotyping. Again, absolute change in ECAR was 
plotted against absolute change in OCR following injection of stressor 
compounds. Apoptotic neutrophil MOI 10:2 Healthy AM; MOI 15:2 COPD 
AM. 
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4.7 COPD MDM exhibit reduced energetic reserves when 
compared to Healthy donors 
 
To establish if the altered bioenergetics observed in COPD AM were driven 
by the lung microenvironment or reflected a systemic defect, we evaluated 
cellular energetics in COPD and Healthy donor peripherally derived MDM.  
Seahorse metabolic profiling of COPD MDM revealed depleted reserves in 
both oxidative metabolism and glycolysis, compared to Healthy donors. 
COPD MDM had significantly reduced Spare Respiratory Capacity (5.16±0.9 
vs 2.75±0.6, a 47% reduction), Glycolytic Reserve( 0.19±0.03 vs 0.05±0.02, a 
75% reduction) and a significantly reduced Metabolic Potential (22%vs159%) 
( Figure 4.7.1). Smoking status did not significantly alter Spare Respiratory 
Capacity in COPD MDM (unpaired t-test, p=0.17). The number of ex-smoker 
COPD donors assessed in the Glycolysis Stress Test was too small for 
statistical analysis.  
Reduced energetic capacity in COPD MDM existed in the presence of basal 
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Figure 4.7.1: COPD Monocyte-Derived Macrophages display altered 
metabolic profiles with reduced energy reserves.  
Mitochondrial Stress (A + C) and Glycolytic (B) stress testing was performed 
in COPD and Healthy Donor MDM. Reserves in both Oxidative metabolism 
(A) and Glycolysis (B) were significantly reduced in COPD MDM. (C) 
Metabolic potential was significantly reduced in COPD MDM. Green 
circles/squares indicate current smokers. P values calculated by unpaired t-

















































































Chapter 4 : COPD Macrophages display an altered metabolic profile 
  106 
 
 
Figure 4.7.2: Basal metabolic rates are comparable in COPD and 
Healthy MDM. 
Mitochondrial Stress (A) and Glycolytic (B) stress testing was performed in 
COPD and Healthy Donor MDM. There was no significant difference in Basal 
OCR ( A ) and ECAR ( B) rates between COPD and Healthy MDM. Green 
circles/squares indicate current smokers P values calculated by unpaired t-
test, P£0.05 used to determine significance. (A) p= 0.56, (B) p= 0.84.  Data 
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4.8 Energy phenotyping reveals a divergent response in COPD 
MDM compared to COPD AM 
 
Whilst COPD AM and MDM both displayed reduced energy reserves, it was 
unclear if COPD MDM would share the marked reliance on glycolysis exhibited 
by COPD AM.  
Unlike COPD AM, COPD MDM had equivalent OCR/ECAR ratios compared to 
Healthy Donors. They had a comparable ATP-linked-OCR profile compared to 
Healthy MDM, although, similar to COPD AM ,there was a trend towards ATP-
linked-OCR representing a higher proportion of the Maximal Respiratory 
Capacity (38% vs 47%) ( Figure 4.8.1 D).  
Furthermore, phenotyping of the energy response in COPD MDM also revealed 
a divergent profile to that of COPD AM (Figure 4.8.2). COPD MDM had a 
reduced energetic response compared to Healthy MDM, but this did not 
predominately effect one metabolic pathway over the other, with similar 
reductions seen in both OCR and ECAR. Due to the more varied basal rates 
detected in MDM than AM, increases in OCR & ECAR in COPD MDM, were 
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Figure 4.8.1: COPD MDM display similar rates of ATP linked OCR to 
Healthy MDM. 
There was no significant difference in Basal OCR/ECAR ratios between 
COPD and Healthy donor MDM. OCR-linked-ATP was reduced but not 
significantly, in COPD MDM compared to Healthy MDM. ATP-Linked-OCR 
was a similar percentage of both Basal and Maximal respiration in Healthy 
and COPD MDM. P values calculated by unpaired t-test, P£0.05 used to 
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Figure 4.8.2: Energy Phenotyping of COPD MDM revealed a suppressed 
maximal energetic response, but comparable utilization of oxidative 
metabolism and glycolysis.  
Mitochondrial stress testing was performed to phenotype the energy 
response to injection of standard seahorse stressor compounds in both 
COPD and Healthy donor MDM. In all but one donor , COPD MDM failed to 
reach the maximal energetic response of Healthy MDM- represented by the 
dotted line. Testing did not reveal a differential utilization of either pathway to 























COPD MDM : % increase in ECAR/OCR 
 with stressor compounds
Healthy Control= 100% 
  
 
Chapter 4 : COPD Macrophages display an altered metabolic profile 
  110 
 
4.9 Resting state COPD Macrophages upregulate the glycolytic 
pathway, as detected by LC-MS  
 
Seahorse profiling provides dynamic information on the metabolic capacity 
and phenotype of macrophages. However, as it quantifies broad dynamic 
changes and is based on inferred measurements, we sought to measure 
individual metabolite abundance via High Performance Liquid 
Chromatography Mass Spectrometry (HPLC-MS). 
HPLC-MS analysis of both COPD and Healthy donor macrophages revealed 
a significant and global increase in the abundance of glycolytic 
intermediaries, relative to Healthy Controls (Figure 4.9.1 A-B). Crucially, this 
happened throughout the glycolytic pathway suggesting this was not driven 
by a break in flux through glycolysis leading to accumulation of preceding 
metabolites ( Figure 4.9.1 C). In contrast to glycolytic intermediaries, we did 
not detect a significant difference in TCA cycle metabolite abundance in 
COPD AM compared to Healthy donors (Figure 4.9.2 A). This indicates that 
in COPD AM there is a targeted increase in glycolysis, rather than global 
upregulation of metabolism. (Due to an issue with protein normalisation, TCA 
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Figure 4.9.1: Resting state COPD AM and MDM exhibit a global increase 
in Glycolytic intermediaries. 
Resting state AM (A) and MDM (B) from COPD and Healthy donors were 
lysed in methanol to determine metabolite abundance via Liquid-
Chromatography-Mass-Spectrometry. Abundance is plotted as relative to 
Healthy Controls (Fold Change). Both COPD AM and MDM have an increase 
in glycolytic intermediaries throughout the Glycolytic pathway (C). (A) n=8/6 , 
(B) n= 4. P value calculated via  2-way ANOVA. P* £0.05, ** P£0.01. Data 
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Figure 4.9.2. COPD and Healthy Donor AM display comparable levels of 
TCA cycle intermediaries.  
Resting state AM from COPD and Healthy donors were lysed in methanol to 
determine relative metabolite abundance via Liquid-Chromatography-Mass-
Spectrometry. There was no significant difference detected in TCA cycle 
metabolite abundance (A). COPD AM metabolite abundance is shown 
relative to Healthy donors (Fold change) N=8/6. P value calculated via 2-way 
ANOVA. P£0.05 used to determine significance, (A) p= 0.336, Data represents 
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4.10  Energy Charge is reduced in COPD AM compared to 
Healthy donors  
 
COPD AM displayed reduced reserves in both Glycolysis and Oxidative 
metabolism coupled with an over reliance on glycolysis, a less efficient 
metabolic pathway. We sought to determine the energetic consequences of this, 
particularly in the context of impaired phagocytosis and efferocytosis observed 
in COPD macrophages. Adenosine Triphosphate (ATP) is often referred to as 
the "molecular currency of intracellular energy transfer” and is used to power 
diverse cellular functions. Hydrolysis of the phosphate groups in ATP 
generates ADP and subsequently AMP, releasing a phosphate group and 
thus molecular energy with each reaction.  
LC-MS analysis of COPD AM uncovered a significantly altered absolute 
abundance of ATP intermediaries, with reduced ATP levels in COPD AM (Figure 
4.10 A). Energy charge as calculated by the equation [ ATP + ½(ADP) / ATP + 
ADP + AMP ], is a widely utilised index for measuring the energy status of a 
cell. COPD AM displayed significantly reduced Energy Charge compared to 
Healthy AM. Similarly the ATP:ADP ratio was significantly reduced in COPD 
AM. A reduction in both ratios coupled with alterations in absolute 
abundance, indicates that it is not just the absolute amount of ATP available, 
but also the energetic status of ATP molecules present, that is reduced in 
COPD.   
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Figure 4.10: Resting state COPD AM have reduced Energy availability 
compared to Healthy Donor AM . 
Resting state AM from COPD and Healthy and donors were lysed in 
methanol to determine relative metabolite abundance via Liquid-
Chromatography-Mass-Spectrometry. ATP abundance was reduced in 
COPD AM ( A) as was calculated energy charge(B) and ATP:ADP ratios (C), 
compared to Healthy AM. COPD AM metabolite abundance is shown relative 
to Healthy donors . P value calculated via  2-way ANOVA with Sidak’s 
multiple comparisons (A), Unpaired T-test (B+ C) , * P£0.05, ** P£0.01. Data 
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4.11  Differential substrate availability for glycolysis does not 
account for altered metabolism in COPD macrophages 
 
As substrate availability can exert a high degree of influence on macrophage 
metabolism, we measured glucose uptake in COPD and Healthy donor 
macrophages. Uptake of 2-NBDG, a commonly utilised fluorescently labelled 
glucose analogue, revealed comparable levels of glucose uptake in COPD  
and Healthy donor MDM (Figure 4.11 A). Due to marked auto fluorescence 
we were unable to conduct this assay in COPD AM. 
Cells are glucose deprived for 45 mins prior to the Seahorse Glycolysis 
Stress test , consequently there is a large rise in ECAR following the initial 
glucose injection. We interrogated the increase in ECAR rates following 
glucose injection as an equivalent rise in ECAR in the 5 minutes following 
glucose injection would suggest a similar rate of glucose uptake between 
COPD and Healthy donor macrophages. We did not detect any difference in 
fold change increase in ECAR pre and post glucose injection in either AM or 
MDM (Figure 4.11 B-C) . As prolonged glucose deprivation can lead to 
upregulation of glucose transporters , we used pre-test 16 hour glucose 
deprivation as a positive control. Reassuringly this ratio did detect an inferred 
augmentation of glucose uptake in both AM and MDM (Figure 1.11 B-C).  
Glycogen stores can be broken down to shuttle substrate into glycolysis, 
consequently we measured glycogen stores in macrophages from COPD and 
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Healthy donors. Although stores were low overall, there was no significant 
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Figure 4.11: Differences in glycolytic rates are not determined by 
differential glucose uptake/glycogen breakdown in COPD Macrophages. 
 (A) Glucose uptake was measured by culturing cells with 2-NBDG, a 
fluorescently-labelled deoxyglucose analogue for two hours prior to 
measuring uptake on flow cytometry. Uptake rates were normalised to 
median cell fluorescence of unstained cells. There was no significant 
difference detected between donor groups. (B)The increase in ECAR rates 
prior to and following injection of Glucose during Glycolysis Stress Tests was 
measured in AM ( B ) and MDM (C). Prior glucose deprivation x 16 hrs (NG) 
was used as a positive control.(D) Using a colorimetric assay, glycogen 
stores in MDM and AM were measured. P£0.05 used to determine 
significance. Data represents individual values and mean ± SEM.   MFI= 
Median Fluorescence Intensity, FMO =Fluorescence minus one, unstained 
cells.  
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4.12  Profiling of Bronchoalveolar lavage fluid suggests that 
availability of substrate in the alveolar space does not differ 
between COPD and Healthy donors 
 
To determine if substrate availability in Bronchoalveolar lavage (BAL) fluid 
was influencing metabolic phenotypes in COPD, we quantified the two main 
substrates utilised by Alveolar macrophages- Glucose and Glutamine - in 
BAL from COPD and Healthy Donors.  Both Glucose and Glutamine levels 
were comparable between the two groups (Figure 4.12 A+B). Interestingly 
lactate levels were elevated in COPD BAL (Figure 4.12 C). Coupled with 
increased lactate levels intracellularly in AM, as detected by LC-MS,  this 
provides further evidence for increased glycolysis in COPD macrophages.   
It is important to note that BAL return can vary with patients and so samples 
retrieved from one donor may be more dilute than another. It is challenging to 
normalise BAL in the context of our study group, as proteins such as Albumin 
or the cellularity of the BAL, will vary between disease state and Healthy 
lung. However, in profiling BAL fluid our aim was to identify if there were any 
large discrepancies present in substrate levels.   
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Figure 4.12: Profiling of Bronchoalveolar lavage fluid suggests 
substrate availability fluid does not account for metabolic differences in 
COPD macrophages. 
Colorimetric assays were used to determine (A) Glucose, (B) Glutamine and 
(C) Lactate concentration in Bronchoalveolar Lavage (BAL) fluid from COPD 
and Healthy donors. P value calculated by unpaired t-test, * P£0.05. Data 
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4.13  COPD AM display a refractory metabolic profile. 
 
As discussed, metabolism is central to macrophage function and 
macrophage ability to undergo metabolic programming in response to varying 
stimuli is a critical feature of their plasticity. It is generally accepted that “M1” 
or pro-inflammatory stimulation leads to enhanced glycolysis in 
macrophages, where as “M2” or reparative type stimuli induce oxidative 
phosphorylation.  
Apoptotic neutrophils represent an M2 stimulus but are also a source of 
substrate for metabolism following efferocytosis and subsequent 
breakdown105. To challenge metabolic plasticity and also to mirror our 
functional assays, we co incubated AM from COPD and Healthy donors with 
20hr apoptotic neutrophils (AN). AN were co incubated with AM at an MOI 
10:2 in Healthy Donors and 15:2 in COPD AM ( to allow for reduced 
efferocytosis), for 90 minutes prior to their removal. A Mitochondrial stress 
test and Glycolytic stress test was subsequently performed.  
Healthy AM displayed a significant increase in Spare Respiratory Capacity 
(SRC) following co-incubation with AN, with no change in Spare Respiratory 
Capacity evident in COPD AM ( Figure 4.13 A). Strikingly there was no 
increase in Glycolytic Reserve in either Healthy or COPD AM following co-
incubation with AN ( Figure 4.13 B). Furthermore, treatment of Healthy AM 
with established M2 polarising stimuli, IL10 &IL4/13, failed to induce an 
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increase in SRC ( Figure 4.13 C). Taken together these data suggest that the 
increase observed in SRC in Healthy AM following co-incubation with 
apoptotic neutrophils, is not due to a polarisation mediated increase in 
oxidative metabolism, instead, it is potentially driven by shuttling of 
scavenged substrate into this pathway. Despite an increased MOI to partially 
compensate for reduced efferocytosis rates, COPD AM did not show any 
change in metabolic parameters following presumed low level efferocytosis.  
   
  
 
Chapter 4 : COPD Macrophages display an altered metabolic profile 
  122 
 
 
Figure 4.13: Healthy donor macrophages display efferocytosis 
mediated enhancement of oxidative metabolism. 
Healthy and COPD donor macrophages were co incubated for 90mins with 20 
hr apoptotic neutrophils (+AN) prior to performing Mitochondrial (A) and 
Glycolytic (B) stress testing. Spare Respiratory Capacity (SRC) and Glycolytic 
Reserve (GR) were calculated as before. (A) Healthy AM (n=8) have an 
increased SRC compared to COPD AM (n=5) .Healthy AM display a significant 
enhancement of their respiratory capacity following neutrophil efferocytosis.  
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(Figure 4.13 continued) (B) Healthy AM( n=5) have an increased GR 
compared to COPD AM (n=3), there was no change in GR induced by 
neutrophil efferocytosis in either group. (C) Healthy Donor AM (n=3) were co 
incubated with 20hr apoptotic neutrophils (+AN) or treated for 16 hours with 
20ng/ml IL-10 or IL-4/13. M2 polarizing stimuli did not induce a change in 
respiratory capacity , in contrast with efferocytosis of apoptotic neutrophils. P 
values calculated via (A-B) Two-way ANOVA (C) One-way ANOVA , with Sidak’s 
multiple comparisons. *P£0.05, ****P£0.0001. Data represents individual values 
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These data highlight the markedly altered metabolic profile of COPD 
macrophages, both at baseline and in response to stimulation, with a likely 
profound effect on phenotype and cellular energetics.  
It was interesting to note that the COPD AM transcriptome is intrinsically 
different to that of Healthy AM, even at baseline. In particular, the discovery 
that metabolic regulation was one of the most differentially expressed 
modules between the COPD and Healthy AM, provided evidence for our 
hypothesis that primary metabolism and cellular energetics are driving the 
phenotype of macrophage dysfunction in COPD. Perhaps the most striking 
finding however, was the divergence in transcriptional responses to co-
incubation with S. pneumoniae. Bacterial pathogens are known to invoke an 
immediate glycolytic response but at 4 hours Healthy donor AM markedly 
upregulated genes for oxidative phosphorylation (oxphos). This likely 
represents a time dependent  a switch in metabolism106. COPD AM, by 
comparison, failed to transcriptionally activate the oxphos module, instead 
there was a presumably persistent upregulation of glycolytic genes, at 4 
hours. Though COPD AM have reduced bacterial phagocytosis, a reduction 
of »25% is unlikely to account for this discrepancy. Rather, this suggests an 
apparent failure to undergo appropriate metabolic reprogramming. This was 
evident also in the contrasting responses to co-incubation with apoptotic 
neutrophils. While Healthy donor AM increased oxidative metabolism 
  
 
Chapter 4 : COPD Macrophages display an altered metabolic profile 
  125 
 
following efferocytosis, COPD AM metabolism remained unchanged. This 
occurred despite increasing the quantity of apoptotic neutrophils co-
incubated with in COPD, to account for reduced efferocytosis. The findings 
raise the possibility that COPD macrophages have a refractory metabolic 
phenotype and may be unable to sense or respond appropriately to their 
environment. 
Seahorse profiling of COPD macrophages revealed a profound depletion of 
critical energy reserves in COPD AM and MDM, in both glycolysis and 
mitochondrial respiration. A consequent reduction in ATP and energy charge 
was confirmed, using LC-MS.  It is tempting to think that this metabolic 
exhaustion phenotype may be due to the hostile lung microenvironment 
encountered in COPD, characterised by poor substrate availability and 
chronic oxidant stress. Crucially, however, this phenotype was present in 
both AM and peripherally circulating monocytes (which we cultured into 
MDM) . Secondly, cells were cultured ex vivo in oxygen and glucose replete 
media prior to performing assays. This suggests that alterations in metabolic 
profile of COPD macrophages are “hard wired” and that cellular energetics in 
COPD remain altered despite culture conditions. The presence of a systemic 
defect in macrophage function raises important questions around epigenetic 
modification of cellular function in COPD, which merits further investigation.  
Interestingly, while COPD AM and MDM both experienced depleted energy 
reserves, they exhibited a divergent dependence on glycolysis. Energy 
phenotyping revealed that COPD AM had reduced energy capacity 
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compared to Healthy AM, but COPD AM were comparatively overly reliant on 
glycolysis as the main source for ATP. This was even more pronounced 
when additional ATP was required (following co-incubation with Apoptotic 
neutrophils). It is possible that mitochondrial dysfunction , as previously 
described in COPD and suggested in our data by differences in OCR-Linked-
ATP ratios between COPD and Healthy AM, may be driving this over reliance 
on glycolysis96. COPD MDM, in contrast, had an equally reduced energetic 
capacity across both glycolysis and oxidative metabolism, suggesting that 
COPD MDM may possess a  higher degree of metabolic plasticity than AM. 
The monocytes, from which we cultured these MDM, circulate in a more 
substrate enriched environment and are less exposed to oxidative stress and 
subsequent mitochondrial damage than AM, which may account for this 
finding. 
LC-MS quantification of individual metabolite abundance revealed that COPD 
AM and MDM had significantly higher levels of glycolytic intermediaries, 
compared to Healthy Controls. Coupled with the glycolytic dominance 
observed in energy phenotyping and the transcriptional responses of COPD 
macrophages to infection, this provides further compelling evidence for a 
refractory metabolism in COPD. As discussed, a persistently glycolytic 
metabolic programme will induce phenotypic changes in COPD 
macrophages via crosstalk between metabolic pathways and signalling via 
metabolic intermediaries and enzymes.  
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There are some discrepancies between Seahorse data and the LC-MS 
findings which require discussion - namely comparable basal ECAR readings 
between COPD and Healthy donors versus increased glycolysis in COPD as 
detected via LC-MS. This discrepancy may relate to methods of detection 
and or assay conditions. While seahorse provides excellent information about 
dynamic metabolic changes, it is an indirect measure of glycolysis. Thus, 
dynamic changes eg quantifying Glycolytic reserve, are likely more accurate 
than baseline Seahorse readings. Secondly, for the Glycolytic Stress Test, 
cells are deprived of glucose for 45 minutes prior to the test. This period of 
relative starvation may result in differential basal glycolysis rates between 
COPD and Healthy macrophages, giving rise to the observed discrepancy 
between LC-MS and Seahorse findings. Similarly, the utilisation of indirect 
measurements during Seahorse may account for the differences observed in 
basal OCR rates (reduced in COPD) against comparable TCA cycle 
intermediaries abundance in LC-MS.  
Lastly, differences in substrate availability do not appear to be a driver for 
altered metabolism in COPD macrophages. Comparable levels of BAL 
Glucose and Glutamine coupled with equal intracellular glycogen storage, 
suggest that access to substrate is not directing the distinctive metabolic 
phenotype observed in COPD macrophages.  
In summary, in keeping with previous findings of elevated glycolysis in COPD 
lung tissue and airway smooth muscle cells , COPD AM and MDM 
upregulated glycolysis, as detected by Affymetrix array, Seahorse energy 
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phenotyping and LC-MS measurement of metabolite abundance 93 94. 
Crucially ,this increase in glycolysis was coupled with reduced energy 
reserves in both glycolysis and oxidative metabolism and a reduced energy 
charge. Taken together these data suggests that COPD macrophages lack 
the requisite metabolic arsenal to carry out high energy demanding 
processes such as efferocytosis and phagocytosis and that defective 
macrophage function in COPD may be a metabolic phenotype. In particular 
they display a rigid metabolic phenotype which suggests an inability to 
undergo appropriate metabolic reprogramming (Figure 4.12). Future 
directions should focus on the possibility that mitochondrial impairment-due 
to high level of oxidative stress- is responsible for the lack of metabolic 
plasticity observed in COPD. Similarly, examination of central metabolic 
sensing pathways such as mTOR may yield exciting insights into this 
phenotype. Additionally, certain noteworthy genes, identified as significantly 
altered at baseline in the transcriptomics data-set, merit particular attention. 
ME1 (Malic Enzyme 1) is the rate regulating enzyme for the cytosolic malate-
pyruvate shut. In catalysing malate to pyruvate, it generates NADPH for 
redox power and fatty acid synthesis and the pyruvate generated can in turn 
be shuttled back into the TCA cycle. As high oxidative stress , mitochondrial 
dysfunction and supressed oxidative phosphorylation are features of COPD,  
changes in ME1 transcription may be of high importance in generating an 
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5 COPD macrophage dysfunction is rescued by 
activation of the Nrf2 module 
 
5.1 Introduction 
Endogenously produced reactive radical species are a normal by-product of 
cellular physiology. Cell derived oxidants or reactive oxygen species (ROS) 
such as superoxide anion (O2-) and hydrogen peroxide (H2O2) are produced 
mostly by the mitochondria during respiration (mROS) but also by the 
NADPH oxidase unit in response to pathogens and via oxidoreductase and 
metal-binding reactions taking place in the cell. At physiological (low) levels 
ROS are considered critical for cell signalling and maintaining homeostasis. It 
is well documented that in macrophages, ROS abundance can influence a 
diverse array of cellular functions including induction of apoptosis, 
polarisation, migration and phagocytosis107,108. Similarly, ROS production via 
the NADPH oxidase unit, are crucial for bacterial killing109. In fact, deficiency 
of NADPH generated ROS gives rise to Chronic Granulomatous disease, 
characterised by recurrent severe infections.  
As well as endogenously generated ROS, macrophages are also exposed to 
a variety of exogenous sources of ROS. Apoptotic cells can release ROS into 
the extracellular environment and ROS production can be induced by 
exposure to inflammatory cytokines. However, the largest contributor to 
exogenous ROS generation in the lung, is environmental exposure. A single 
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cigarette contains upwards of 1017 free radicals110. Tobacco smoke also 
contains high quantities of toxic compounds capable of inducing intracellular 
ROS production. More recently, increasing attention is being paid to the high 
volume of particulate matter caused by air pollution. This particulate matter is 
inhaled and retained in the lung where, similar to tobacco smoke, it has the 
capacity to generate reactive radical species111.   
As ROS production is a normal variant of cellular function, cells are well 
adapted to cope or “neutralise” ROS via enzymatic and non-enzymatic anti-
oxidant responses, maintaining a healthy redox state within the cell. However 
if ROS levels become too high, either by aberrant intracellular production or 
via high level exposure to exogenously produced ROS, then these initial 
coping mechanisms can become overwhelmed, resulting in oxidative stress 
and consequent damage to DNA, proteins and lipid peroxidation. Organelles 
such as mitochondria – which due to limited repair mechanisms are 
exquisitely sensitive to oxidative stress- become damaged, leading to further 
mROS release and the generation of a self-perpetuating cycle of damage. 
Hence the cellular defence to oxidative stress, which is primarily regulated on 
a transcriptional level, is highly tuned. 
The transcription of genes responsible for combatting oxidant stress is 
regulated by the ARE- the antioxidant response element. The transcription 
factor Nrf2 is considered the master regulator of the antioxidant response 
and acts on these AREs (cis-acting elements), thereby inducing the 
expression of key anti-oxidant and cytoprotective genes, minimising 
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oxidative-stress induced damage. The ARE was initially identified in the 
promoter regions of two key detoxifying genes – NQO1 (NAD(P)H:quinone 
oxidoreductase 1) and GSTA2 (glutathione S-transferasea2)112,113. Since 
then it has been found to regulate upwards of 600 genes. Activation of the 
ARE leads to upregulation of phase 2 detoxifying genes, particularly those 
relating to the availability of Glutathione, the chief endogenous antioxidant. 
Antioxidants such as such as Heme Oxygenase 1 ( HO1) and Superoxide 
dismutase (SOD1) are also upregulated via ARE activation. While these 
compounds and enzymes are able to bind to, and reduce reactive anions and 
metals, they rely on nicotinamide pairs NADP+/NADPH (Nicotinamide 
adenine dinucleotide phosphate) and NAD+/NADH (Nicotinamide adenine 
dinucleotide) to enable these reactions. These co factors donate a hydrogen 
ion to reducing equivalents such as Glutathione and Thioredoxin, restoring 
them from their oxidised to reduced form. Here again Nrf2 mediated 
activation of the ARE dictates redox power by increasing NAPDH generation. 
Expression of G6PD (Glucose-6-phosphate dehydrogenase) and PGD 
(Phosphogluconate dehydrogenase) -which increase NADPH generation 
through the Pentose Phosphate Pathway- and ME1 (Malic Enzyme 1) and 
IDH1 (Isocitrate dehydrogenase 1)  -via NADPH generating shunts in the 
Kreb’s Cycle- are regulated by Nrf2. Interestingly, Nrf2 mediated ARE 
activation regulates certain antioxidant gene expression under basal 
conditions also, suggesting the enhancer plays a critical role in maintaining 
redox balance , not only during stressed conditions but also in neutralising 
ROS generated under physiological conditions114.In addition, recent evidence 
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suggests that Nrf2 anti-inflammatory effects are not just limited to the 
elimination of ROS. Nrf2 was found to interrupt lipopolysaccharide-induced 
transcriptional upregulation of proinflammatory cytokines, including IL-6 and 
IL-1β, cementing it as the cardinal regulator of cellular defence to oxidant 
stress115.  
Emerging experimental evidence suggests that Nrf2 regulated networks are 
not limited to antioxidant responses, but also modulate primary metabolism 
and bioenergetics (Figure 5.1). Studies have shown the Nrf2 activation 
increases glucose uptake and as mentioned, increases flux through the 
Pentose Phosphate Pathway (PPP) . Moreover, interference with glucose 
supply or flux through the PPP leads to a reduction in Nrf2 mediated 
Antioxidant responses, emphasising the crosstalk between metabolism and 
detoxification 116,117. In keeping with impaired mitochondrial oxidation,  a 
seminal study establishing the role of Nrf2 in cellular energetics 
demonstrated impaired mitochondrial respiration, reduced mitochondrial 
membrane potential and a reduced ATP level, in Nrf2-/- mice 118 . Conversely, 
Nrf2 deficiency lead to an increase in glycolytic intermediaries and an 
increase in Glycolysis-derived ATP 118,119 . While it was not definitely 
established in either of these studies, it was suggested that Nrf2 mediated 
improvement in oxidative stress protected the mitochondria from damage, 
enabling it to process substrate successfully. It has also been hypothesised 
that increased flux through the non oxidative branch of the PPP generates 
the requisite nucleotides for mitochondrial biogenesis120. Thus it would 
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appear that Nrf2 activation can induce metabolic reprogramming which 
supports the anti-oxidant response and vice versa.  
 
Figure 5.1: Nrf2 mediated modulation of cellular metabolism and anti-
oxidant responses. Known Nrf2 targets are listed in black italics.  
ARE= Anti-oxidant Response Element. GCL= Glutathione Cysteine Ligase, 
xCT=Cystine transporter, GSR= Glutathione Synthase Reductase, 
GLUT1=Glucose Transporter 1, G6PD= Glucose-6-phosphate 
dehydrogenase, PGD=Phosphogluconate dehydrogenase, TALDO1= 
Transaldolase 1, TKT=Transketolase, NADP+/NADPH=Nicotinamide adenine 
dinucleotide phosphate,  ME1=Malic Enzyme 1, PDH=Pyruvate 
Dehydrogenase. IDH1=Isocitrate dehydrogenase 1.  
 
Nrf2 tissue expression is most pronounced in the lung, intestine and kidney- 
sites where key detoxification occurs. In the lungs, it is predominantly 
expressed by alveolar macrophages and epithelial cells. Under normal 
conditions Nrf2 is predominantly cytoplasmic where its expression is 
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regulated by Kelch ECH Associating Protein 1 (KEAP-1). A recurrent theme 
in oxidant signalling and antioxidant regulation is reactive cysteine thiol–
based redox signalling, which is the premise for Nrf2 regulation by KEAP1. 
When basal levels of oxidative stress are low, KEAP-1 binds to the N2 Ne-h 
terminal of NRF2, leading to its cytoplasmic sequestration, ubiquitination and 
subsequent proteasomal degradation. However in the presence of oxidative 
electrophiles, key modifications of the cysteine thiol residues on KEAP-1, 
lead to its dissociation from Nrf2. Nrf2 is then free to migrate to the nucleus 
where it heterodimerizes with another basic leucine zipper protein, such as 
small Maf or Jun and then binds to the antioxidant response element (ARE) 
in target gene promoters121. At present our understanding is that Nrf2 self 
regulates by reducing oxidative stress and so increasing its sequestration by 
KEAP1. In addition to this, one study has found that Nrf2 can induce KEAP1 
expression, establishing a feedback loop 122.Another transcription factor 
Bach1, is known to competitively bind to the ARE, supressing gene 
expression146. Hence the status of the Nrf2/KEAP1/Bach1 axis ultimately 
dictates the anti-oxidant response.  
High levels of oxidant stress have been implicated in a large number of 
pathological conditions such as Alzheimer’s, Multiple Sclerosis , Diabetes 
and COPD. In 2004 a seminal study identified that Nrf2 deficient mice were 
extremely sensitive to oxidant stress and developed early-onset emphysema 
when exposed to cigarette smoke extract123. Following on from this, research 
examining the role of Nrf2 in COPD patients, established that both Nrf2 
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mRNA and protein were reduced in Alveolar Macrophages from COPD 
subjects, compared with age matched controls and regardless of smoking 
status124. A similar study found that Nrf2 protein levels were reduced in whole 
tissue homogenates from COPD patients. Importantly, in this study, they 
quantified nuclear and cytosolic Nrf2, Bach1 and Keap1 in AM and confirmed 
decreased nuclear and cytosolic Nrf2, increased nuclear Bach1 and 
increased cytosolic Keap1, in the emphysema group compared to controls. 
Reduced Nrf2 levels in the AM of emphysema patients correlated with 
reduced expression of key ARE genes such as HO-1 and NQO1 and 
importantly, expression of antioxidant genes inversely corelated with airway 
obstruction125 . 
This body of research raises a crucial question – if Nrf2 is induced by 
oxidative stress, then why are both cytosolic and nuclear Nrf2 levels reduced 
in COPD , a condition defined by high levels of oxidative stress. While it is 
tempting to consider that persistent Nrf2 signalling may lead to eventual 
desensitisation, constitutive Nrf2 expression continues to confer survival 
benefit in certain cancer cell lines126. Instead, the association of COPD with 
genetic polymorphisms in KEAP1 and GSR (Glutathione synthase reduction), 
coupled with increased nuclear Bach1 levels, may offer an explanation for 
altered Nrf2 signalling in COPD 127.  
Having established that Nrf2 activity plays a role in COPD, research is 
currently focused on the potential augmentation of this pathway as a 
therapeutic strategy. Sulforaphane is a bioactive phytochemical derived from 
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cruciferous vegetables. It was first identified in 1992 as a major inducer of the 
antioxidant response element 128. It is now known that Sulforaphane is able 
to react with the thiol groups of Keap1, covalently binding to KEAP1 and 
forming thionacyl adducts, promoting its dissociation from Nrf2 and 
subsequent activation of ARE. The ability of SFN to activate Nrf2-driven 
detoxifying genes is well documented both in vitro and in vivo, in murine and 
human models 129,130. Based on the above evidence for impaired Nrf2 activity 
in COPD, a cardinal study by Harvey et al showed that Sulforaphane 
enhanced bacterial phagocytosis in COPD Alveolar Macrophages via 
upregulation of the scavenger receptor MARCO49. However its role in COPD 
monocyte derived macrophages and efferocytosis has yet to be established. 
As sulforaphane is not a specific activator of Nrf2, there are also some 
obvious concerns regarding co-activation of alternative pathways and off 
target effects131.  
We hypothesised that, in response to infection with S. pneumoniae ,COPD 
AM would have a defective antioxidant response. We sought to examine the 
therapeutic role of highly specific Nrf2 activation in restoring function to 
COPD AM and MDM . Using a transcriptomics approach, we aimed to 
identify the mechanism of action of Nrf2 activators on COPD macrophages. 
Lastly we wished to clarify if a potential Nrf2 mediated augmentation of 
macrophage function would be limited to cells with baseline abnormalities, or 
if, in fact macrophages from Healthy donors could also be enhanced.    
  
 
Chapter 5 : COPD macrophage dysfunction is rescued by activation of the 
Nrf2 module 
  138 
Results: 
5.2 COPD Alveolar Macrophages fail to appropriately upregulate 
the Nrf2 module following infection with serotype D39 
Streptococcus Pneumoniae 
 
To further dissect the COPD macrophage dysfunction we examined the 
transcriptional response of Alveolar Macrophages to infection with 
Streptococcus pneumoniae. Both COPD and Healthy Donor Alveolar 
Macrophages were exposed for 4 hours to serotype D39 S. pneumoniae prior 
to lysis and subsequent analysis via affymetrix array. As previously 
discussed in Chapter 3, there was a markedly reduced transcriptional 
response to infection seen in COPD AM compared to Healthy AM (Figure 
3.18). Interestingly, this was particularly pronounced when examining the 
transcriptional response to oxidant stress (Figure 5.2 A). Detailed 
interrogation of the stress response revealed a failure by COPD AM to 
appropriately upregulate antioxidant modules, many of which are established 
Nrf2 targets, following co-incubation with S. pneumoniae (Figure 5.2 B). 
These included several detoxifying pathways for combatting cellular levels of 
reactive oxygen species (ROS). The transcriptional levels of vital ROS 
scavengers such as SOD1, which reduces superoxide and NQO1 which fully 
oxidizes quinones to prevent formation of semiquinones and subsequent 
ROS generation, were all upregulated in Healthy Donor macrophages but 
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remained unchanged in COPD.  More strikingly still, several key regulatory 
steps of Glutathione, which are subject to Nrf2 activation, were upregulated 
in Healthy AMs in response to infection, with no transcriptional change 
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Figure 5.2: Affymetrix array reveals aberrant stress response to 
infection in COPD donors. 
AM from COPD and Healthy donors were co-incubated with D39 S. 
pneumoniae prior to lysis for affymetrix array.(A) The stress response to 
infection is reduced in AM from COPD donors compared to Healthy donor 
AM. (B) A number of established Nrf2 targets, a key transcription factor in the 
response to increased cellular stress, were upregulated in Healthy donors but 
remained transcriptionally unchanged in COPD donor AM. (C) Schematic 
representation of Nrf2 mediated antioxidant pathways listed in (B). Nrf2 
targets are circled in red. 
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C Examples of Nrf2 mediated Antioxidant pathways which are upregualted in Healthy AM 
only, after infection with S. pneumoniae.
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5.3 Treatment with the Nrf2 activator, Sulforaphane, upregulates 
the Anti-Oxidant Response element in Alveolar and 
Monocyte-derived macrophages 
 
Following identification that COPD AM failed to appropriately upregulate 
antioxidant responses, we sought to establish if Nrf2 mediated activation of the 
ARE could reverse COPD macrophage dysfunction .  
Sulforaphane is a naturally occurring electrophilic compound which is a potent 
inducer of the antioxidant response. As discussed, sulforaphane mimics oxidant 
stress in the cytosol by modifying key cysteine residues on KEAP132. This leads 
to KEAP1 dissociation from the transcription factor Nrf2, when then migrates to 
the nucleus and activates the Anti-oxidant response element (ARE), leading to 
upregulation of 100s of key detoxifying genes. 
Heme oxygenase 1 (HO-1) catalyses the degradation of heme 
to biliverdin/bilirubin, ferrous iron, and carbon monoxide. Increased HO-1 protein 
and mRNA expression is widely accepted as a marker for ARE activation. 
Healthy AM (Figure 5.3 C) and MDM (Figure 5.3 D) treated with Sulforaphane 
10µm for 16 hours have increased expression of HO-1 as measured by Western 
Blot. This Western blot was generated by Dr Martin Bewley, a post-doctoral 
researcher in the lab of our collaborator on this project, Professor David Dockrell 
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Figure 5.3: Sulforaphane disrupts the KEAP1/NrF2 complex to activate 
the Anti-oxidant Response Element (ARE). 
(A) The chemical structure of Sulforaphane. (B) Sulforaphane modifies key 
cysteine residues on KEAP1, leading to its dissociation from Nrf2 and 
activation of the ARE. (C) AM and (D) MDM were pretreated for 16hrs with 
increasing doses of sulforaphane, then lysed and blotted for expression of 
Heme-oxygenase 1 (HO-1). B-actin was used as a loading control.  
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5.4 Activation of Nrf2 by Sulforaphane partially recues impaired 
bacterial macrophage phagocytosis in COPD , with preserved 
anti-microbial killing 
 
In COPD donors there was a significant increase in bacterial phagocytosis of 
opsonised  S14 S. pneumoniae following 16 hour pretreatment with 
Sulforaphane 10µm. COPD AM bacterial phagocytosis was increased by a 
mean of 383 cfu/ml(12%) and MDM by 341cfu/ml (11%) with Sulforaphane 
treatment (Figure 5.4 A) There was no significant increase in macrophage 
bacterial phagocytosis in either MDM or AM from Healthy donors (Figure 5.4 A + 
B)  
Although Sulforaphane treatment did improve bacterial phagocytosis in COPD 
macrophages, it did not elevate it to the same level as that of healthy donors. 
(mean Healthy AM = log10 2.93±0.18cfu/ml vs Mean COPD AM + Sulforaphane 
log10 2.87±0.08cfu/ml. Mean Healthy MDM log10 3.32±0.1cfu/ml vs Mean COPD 
MDM + Sulforaphane log10 2.89±0.1cfu/ml ) 
Reactive oxygen species (ROS) are key components of the antimicrobial 
repertoire of macrophages. As activation of the ARE improves redox balance 
and neutralizes ROS, we questioned if Sulforaphane treatment could impair 
bacterial killing capacity in treated cells. As evidenced in Figure 5.4 C, pre-
treatment with Sulforaphane increased internalisation rates while preserving 
bacterial killing in COPD macrophages. 
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Figure 5.4: Treatment with Sulforaphane increases phagocytosis of 
serotype 14 S. pneumoniae in COPD without compromising intracellular 
bacterial killing. 
(A) COPD AM and (B) MDM were pretreated with Sulforaphane 10µM for 16 
hours prior to challenge with opsonised serotype 14 S.pneumoniae and 
numbers of viable intracellular bacteria were assessed 4 hours post 
challenge or (C) COPD AM at the designated time post antibiotics. (A) n= 3/ 
17; (B) n= 6/13;(C) n= 3. P values calculated by paired t-test, *P £0.05, ** 
P£0.01 , *** P£0.001. 
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5.5 Treatment with Sulforaphane rescues defective efferocytosis 
in both Alveolar and Monocyte-Derived Macrophages in 
COPD patients 
  
AM and MDM from COPD and Healthy Donors were co-incubated with 
apoptotic neutrophils labelled with the membrane dye PKH26 for 90 mins before 
efferocytosis rates were measured on flow cytometry. Pre-Treatment with 10µm 
Sulforaphane for 16 hours significantly enhanced efferocytosis rates in 
macrophages form COPD but not Healthy donors (Figure 5.5 A + B). Mean 
efferocytosis was increased in COPD AM from 14.3±1.9% to 29.6±4.5%, a 
106% increase and MDM from 16.9±1.5% to 26.3±2.4%, a 54% increase 
following treatment with Sulforaphane in COPD donors. Following Sulforaphane 
treatment mean efferocytosis rates remained lower in treated COPD 
macrophages than Healthy donors cells (AM = 41.1±2.3% vs 29.6±4.5%; MDM 
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Figure 5.5: Treatment with Sulforaphane partially recues efferocytosis 
in  COPD macrophages.  
(A) COPD AM and (B) MDM were pre-treated with Sulforaphane 10µM for 16 
hours prior to co-incubation with PKH26 labelled 20hr apoptotic neutrophils. 
Efferocytosis was measured via flow cytometry. (A) n= 5/11; (B) n = 7/14. P 
values calculated by paired t-test, * P £0.05, *** P£0.001. 
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5.6 Treatment with a novel, highly specific Nrf2 activator also 
upregulates HO-1 in COPD macrophages  
 
While Sulforaphane has been found to activate the ARE in a wide range of 
cells and tissues, there are concerns regarding its specificity and thus its 
suitability as a therapeutic agent133. Sulforaphane mimics oxidant stress by 
altering cysteine modules on KEAP1 but this process is not specific to 
KEAP1 and it may alter cysteine modules on other complexes. It is known to 
have a number of off target effects such as cell cycle arrest, DNA 
hypomethylation, and to cause alterations in long terminal repeat 
transcriptional activity, potentially conferring genome instability 134,135. It is 
also recognised to induce non Nrf2 mediated suppression of IL-1b136. In 
addition, Sulforaphane possesses an undesirable pharmacokinetic profile. In 
its naturally occurring state it is an oil and so has poor aqueous and thermal 
stability. It has a low potency and bioavailability is influenced by gut 
microbiota, with consequent issues arising around predictable dosing 
scheduling 137,138 . 
Due to its lack of specificity, it was not clear if improved macrophage function 
in COPD macrophages following treatment with Sulforaphane, was 
specifically due to upregulation of the Nrf2 mediated antioxidant response. 
Fortunately, we were able to test this hypothesis by obtaining a panel of 
highly specific Nrf2 activators, Compounds A, B and C, through a 
collaboration with GSK via COPDMAP. These compounds are currently 
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unpublished and although their specific structure is unknown to us, they work 
by disrupting protein-protein interactions between Nrf2 and KEAP1, with 
nanomolar efficacy.  
Treatment with Compounds A, B and C activated the ARE in both COPD and 
Healthy donor MDM, as measured by HO-1 activity (Figure 5.6 A+B). There 
was a greater uplift in HO-1 expression following treatment with Compound A 
than there was with the non-specific activator Sulforaphane, though 
interestingly HO-1 expression in COPD MDM following treatment did not 
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Figure 5.6: Highly specific activation of Nrf2 upregulates HO-1 in 
Healthy and COPD Donor MDM. 
 (A) Healthy donor and (B) COPD donor MDM were pretreated with novel 
highly specific Compounds A , B and C at increasing doses and 
Sulforaphane 10µM for 16 hours then lysed and blotted for expression of 
Heme-oxygenase 1 (HO-1). B-actin was used as a loading control. The 
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5.7 Treatment with the specific Nrf2 activator, Compound A 
significantly enhances both bacterial phagocytosis and 
efferocytosis in AM and MDM from COPD donors, but not 
Healthy donors 
Following a review of both our data and pharmacokinetic data generated by 
our GSK collaborators, it was decided by their novel drug review panel that 
all further testing in COPD donors would focus only on Compound A from the 
originally provided panel.  
Using Compound A ,we were able to replicate the uplift in bacterial 
internalisation and efferocytosis rates in COPD macrophages seen with 
Sulforaphane treatment , confirming that this was a specific Nrf2 activation 
phenomenon (Figure 5.7 A-D ). Again, there was no significant change in 
bacterial internalisation rates following treatment with Compound A in 
macrophages from Healthy Volunteers.  
Treated COPD AM and MDM showed significantly increased levels of 
phagocytosis (Figure 5.7 A+C). In COPD AM, mean cfu/ml of 633±1.3 in 
vehicle treated cells increased to 1174±1.5cfu/ml in Compound A treated 
cells, an 85% increase. Similarly, in COPD MDM, mean cfu/ml of 909 in 
vehicle treated cells rose to a mean of 2032±1.8cfu/ml following Compound A 
treatment, a 123% increase. Healthy AM failed to show significantly 
enhanced phagocytosis following treatment with Compound A.  
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Treatment with Compound A also enhanced efferocytosis in COPD AM and 
MDMs but as with phagocytosis rates, rates of change in Healthy Volunteer 
AMs failed to reach statistical significance (Figure 5.7 B+D). Mean 
efferocytosis rates increased from 6.3±1,4% to 8.7±1.6% (a 35% increase) in 












Chapter 5 : COPD macrophage dysfunction is rescued by activation of the 
Nrf2 module 
  152 
 
Figure 5.7: The Nrf2 activator, Compound A ,enhances efferocytosis 
and bacterial phagocytosis in COPD AM and MDM.  
COPD and Healthy AM ( A, C) and MDM (B ,D) were pretreated for 16 hours 
with the Nrf2 agonist, Compound A  at 7.5nM. (A, B) Cells were then co-
incubated with opsonised S14 S. pneumoniae, 4hrs post challenge the 
number of viable bacteria was measured. (C, D) Cells were pre-treated prior 
to co-incubation with PKH26 labelled 20hr apoptotic neutrophils, efferocytosis 
rates were measured by flow cytometry. (A) n= 3/7;(B) n= 5/10; (C) n=5/8;(D) 
n=5/13 . P values calculated by paired t-test, **P£0.01, **** P£0.0001. 
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Compound A enhances COPD macrophage bacterial internalisation and 
efferocytosis in a dose dependent manner without impairing bacterial killing                 
 
To establish the potency and efficacy of Compound A in macrophages, in 
tangent with our standard functional assays, we performed dose response 
curves of phagocytosis of opsonised S14 S pneumoniae and efferocytosis of 
20 hr apoptotic neutrophils. Doses were calculated using the IC50 previously 
generated by GSK in Beas-2B cells.  
There was no obvious functional benefit seen above a dose of 7.5nM in 
either efferocytosis or bacterial internalisation(Figure 5.8 A, B and C) . 
Unfortunately, as there is only a n=2 for this data, we were unable to 
determine significance. To ensure cfu/ml counts in Figures 5.8 B+C, 
represented changes in internalisation rather than changes in bacterial killing 
rates, a killing assay was performed in COPD AM. Compound A did not 
appear to impair early phase killing of S. pneumoniae in COPD 
macrophages, as assessed by an adjusted gentamicin protection assay 
(Figure 5.8 D). However, this graph represents an n=1 only. Based on these 
results and those generated by GSK this drug is now progressing to phase Ib 
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Figure 5.8: Dose response of Compound A in COPD MDM and AM , with 
no change detected in early bacterial killing following treatment. 
(A,C,D) COPD AM and MDM (B) were pretreated with Compound A and 
Sulforaphane 10µM for 16 hours prior to challenge with (A) PKH26 labelled 
20hr apoptotic neutrophils and (B+C) opsonised serotype 14 S.pneumoniae 
,with numbers of viable intracellular bacteria assessed 4 hours post 
challenge or (D) at the designated time post antibiotics. (A ), n=2;(B+ C) 
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5.8 Utilizing a published specific Nrf2 activator, Compound 7 , to 
target macrophage dysfunction in COPD 
 
As the panel of compounds supplied to us by GSK is currently 
unpublished, we had significant concerns about the feasibility of publishing 
this work within the desired time frame. Consequently we sought to re 
produce the uplift seen with Compound A, in a similar but already 
published GSK Nrf2 activator. Compound 7 ,analogous to Compound A, is 
a non-electrophile small molecule which works by disrupting protein-protein 
interactions on KEAP1, as opposed to modifying cysteine residues like 
Sulforaphane. Compound 7 occupies the binding site for Nrf2 on KEAP1 
and so is a highly specific activator of Nrf2 (Figure 5.9 A+B). It is also one 
of the few types of PPI inhibitor to be thoroughly tested for off targets and 
is highly selective for disruption of the NRF2- KEAP1 interface139. 
Compound 7 works by occupying the C-terminal Kelch repeat domain, which 
is a protein-recognition module for NRF2 on KEAP1 (Figure 5.9 B). As seen 
with Sulforaphane and Compound A, Compound 7 also leads to upregulation 
of the ARE – as measured by HO-1 , NQO1 and GCLC-  in COPD MDM and 
AM ( Figure 5.9 A+C) identifying it as a suitable compound to utilize in our 
functional assays.  
I generated these samples and the western blot was run by Ms Jennifer 
Marshall, a research technician in the lab of Prof David Dockrell and has 
since been published 38.  
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Figure 5.9: Compound 7 prevents Nrf2/KEAP1 binding , leading to 
activation of  the Anti-oxidant Response Element (ARE).  
(A) Compound 7 occupies the binding site for Nrf2 on KEAP-1 leading to 
migration of Nrf2 into the nucleus where it binds to and activates the ARE. 
(B) COPD MDM and AM (C) were pretreated with Compound 7 0.065uM for 
16 hours then lysed and blotted for expression of Heme-oxygenase 1 (HO-1) 
and GCLC, NQO1. B-actin was used as a loading control. 
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5.9  The Nrf2 agonist Compound 7, significantly enhances 
efferocytosis and bacterial phagocytosis in COPD MDM and 
AM, but not in Healthy donor macrophages  
 
Pre-treatment with Compound 7, 0.065µM for 16 hrs, improved macrophage 
function in COPD AM and MDM. Bacterial phagocytosis of opsonised S14 S. 
pneumoniae in both COPD AM and MDM was significantly increased 
following treatment ( Figure 5.10 A+B). There was a mean increase in AM 
bacterial phagocytosis of 594cfu/ml (a 92% increase) and in MDM of 
1481cfu/ml (an 80% increase). In COPD donors mean efferocytosis in AM 
increased from 8.27±2.1% to 11.77±2.8% (a 42% increase) and in MDM from 
22.4±1.5% to 27.4±2.1% (an increase of 19%) following treatment with 
Compound 7 (Figure 5.10 C+D). As seen with Compound A and 
Sulforaphane, there was no significant increase in either bacterial 
phagocytosis or MDM efferocytosis in Healthy donor macrophages following 
treatment with Compound 7. Due to limitation with donor numbers we could 
only perform Healthy AM efferocytosis with Compound 7 in 2 donors and so 
were unable to carry out statistical analysis on this group.   
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Figure 5.10: The Nrf2 agonist Compound 7, enhances efferocytosis and 
bacterial phagocytosis in COPD MDM and AM.   
COPD AM (A, C) and MDM (B, D) were pretreated for 16 hours with the Nrf2 
agonist Compound 7 at 0.065µM. (A, B) Cells were then co-incubated with 
opsonised S14 S. pneumoniae, 4hrs post challenge the number of viable 
bacteria was measured. (C, D) Cells were pre-treated prior to co-incubation 
with PKH26 labelled 20hr apoptotic neutrophils, efferocytosis rates were 
measured by flow cytometry. (A) n= 3/6;(B) n= 4/5; (C) n=2/6;(D) n=5/6. P 
values calculated by paired t-test, **P£0.01, ***P£0.001. 
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5.10  Treatment with Compound 7 induces transcriptional change 
in COPD and Healthy Alveolar Macrophages  
 
As activation of Nrf2 had improved COPD macrophage efferocytosis and 
bacterial phagocytosis, we sought to identify the mechanism of action using 
an unbiased transcriptomics approach.  
When generating the data set discussed in 4.2, we also compared the 
transcriptional response to Nrf2 activation between Healthy and COPD AM. 
We chose to use GSK’s Compound 7 for this assay as its exact mechanism 
of action and structure is known to us and it has been published in the public 
domain139. As before, COPD and Healthy donor AM ( n=3 for both groups) 
were cultured for 16 hours +/- Compound 7 prior to collecting RNA for total 
RNA-seq.  
Treatment with Compound 7 induced a significant transcriptional change in 
both COPD and Healthy donor AM (Figure 5.11 A-D). A total number of 134 
genes in COPD AM  and 105 genes in Healthy donor AM met the criteria for 
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Figure 5.11: Nrf2 activation induces a significant transcriptional 
response in COPD and Healthy Donor AM. 
AM were isolated from COPD (A+C) and Healthy (B+D) donors via 
bronchoalveolar lavage and treated with the Nrf2 activator, Compound 7 for 
16 hrs prior to collecting RNA for Total RNA-seq.(A) Heatmap of normalized 
Z-scores for each gene identified as significantly altered between COPD (A) 
and Healthy AM (B) + Compound 7. Green indicates a relative high 
expression state, red indicates a relative low expression state. (B) Volcano 
plots displaying the log2 fold change between COPD (C) and Healthy (D) AM 
+ Compound 7. Log10 P values are plotted on the y-axis. Blue dots are genes 
that are both highly altered as well as contain a significant P value = FC > 
log21.5 and P value  £0.05 . No of blue dots in (C) n= 134 (D) , n= 105 . 
Orange dots contain genes which are FC >log21.5 but P value > 0.05, Red 
dots contain genes which are FC <log21.5 but p value £0.05. n=3 both 
groups. fc= Fold Change, DE = Differentially Expressed.  
A B
COPD vs COPD + Compound 7 Healthy vs Healthy + Compound 7
DC
C255 + 7C264 +7
COPD AM COPD AM +
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5.11  COPD AM transcriptional profile more closely resembles 
Healthy AM , after treatment with Compound 7 
 
Treatment of COPD AM with Compound 7 induces bidirectional change in gene 
expression which “resets” the COPD AM transcriptome to more closely 
resemble Healthy AM ( Figure 5.12.1 A+B).  
Correlation analysis across the 27,000 gene set confirmed that COPD AM were 
more highly correlated with Healthy AM following treatment with Compound 7 
(R2= 0.8881 to R2= 0.9027) ( Figure 5.12.2 A). Furthermore genes which were 
significantly differentially expressed between COPD and Healthy AM at baseline 
(red dots) can be seen to correlate more closely after treatment of COPD AM 
with Compound 7 (Figure 5.12.2 B). There are a number of outliers, however, 
indicating that the shift in previously DE genes between COPD and Healthy AM 
at baseline, account for some , but not all of the changes responsible for the 
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Figure 5.12.1: Nrf2 activation induces a transcriptional shift in COPD 
AM towards Healthy AM.  
All cells were cultured for 16 hours (COPD AM +/- Compound 7) prior to 
collection of RNA for Total RNA-seq.(A-B) Heatmap of normalized Z-scores 
for each gene identified as significantly reduced (A) or induced (B) between 
COPD AM vs Healthy AM which are then restored in COPD AM + Compound 
7. Green indicates high expression, red indicates low expression.  
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Figure 5.12.2: COPD AM correlate more closely with Healthy AM after 
treatment with Compound 7. 
Scatter plots were generated by plotting the average Log2 Tags Per Million 
(TPM) scores for a given sample cohort (i.e. Healthy AM ) vs the average 
Log2 TPM scores for a second sample cohort (i.e. COPD AM + Compound 
7). R2 squared values are calculated from the slope of the correlation 
trendline. Correlation analysis confirms a higher correlation between Healthy 
AM and COPD AM following treatment with Compound 7 (A - B).  n 
particular, significantly differentially expressed (DE) genes between COPD 
and Healthy AM at baseline, which are highlighted in (A), are seen to move 
towards the trendline in (B), indicating a “resetting” of abnormal expression in 
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5.12  Transcriptional changes induced by Compound 7-mediated 
Nrf2 activation, are disease specific  
 
To better understand the disease specific changes induced by Nrf2 
activation, we compared the transcriptional profile of COPD + Compound 7 to 
Healthy AM + Compound 7. Interestingly, there were no overlapping genes 
either up or downregulated between COPD and Healthy Donor AM following 
treatment,  suggesting that activation of Nrf2 via Compound 7 exerts a 
disease specific effect (Figure 5.13 A + D). Moreover, the lead Gene 
Ontology (GO) terms transcriptionally altered in COPD AM versus Healthy 
AM encompassed different biological processes. Of particular note was that  
“Regulation of Metabolic processes” was the most differentially upregulated 
biological process in COPD AM following Nrf2 activation (Figure 5.13 
B).Importantly, included within this grouping, were two genes with central 
roles in regulating metabolism - RPTOR, which in conjunction with mTORC1 
signalling and MAPK14 ,controls a regulatory, non-catalytic subunit of AMP 
kinase. Also included was TKL1 (Transketolase 1) which catalyses the 
conversion of ribose-5-phosphate to glyceraldehyde-3-phosphate phosphate 
in the pentose phosphate pathway. The NADPH oxidase, NOX1 was 
downregulated in COPD AM following treatment with Compound 7. NOX1 
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Figure 5.13: Nrf2 activation induces a divergent transcriptional 
responses in COPD vs Healthy donor AM.  
AM were treated with the Nrf2 activator, Compound 7, for 16 hours prior to 
collection of RNA for Total RNA-seq. (A-F). Venn diagram showing the 
number of shared genes upregulated in COPD and Healthy donor AM in 
response to Nrf2 activation n= 0. (B-C) The top Gene Ontology (GO) terms 
upregulated in COPD (B) and Healthy (C) AM following treatment with 
Compound 7. N=3 for each group 
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Figure 5.13 continued : (D) Venn diagram showing the number of shared 
genes downregulated in COPD and Healthy donor AM in response to Nrf2 
activation n= 0. (E-F) The top Gene Ontology (GO) terms downregulated in 
COPD (E) and Healthy (F) AM following treatment with Compound 7. N=3 for 
each group. HAM= Healthy AM. 
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5.13  Nrf2 activation via Compound 7 reprogrammes COPD AM 
metabolism leading to improved cellular energetics  
 
As GO analysis had identified that “Regulation of Metabolic processes ” was 
the biological process most significantly altered by treatment with Compound 
7 in COPD AM, we focused our attention on identifying the specific metabolic 
reprogramming induced by Nrf2 activation. 
As discussed Nrf2 can modulate glucose uptake and flux through the 
pentose phosphate pathway 116. It also enhances glucose oxidation by 
promoting flux through Pyruvate Dehydrogenase, increasing substrate entry 
into the TCA cycle140. Consequently, using LC-MS,  we sought to define 
changes in baseline metabolism induced by Nrf2 activation, by measuring 
relative changes in intermediary abundance. NADPH is both rapidly 
degraded in the cell and also very poorly detected by LC-MS , as are 
Pentose Phosphate Pathway intermediaries.Therefore, our analysis was 
limited to Glycolysis and the TCA cycle.  
Compound 7 mediated Nrf2 activation did not significantly alter Glycolytic 
metabolite abundance. However, it did significantly increase TCA cycle 
intermediaries , relative to baseline abundance in untreated COPD AM. 
Importantly, abundance of all TCA cycle intermediaries was increased, 
suggesting this was not a result of an interruption of flux through the cycle 
leading to accumulation of preceding metabolites (Figure 5.14.1).  
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Crucially Nrf2 activation, perhaps via modulation of the TCA cycle, enhanced 
cellular energetics. Energy Charge is calculated by the equation [ ATP + 
½(ADP) / ATP + ADP + AMP ], and is a widely utilised index for measuring the 
energy status of a cell. Compound 7-mediated Nrf2 activation significantly 
improved both Energy Charge and ATP:ADP ratios. (Figure 5.14.2) .  
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Figure 5.14.1: Nrf2 activation leads to a significant increase in TCA 
cycle metabolite abundance.  
COPD AM were treated with the Nrf2 activator, Compound 7, for 16 hours 
prior to lysing cells in methanol to determine metabolite abundance via 
Liquid-Chromatography-Mass-Spectrometry. Abundance is plotted as relative 
to untreated COPD AM (Fold change). (A) Treatment with Compound 7 
significantly increased relative metabolite abundance throughout the TCA 
cycle in comparison to Glycolysis (B) which was not significantly altered. N 
=7/6 throughout. P value calculated via  2-way ANOVA, P £0.05 was used to 
determine significance, ***P£0.001. Data represents individual values and 
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Figure 5.14.2 Nrf2 activation improves cellular energetics. 
COPD and Healthy AM were treated with the Nrf2 activator , Compound 7, 
for 16 hours prior to lysing cells in methanol to determine metabolite 
abundance via Liquid-Chromatography-Mass-Spectrometry. (A) Energy 
charge and (B) ATP:ADP ratios were significantly improved following 
treatment with Compound 7. N=5 throughout. P value calculated via 1-way 
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5.14  Nrf2 improves cellular redox balance in COPD AM. 
 
As we had observed a failure in COPD AM  to appropriately upregulate 
antioxidant responses following infection with S. pneumoniae (Figure 5.2), we 
sought to establish if Compound 7-mediated Nrf2 activation had indeed 
restored redox balance in COPD AM. The ratio of reduced to oxidised 
Glutathione (GSH:GSSG), is considered a marker of cellular health and 
favourable redox balance. Key genes regulating glutathione synthesis and 
reduction were upregulated in Healthy AM but not in COPD AM on exposure 
to S. pneumoniae ( Figure 5.2). As Glutathione Reductase (GSR) uses 
NADPH to reduce oxidised Glutathione, the GSH:GSSG ratio also acts as a 
measure of NADPH production.  
Activation of the Nrf2 module via Compound 7 increased absolute glutathione 
abundance in COPD AM, in keeping with it known role in activating 
Glutamine Cystine ligase, the rate limiting enzyme of glutathione 
synthesis141. Nrf2 activation also increased the ratio of GSH:GSSG, 
establishing an improved redox state following treatment with Compound 7 
(Figure 5.15). Furthermore, as NADPH is required to maintain GSH, this 
suggests increased availability of NADPH in COPD AM, following treatment 




Chapter 5 : COPD macrophage dysfunction is rescued by activation of the 
Nrf2 module 
  172 
 
Figure 5.15: Nrf2 activation improves cellular redox state. 
COPD and Healthy AM were treated with the Nrf2 activator, Compound 7, for 
16 hours prior to lysing cells in methanol to determine metabolite abundance 
via Liquid-Chromatography-Mass-Spectrometry. (A) The ratio of reduced to 
oxidised glutathione was significantly improved by treatment with Compound 
7. (B) The overall abundance of Glutathione was increased following 
treatment with Compound 7. P value calculated via 1-way ANOVA and 
Sidak’s multiple comparisons.* P£0.05, ** P£0.01. Data represents individual 
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5.15  Activation of the Nrf2 Module does not increase macrophage 
phagocytosis or efferocytosis in Healthy Volunteers, including 
under hostile culture conditions:  
 
As Nrf2 activation induced a divergent transcriptional programme in resting 
state Healthy and COPD AM , we questioned if Nrf2 enhancement of 
macrophage activity i.e. phagocytosis and efferocytosis, may be limited to a 
diseased state. We had previously observed that blood monocyte-derived 
macrophages from Healthy volunteers, pre-treated with Compound A-C or 
Sulforaphane did not show significantly altered phagocytosis of serotype 14 
Streptococcus pneumoniae or PKH26 labelled neutrophils (Figure 5.16 A-B). 
Consequently we sought to mimic elements of the COPD microenvironment 
while culturing Healthy Control MDM, to establish if this would unmask an 
effect of Nrf2 agonists in healthy volunteer cells. 
The COPD lung is characterized by chronic inflammation, oxidant stress and 
inflammation induced hypoxia, which AM and MDM must be able to readily 
adapt to142,143. These cells are also highly regulated by nutrient availability19. 
As increasing numbers of cells are recruited, there is a progressive scarcity 
of crucial substrates such as oxygen and glucose.  Thus, to mimic the hostile 
environment of COPD , healthy MDM were cultured in hypoxia (defined as 
1% O2) for ten days or in glucose deplete media with dialysed Fetal Calf 
Serum (FCS) for 16 hours prior to use. All MDM were pre-treated with either 
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vehicle or Compounds A, B, C or Sulforaphane prior to performing assays 
(Figure 5.16.2) 
Interestingly exposure to hostile environments prior to, and during these 
assays, did not unmask an Nrf2 activation effect in Healthy donor 
macrophages, though it is important to note these are small numbers. This 
does still suggest, however, that the uplift in macrophage function seen with 
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Figure 5.16.1: Nrf2 activation does not enhance MDM phagocytosis or 
efferocytosis in Healthy Volunteers.  
MDM isolated from Healthy Controls were pre-treated with Nrf2 agonists - 
Compounds A, B and C 10nM and Sulforaphane 10µM -for 16 hours prior to 
challenge with (A) opsonised S. pneumoniae S14 , 4hrs post challenge the 
number of viable bacteria was measured (n=5) .(B) Following pretreatment 
cells were co-incubated with PKH26 labelled 20hr apoptotic neutrophils, 
efferocytosis rates were measured by flow cytometry (n=5) P value 
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Figure 5.16.2: Nrf2 activation augments neither efferocytosis nor 
phagocytosis in cells cultured in hypoxic and glucose deprived 
environments. 
MDMs were cultured in (A) hypoxia (1% O2) x 10 days or (B) glucose 
deprived media with dialysed FCS x 16hrs prior to co-incubation with PKH26 
labelled apoptotic neutrophils, efferocytosis rates were measured by flow 
cytometry. (C) MDM’s cultured in glucose deprived media with dialysed FCS 
x 16hrs prior to co-incubation with S. pneumoniae S14, 4hrs post challenge 
the number of viable bacteria was measured. All MDM were pretreated for 16 
hours with Nrf2 agonists - Compounds A, B and C 10nM and Sulforaphane 
10µM prior to performing assays. Fold change was calculated as the ratio of 
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5.16  ME1 expression is reduced in COPD AM at baseline and 
augmented following treatment with Nrf2 . 
 
Lastly, we had identified ME1 (Malic Enzyme 1) as a significantly differentially 
expressed gene between COPD and Healthy AM at baseline. ME1 increases 
NADPH production by converting cytosolic Citrate to Pyruvate .The Pyruvate 
thus generated, can be shuttled back into the TCA cycle or converted to 
Acetyl Co-A for Fatty Acid Synthesis ( Figure 5.17 C). The newly generated 
NADPH can be used to maintain redox balance or again, for reductive 
biosynthesis. In fact, ME1 has been shown to generate approximately 60% of 
the cytosolic NADPH pool ,in normoxic conditions147. ME1 activity has also 
been shown to influence both metabolism and antioxidant responses. ME1 
knock down in the human colon cancer cell line, HCT116 , resulted in 
increased lactate production and disruption of redox balance, as measured 
by induction of HO-1104.   
Total RNA-seq data confirmed that ME1 expression is significantly reduced 
at baseline in COPD AM , compared to Healthy AM ( Figure 5.17 A). ME1 
expression was highly upregulated in two of the donors in the transcriptomics 
dataset but did not reach significance, as a limited change only was detected 
in the third donor. Therefore , PCR quantification of ME1 expression was 
undertaken in both the original “transcriptomics data set donors” and a further 
3 COPD donors. This revealed a significant increase in ME1 expression 
following treatment with Compound 7 ( Figure 5.17 B).  Based on this 
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preliminary data and published studies, we are now exploring if reduced ME1 
levels may play a significant role in altered metabolism in COPD . 
Furthermore we will investigate if augmentation of ME1 expression is central 
to the observed Nrf2-mediated rescue macrophage dysfunction in COPD.  
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Figure 5.17: Nrf2 activation restores ME1 expression in COPD AM. 
(C) Malic Enzyme 1 (ME1) increases NADPH and pyruvate production via 
the malate-pyruvate shunt. (A) Transcriptomic analysis revealed a significant 
reduction in COPD AM compared to Healthy AM at baseline.(B) PCR 
quantification of ME1 expression  revealed a significant increase in COPD 
AM following treatment with Compound 7. (A) n= 3, (B) n= 6. P values 
calculated by unpaired (A) and paired (B) t-test.  
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5.17  Discussion 
 
The data in this chapter provides compelling evidence for the role of Nrf2 
activation in reversing macrophage dysfunction in COPD .  
In COPD AM, the failure to upregulate several Nrf2-controlled antioxidant 
modules in response to S. pneumoniae, provides vital mechanistic insight 
into macrophage dysfunction in COPD. The antioxidant response induced in 
Healthy AM, included key detoxifying pathways for combatting cellular levels 
of ROS, a major cause of cell and tissue damage in COPD144 .The 
transcriptional levels of vital ROS scavengers such as SOD1, which reduces 
superoxide and NQO1, which fully oxidizes quinones to prevent formation of 
semiquinones and subsequent ROS generation, were all upregulated in 
Healthy Donor macrophages but remained unchanged in COPD.  More 
strikingly still, several key regulatory steps of Glutathione, which are subject 
to Nrf2 activation, were upregulated in Healthy AM, in response to infection, 
with no transcriptional change induced in COPD AM. As one of the chief 
endogenous antioxidants, the ratio of reduced (GSH) to oxidised glutathione 
(GSSG) is often used as readout of the redox potential of a cell. Failure to 
upregulate glutathione synthesis in response to infection in COPD AM 
represents a severely impaired transcriptional response to a noxious 
stimulus. It renders the cell incapable of maintaining adequate redox balance 
in the context of infection, with ensuing high levels of oxidant stress, aberrant 
cell signalling and damage to sensitive organelles such as mitochondria 145.  
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In keeping with a failure of COPD AM to upregulate antioxidant responses, 
activation of Nrf2 via a panel of specific and non-specific compounds, 
partially rescued both phagocytosis and efferocytosis in COPD AM and 
MDM. Noticeably, there was a differential impact on macrophage dysfunction 
between Sulforaphane and the novel Nrf2 compounds. The greatest uplift in 
bacterial phagocytosis was seen with the novel GSK Nrf2 activators whereas, 
a greater enhancement was seen in efferocytosis with Sulforaphane. It is 
possible that, as of yet unidentified, off-target effects of Sulforaphane are 
improving efferocytotic function. A study by Campanella et al provides a 
possible alternative explanation. They used a novel Nrf2 activator which was 
a non-covalently binding KEAP1 protein-protein interaction inhibitor (PPI), 
similar to our Compounds- A and 7. They discovered a differential effect on 
mitochondrial function, particularly mitophagy, between their PPI compound 
and Sulforaphane 146. It is possible that an increase in mitophagy, with 
resulting improved mitochondrial health, is of an additional benefit in bacterial 
phagocytosis. COPD AM displayed impaired mitochondrial responses to S. 
pneumoniae, which was presumed to be due to impaired mitochondrial 
health 69. Improved mitophagy may reverse this phenomenon and explain 
why PPI compounds such as Compound A + 7  induce a relatively greater 
improvement in bacterial phagocytosis rather than efferocytosis. Regardless 
of the degrees of improvement between processes, the ability to enhance 
both efferocytosis and phagocytosis using highly specific Nrf2 activators, is 
further evidence still for a shared underlying mechanism driving macrophage 
dysfunction in COPD macrophages.  
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We had previously hypothesised that incomplete rescue of COPD 
macrophage phagocytosis and efferocytosis by Nrf2 agonists, was due to a 
limited induction of the ARE via Nrf2, as measured by HO-1 expression. 
While acknowledging that our Healthy and COPD MDM lysates were run on 
separate blots, the expression of HO-1 relative to b-actin was increased in 
COPD MDM with Sulforaphane and Compound A , but still appeared lower 
than in Healthy MDM. We postulated that increased levels of Bach1, which 
competitively binds to the ARE and have previously found in COPD AM, 
could potentially account for this phenomenon 125. It was therefore of great 
interest to observe that while treatment with Compound 7 appeared to 
“normalise “ the COPD transcriptome towards that of Healthy AM, a degree 
of divergence in transcriptomes persisted between the two donor groups. 
Therefore, alternatively, failure to fully reverse impaired macrophage function 
in COPD ,may occur because certain abnormally expressed genes in COPD 
AM are refractory to Nrf2 modulation. If this proved to be the case, the 
potential for epigenetic modification of COPD macrophages in preventing 
transcription of particular genes, may prove highly significant. Either the 
differential induction of the ARE following treatment, or the inability of Nrf2 to 
modulate all relevant gene sets in COPD macrophages, may explain why 
Sulforaphane and our panel of specific Nrf2 agonists, can greatly improve 
macrophage function in COPD, but are unable to fully reverse the phenotype. 
The identification of “Metabolic processing” as a lead biological process 
altered by Nrf2 activation in COPD AM, was particularly noteworthy in the 
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context of our observed metabolic phenotype, outlined in Chapter 3. As 
discussed, we observed exhausted energy reserves and comparatively 
upregulated glycolysis with downregulated oxidative metabolism in COPD 
macrophages. In keeping with enhancement of macrophage phagocytosis 
and efferocytosis with Nrf2 activation, treatment of COPD AM with 
Compound 7 significantly increased flux through the TCA cycle and improved 
Energy Charge. This may well reflect an improvement in mitochondrial health 
and consequently bioenergetics, due to enhanced redox balance - treatment 
with Compound 7 also significantly improved the GSH:GSSG ratio. Previous 
exploration of the effect of Nrf2 deletion in murine embryonic fibroblasts, 
confirmed impaired mitochondrial health with subsequent reduction in 
mitochondrial generated ATP 118 . Another possibility is that Nrf2 activation 
reprogrammes metabolism in COPD macrophages. For example,  RPTOR 
(Regulatory-associated protein of mTOR) was found to be significantly 
upregulated in COPD AM following treatment with Compound 7. RPTOR 
plays a major role in sensing and orchestrating the response to nutrient and 
energy state in macrophages (via its role in the mTORC1/ AMPK axis) 147. 
Lastly, the role of ME1 induction via Nrf2 is of particular interest to us, 
especially as it is a significant differentially expressed gene between COPD 
and Healthy AM at baseline. ME1 ( Malic Enzyme 1) is a NADP-dependent 
cytosolic enzyme which generates NADPH during the conversion of Malate 
to Pyruvate. Therefore increasing ME1 expression could improve redox 
balance in the cell by generating more NADPH, and also increase flux 
through the TCA cycle by producing Pyruvate.  Thus ME1 upregulation, 
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warrants further characterisation in the context of Nrf2 mediated 
enhancement of COPD macrophage function.   
Interestingly, in contrast to COPD MDM, Nrf2 stabilisation failed to induce an 
increase in efferocytosis or bacterial phagocytosis rates in Healthy Volunteer 
AM and MDM and occurred even when MDM were deprived of vital 
substrates- oxygen and glucose. This was despite an increase in HO-1 
protein expression in Healthy MDM following treatment with Compound A 
and Sulforaphane, indicating that augmentation of antioxidant responses with 
subsequent improvement in macrophage function, is disease specific. It is 
possible that when the Nrf2/KEAP1/Bach1 axis is working correctly , as in 
Healthy macrophages, further augmentation of the ARE will not result in an 
increased functional output. Alternatively that fact that Nrf2 induces an 
entirely different transcriptional programme in in Healthy AM than it does in 
COPD AM, suggests that many of the transcriptional effects of Nrf2 are 
dependent on baseline gene expression. These experiments also contradict 
the concept that a substrate limited environment is largely driving the 
macrophage phenotype in COPD, particularly when coupled with the 
persistence of our observed COPD phenotype in an oxygen and glucose 
replete tissue culture environment. 
In summary, we have established that COPD AM fail to appropriately 
upregulate anti-oxidant pathways in response to infection. We have also 
shown partial recuse of COPD macrophage function via pharmacological 
manipulation of these anti-oxidant pathways. A previous study by Harvey et 
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al had shown an increase in bacterial phagocytosis following treatment with 
Sulforaphane49. Our data, however, is the first to establish a role for 
Sulforaphane in enhancing both bacterial phagocytosis and efferocytosis in 
AM and MDM from COPD patients. Moreover, using a highly specific Nrf2 
activator, we have confirmed that this uplift in macrophage function is 
exclusively mediated via upregulation of the Nrf2 module. By conducting 
these experiments in Healthy donors, including Healthy donor macrophages 
which have been substrate deprived, we had confirmed that Nrf2 mediated 
enhancement of macrophage function is also disease specific. 
Transcriptomics data, coupled with measurement of metabolite abundance 
via LC-MS, has outlined a major role for Nrf2 in reprogramming aberrant 
metabolism in COPD macrophages, with consequent improvement in energy 
status . Crucially, this provides a mechansim for Nrf2 mediated restoration of 
macrophage function in COPD.  Future directions will focus on how Nrf2 
activation can influence  mitochondrial health and energetics in COPD 
macrophages, with particular attention to the role of ME1 upregulation . 
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6 Discussion and Future Directions 
 
6.1 Discussion 
COPD is characterised by persistent inflammation of the airways , destruction 
of lung tissue and mucus hypersecretion resulting in airflow limitation and 
impaired gas exchange. Pathogen colonisation and recurrent infective 
exacerbations are the largest contributor to morbidity and mortality within the 
disease34. Failure of COPD macrophages to adequately phagocytose 
bacteria and to instigate inflammation resolution via efferocytosis, places 
macrophage dysfunction at the centre of both disease pathology and 
progression in COPD.  
The aim of the project was to employ a multimodality approach to 
characterise macrophage dysfunction in COPD. We combined transcriptional 
profiling of COPD macrophages, both at rest and in response to a pathogen, 
with functional assays and metabolic phenotyping- again both at rest and 
following stimulation. Critically, we have conducted many of these 
experiments in both AM and MDM to explore if the defects encountered in 
AM are limited to macrophages exposed to the pulmonary niche.  
COPD AM AND MDM have impaired function: 
We have confirmed that COPD macrophages have impaired bacterial 
phagocytosis of S. pneumoniae-one of the most commonly encountered 
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pathogens in COPD-and efferocytosis of apoptotic neutrophils. Crucially, we 
have identified that macrophage dysfunction in COPD is a systemic defect. 
Both Alveolar Macrophages, existing in the inflammatory pulmonary niche, 
and circulating Monocyte-derived macrophages, demonstrate impaired 
phagocytosis and efferocytosis. This firmly establishes that the phenotype of 
impaired macrophage function in COPD is not driven solely by hostile 
microenvironmental signalling within the lung. As all cells were cultured in a 
glucose and oxygen replete environment prior to performing assays, the 
determinants of COPD macrophage dysfunction are evidently hard wired. 
Our transcriptomics data sets confirmed that COPD AM are intrinsically 
different to Healthy AM at baseline. Importantly, COPD AM also mounted a 
divergent and markedly supressed transcriptional response to Streptococcus 
pneumoniae compared to Healthy Donor AM. Interrogation of  transcriptional 
differences between COPD and Healthy AM, highlighted two major areas of 
interest for us to explore - metabolism and the antioxidant response. 
Altered metabolism in COPD: 
Transcriptomic analysis, both at baseline and in response to co-incubation 
with S. pneumoniae, revealed significantly altered metabolic profiles between 
COPD and Healthy AM. At baseline, “metabolic processing” was one of the 
most differentially regulated modules between COPD and Healthy AM, with 
alterations in key genes such as Malic Enzyme 1. Furthermore, comparison 
of the metabolic transcriptional response to S. pneumoniae revealed a 
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dominant glycolytic response in COPD AM, compared to Healthy AM. This 
apparent over reliance on glycolysis in COPD AM, was replicated during 
phenotyping of the energy response using Seahorse technology and again 
when measuring metabolic intermediaries using LC-MS. Seahorse profiling 
revealed a predominantly ECAR driven response to increased energy 
demand in COPD AM. Similarly, a relative increase in the abundance of 
glycolytic intermediaries was detected in COPD macrophages compared to 
Healthy AM, using LC-MS. Crucially, this glycolytic phenotype in COPD 
macrophages, co-existed with impaired bioenergetics, as detected by 
Seahorse. Both AM and MDM from COPD donors displayed exhausted 
energy reserves in oxidative metabolism and glycolysis. The discovery of 
significantly diminished energy reserves, coupled with a reduced energy 
charge as detected by LC-MS, in COPD macrophages is perhaps finding 
most relevant to our observed phenotype of impaired macrophage function in 
COPD. Moreover, reduced energy reserves were detected in both AM and 
MDM , providing further evidence still of a widespread systemic defect in 
macrophage function in COPD.  
It was imperative to determine if the metabolic phenotype discovered in 
COPD macrophages, was driven by substrate availability. We did not detect 
a difference in either glucose uptake, glycogen storage levels or substrate 
availability in the bronchoalveolar lavage fluid . Critically COPD AM also 
failed to reprogramme oxidative metabolism following ingestion of apoptotic 
neutrophils, compared to Healthy AM. Together these data suggest that 
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altered metabolism in COPD, is a product of impaired metabolic plasticity 
coupled with bioenergetic exhaustion rather than environmental regulation 
through substrate availability. 
The role of antioxidant responses in restoring function in COPD 
macrophages: 
Another significant finding in our transcriptomics data set, was a markedly 
reduced antioxidant response in COPD AM, following exposure to S. 
pneumoniae.  This was of particular interest as Nrf2 , the master regulator of 
the antioxidant response, has previously been shown to be reduced in COPD 
AM and Nrf2 -/- mice exhibit early onset emphysema following cigarette 
smoke exposure123,148. We established that treatment with Sulforaphane and 
crucially, highly specific Nrf2 activators, partially restores bacterial 
phagocytosis and efferocytosis in COPD macrophages. The ability to restore 
both processes via pharmalogical manipulation is further evidence still for a 
shared underlying mechanistic defect.  
As Nrf2 is well established to regulate a number of metabolic processes and 
we had already identified a metabolic defect in COPD macrophages, we 
profiled the COPD AM transcriptome following treatment with Nrf2 activators, 
with a focus on metabolism. This revealed that pharmacological activation of 
Nrf2 “reprogrammed”  COPD macrophages to more closely resemble Healthy 
AM. Fascinatingly, this involved major changes in the regulation of 
metabolism. Altered expression of cardinal metabolic regulators such as 
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RPTOR, Transketolase 1 and Malic Enzyme 1 in COPD AM following 
treatment, provided evidence that Nrf2 activation can “recalibrate” elements 
of COPD macrophage metabolism. Moreover, treatment with Nrf2 activators 
increased TCA cycle metabolite abundance and improved energy charge and 
redox balance in COPD AM. These data suggest that Nrf2 treatment, 
potentially by improving redox state, can modify aberrant metabolism in 
COPD macrophages with consequent rescue of Phagocytosis and 
Efferocytosis.  
6.2 Future directions 
The work presented here highlights a number of areas which are worthy of 
further investigation. 
There is ample evidence of impaired mitochondrial health and function in 
COPD macrophages 65, 92, 93, 94, 95. While impaired OCR responses coupled 
with altered OCR/ECAR ratios in COPD macrophages strongly suggest 
mitochondrial damage, we did not have the opportunity, due to cell number 
limitations, to interrogate mitochondrial health specifically in our cohort. This 
is of particular significance when considering the rescue phenotype 
demonstrated by Nrf2 activation. Mitochondria are extremely sensitive to 
oxidative stress, due to their limited repair mechanisms and our data 
confirmed that Nrf2 activation improved redox balance in COPD 
macrophages. Furthermore, there was also an increase in both TCA cycle 
metabolite abundance and Energy Charge, suggesting a favourable 
energetic outcome from Nrf2 activation in these cells. As intact metabolic 
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machinery is indispensable for metabolic plasticity , improvements in 
mitochondrial health due to improved redox balance, may play a role in 
restoring metabolism plasticity to COPD macrophages, reducing reliance on 
glycolysis for ATP generation and improving energy reserves. Measurement 
of mitochondrial DNA to nuclear DNA ratios (mtDNA/nDNA) has previously 
been used to asses for reduced mitochondrial bodies 149. However as this is 
a ratio, and we have already demonstrated that COPD macrophages have a 
quiescent nDNA mediated transcriptional response, this ratio may be globally 
reduced and mask a reduction in mitochondrial number in COPD 
macrophages. Measuring mitochondrial membrane potential, a marker of 
mitochondrial health and a crucial element for energy generation and storage 
in mitochondria,  both pre and post treatment with Nrf2 activators is likely to 
yield a more relevant response 149,150 . Moreover, isolation of individual 
mitochondrial complexes could reveal exciting information of the drivers of 
mitochondrial dysfunction in COPD macrophages and provide further more 
specific therapeutic targets. Our future plan is to assess COPD macrophage 
mitochondrial health and function and importantly  to assess if 
pharmacological activation of Nrf2 generates changes in these parameters 
translate into alterations in OCR readings and mitochondrial reserves. 
Another area of particular future interest, is the potential role of Malic Enzyme 
1 activity in driving the observed phenotype in COPD macrophages. Malic 
Enzyme 1, as discussed ,increases the cytosolic pool of NADPH -enhancing 
redox potential - while also generating Pyruvate for the TCA cycle. The pool 
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of generated NADPH can also be used for Fatty Acid Synthesis and 
Oxidation, which has been shown to play a significant role in driving a “pro 
resolution” phenotype in macrophages. Importantly, ME1 levels were 
significantly transcriptionally reduced in COPD AM at baseline and were 
significantly increased following Nrf2 activation. ME1 expression, particularly 
in a low glucose environment – such as that experienced in the airways - has 
been shown to regulate glucose metabolism, flux through the pentose 
phosphate pathway and the TCA cycle and to regulate cell motility 104,151. 
Moreover, ME1 knock out mice display reduced body weights, reduced body 
and retroperitoneal fat due to impaired lipogenesis 152,153. This phenotype 
certainly echoes the highly catabolic clinical state of many emphysema 
patients, who struggle to maintain a BMI within healthy range, and is 
considered a marker for increased mortality in this cohort 154(155. We are 
currently generating, with our collaborators, a CRISPR-Cas9 ME1 knock out 
in a THP-1 cell line, which we are aiming to metabolically and functionally 
profile using Seahorse technology and efferocytosis assays respectively. 
Once we have characterised the baseline phenotype of these cells , using 
compound 7 we will activate the Nrf2 pathway with the hypothesis that Nrf2 
activation cannot augment efferocytosis in these cells.  
While Nrf2-/- mice have been studied extensively in the context of COPD, to 
date the role of Nrf2 overexpression in protecting against emphysema, has 
not been examined. Long term exposure of Nrf2 OE mice to cigarette smoke 
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could provide valuable insights in to the mechanism of functional rescue seen 
with Nrf2 activation.  
Lastly, this data as a whole, raises fascinating questions regarding the 
systemic nature of macrophage dysfunction in COPD. While elements of 
defective alveolar macrophage function can be attributed to the high levels of 
oxidative stress experienced in the pulmonary niche, the existence of the 
phenotype in circulating bone marrow derived cells merits careful 
consideration. It is possible that signalling from the damaged pulmonary 
niche to the bone marrow is inducing defects, potentially via epigenetic 
modification, in newly released monocytes. However, recurrent infections and 
colonisation in COPD patients is largely limited to the lung . A possible 
explanation for this is impaired tissue imprinting in the lungs of COPD 
patients, due to chronic inflammation. This would give rise to a “dual hit” 
where by baseline defective cells would migrate from the bone marrow to the 
damaged COPD lung. An inability to reprogramme the infiltrating cells 
correctly within the inflammatory niche could result in further loss of function. 
To dissect this theory, it would be essential to recruit and follow an early 
cohort of smokers firstly, to delineate if detected alterations in circulating and 
airway cells, were due directly to cigarette smoke exposure or to disease 
mechanisms and secondly to determine causality between AM and MDM 
dysfunction. Recruitment for this cohort of patients has already begun in 
Edinburgh University.  
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As discussed, it has long been recognised that COPD displays a high level of 
inheritability 156,157. Despite this, GWAS studies failed to reveal a meaningful 
genetic footprint for the disease 27. Thus the role of epigenetic modification in 
COPD or familial imprinting leading to marked susceptibly to the disease, is 
an area of great interest and unmet clinical need. Already, epigenetic 
analysis of established COPD patients have revealed a number of 
differentially methylated sites (DMSs) associated with lung function which 
may play a role in disease development 158. It is particularly interesting to 
reflect on the role of mitochondrial dysfunction in COPD, with respect to 
genetic susceptibility. Mitochondria DNA is inherited only from the maternal 
lineage, however familial trends are not determined by sex of parent 157 – it is 
possible that inherited epigenetic modifications could leading to impaired 
function and or repair mechanisms. Epigenetic analysis of AM and MDM from 
established COPD patients, in parallel with early smokers with preserved 
lung function from our early smoker cohort, and if possible screening of first 
degree relatives, may finally provide critical insights into disease 
susceptibility. The development of drugs targeting epigenetic modification 
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6.3 Conclusions 
This body of work outlines significant systemic functional impairment of 
COPD macrophages. It provides evidence that altered metabolism in COPD 
macrophages, may be driving the observed functional impairment. We have 
shown that COPD macrophages have diminished  antioxidant responses and 
that pharmalogical induction of the antioxidant response, via Nrf2 activation, 
partially rescues functional defects . Moreover our data suggests that 
manipulation of antioxidant responses in COPD macrophages, 
transcriptionally reprogrammes cells, with a particular emphasis on cellular 
metabolism, resulting in restoration of function.  
Future work will focus on mitochondrial health and potential gain of function 
following Nrf2 activation in COPD macrophages, with a view to trialling Nrf2 
activation as a therapy in established disease. The role of ME1 in driving 
aberrant metabolism in COPD macrophages requires specific 
characterisation . Ultimately, the drivers of the systemic defect in the COPD 
macrophage population require investigation using an early cohort of 








1. Watts ER, Ryan E, Walmsley SR, Whyte MKB. Microenvironmental 
Regulation of Innate Immune Cell Function. Vol 41. Weinheim, Germany: 
John Wiley & Sons, Ltd; 2017:947-970. doi:10.1002/9783527692156.ch36. 
2. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort 
HL. The mononuclear phagocyte system: a new classification of 
macrophages, monocytes, and their precursor cells. Bull World Health 
Organ. 1972;46(6):845-852. 
3. Ginhoux F, Guilliams M. Tissue-Resident Macrophage Ontogeny and 
Homeostasis. Immunity. 2016;44(3):439-449. 
doi:10.1016/j.immuni.2016.02.024. 
4. Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident 
macrophages originate from yolk-sac-derived erythro-myeloid progenitors. 
Nature. 2015;518(7540):547-551. doi:10.1038/nature13989. 
5. Guilliams M, De Kleer I, Henri S, et al. Alveolar macrophages develop from 
fetal monocytes that differentiate into long-lived cells in the first week of life 
via GM-CSF. J Exp Med. 2013;210(10):1977-1992. 
doi:10.1084/jem.20131199. 
6. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-
maintain locally throughout adult life with minimal contribution from 
circulating monocytes. Immunity. 2013;38(4):792-804. 
doi:10.1016/j.immuni.2013.04.004. 
7. Janssen WJ, Barthel L, Muldrow A, et al. Fas determines differential fates 
of resident and recruited macrophages during resolution of acute lung 
injury. Am J Respir Crit Care Med. 2011;184(5):547-560. 
doi:10.1164/rccm.201011-1891OC. 
8. Gibbings SL, Goyal R, Desch AN, et al. Transcriptome analysis highlights 
the conserved difference between embryonic and postnatal-derived alveolar 
macrophages. Blood. 2015;126(11):1357-1366. doi:10.1182/blood-2015-01-
624809. 
9. Lavin Y, Winter D, Blecher-Gonen R, et al. Tissue-resident macrophage 
enhancer landscapes are shaped by the local microenvironment. Cell. 
2014;159(6):1312-1326. doi:10.1016/j.cell.2014.11.018. 
10. Desch AN, Gibbings SL, Goyal R, et al. Flow Cytometric Analysis of 
Mononuclear Phagocytes in Nondiseased Human Lung and Lung-Draining 







11. Papp AC, Azad AK, Pietrzak M, et al. AmpliSeq transcriptome analysis of 
human alveolar and monocyte-derived macrophages over time in response 
to Mycobacterium tuberculosis infection. Neyrolles O, ed. PLoS ONE. 
2018;13(5):e0198221. doi:10.1371/journal.pone.0198221. 
12. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage 
activation: time for reassessment. F1000Prime Rep. 2014;6(13):13. 
doi:10.12703/P6-13. 
13. Lambrecht BN. Alveolar macrophage in the driver's seat. Immunity. 
2006;24(4):366-368. doi:10.1016/j.immuni.2006.03.008. 
14. Lawrence T, Gilroy DW. Chronic inflammation: a failure of resolution? Int J 
Exp Pathol. 2007;88(2):85-94. doi:10.1111/j.1365-2613.2006.00507.x. 
15. Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, van Kooten C. IL-
10-producing macrophages preferentially clear early apoptotic cells. Blood. 
2006;107(12):4930-4937. doi:10.1182/blood-2005-10-4144. 
16. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. 
Macrophages that have ingested apoptotic cells in vitro inhibit 
proinflammatory cytokine production through autocrine/paracrine 
mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 
1998;101(4):890-898. doi:10.1172/JCI1112. 
17. Ward C, Murray J, Clugston A, Dransfield I, Haslett C, Rossi AG. 
Interleukin-10 inhibits lipopolysaccharide-induced survival and extracellular 
signal-regulated kinase activation in human neutrophils. Eur J Immunol. 
2005;35(9):2728-2737. doi:10.1002/eji.200425561. 
18. Rodriguez-Prados J-C, Traves PG, Cuenca J, et al. Substrate fate in 
activated macrophages: a comparison between innate, classic, and 
alternative activation. J Immunol. 2010;185(1):605-614. 
doi:10.4049/jimmunol.0901698. 
19. Jha AK, Huang SC-C, Sergushichev A, et al. Network integration of parallel 
metabolic and transcriptional data reveals metabolic modules that regulate 
macrophage polarization. Immunity. 2015;42(3):419-430. 
doi:10.1016/j.immuni.2015.02.005. 
20. Mathers CD, Loncar D. Projections of Global Mortality and Burden of 
Disease from 2002 to 2030. Samet J, ed. PLOS Med. 2006;3(11):e442. 
doi:10.1371/journal.pmed.0030442. 
21. Eisner MD, Anthonisen N, Coultas D, Kuenzli N.  Health Assembly. an 
Official American Thoracic Society Public Policy Statement: Novel Risk 
Factors and the Global Burden of Chronic Obstructive Pulmonary. Am J 






22. Silverman EK. Applying Functional Genomics to Chronic Obstructive 
Pulmonary Disease. Annals ATS. 2018;15:S239-S242. 
doi:10.1513/AnnalsATS.201808-530MG. 
23. Willemse B, Hacken Ten N. Effect of 1-year smoking cessation on airway 
inflammation in COPD and asymptomatic smokers. European Respiratory 
Journal 2005 26: 835-845; DOI: 10.1183/09031936.05.00108904. 
24. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with 
increased mortality in patients with community-acquired pneumonia. 
European Respiratory Journal. 2006;28(2):346-351. 
doi:10.1183/09031936.06.00131905. 
25. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the 
peripheral airways of young cigarette smokers. The New England journal of 
medicine. 1974;291(15):755-758. doi:10.1056/NEJM197410102911503. 
26. AUERBACH O, FORMAN JB, GERE JB, et al. Changes in the bronchial 
epithelium in relation to smoking and cancer of the lung; a report of 
progress. The New England journal of medicine. 1957;256(3):97-104. 
doi:10.1056/NEJM195701172560301. 
27. Deckers J, De Bosscher K, Lambrecht BN, Hammad H. Interplay between 
barrier epithelial cells and dendritic cells in allergic sensitization through the 
lung and the skin. Immunol Rev. 2017;278(1):131-144. 
doi:10.1111/imr.12542. 
28. Robbins CS, Dawe DE, Goncharova SI, et al. Cigarette smoke decreases 
pulmonary dendritic cells and impacts antiviral immune responsiveness. Am 
J Respir Cell Mol Biol. 2004;30(2):202-211. doi:10.1165/rcmb.2003-
0259OC. 
29. Rogers AV, Adelroth E, Hattotuwa K, Dewar A, Jeffery PK. Bronchial 
mucosal dendritic cells in smokers and ex-smokers with COPD: an electron 
microscopic study. Thorax. 2008;63(2):108-114. 
doi:10.1136/thx.2007.078253. 
30. Butler A, Walton GM, Sapey E. Neutrophilic Inflammation in the 
Pathogenesis of Chronic Obstructive Pulmonary Disease. COPD. 
2018;15(4):392-404. doi:10.1080/15412555.2018.1476475. 
31. Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural 
differences in migrating peripheral neutrophils from patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 
2011;183(9):1176-1186. doi:10.1164/rccm.201008-1285OC. 
32. Hogg JC, Chu F, Utokaparch S, et al. The Nature of Small-Airway 
Obstruction in Chronic Obstructive Pulmonary Disease. The New England 






33. Lim D, Kim W, Lee C, Bae H, Kim J. Macrophage Depletion Protects 
against Cigarette Smoke-Induced Inflammatory Response in the Mouse 
Colon and Lung. Front Physiol. 2018;9:47. doi:10.3389/fphys.2018.00047. 
34. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, 
Wedzicha JA. Relationship between bacterial colonisation and the 
frequency, character, and severity of COPD exacerbations. Thorax. 
2002;57(9):759-764. doi:10.1136/thorax.57.9.759. 
35. Oltmanns U, Sukkar MB, Xie S, John M, Chung KF. Induction of human 
airway smooth muscle apoptosis by neutrophils and neutrophil elastase. 
Am J Respir Cell Mol Biol. 2005;32(4):334-341. doi:10.1165/rcmb.2004-
0321OC. 
36. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage 
phagocytosis of bacteria in COPD. European Respiratory Journal. 
2010;35(5):1039-1047. doi:10.1183/09031936.00036709. 
37. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. Impaired 
phagocytosis of nontypeable Haemophilus influenzae by human alveolar 
macrophages in chronic obstructive pulmonary disease. J Infect Dis. 
2006;194(10):1375-1384. doi:10.1086/508428. 
38. Bewley MA, Budd RC, ryan E, et al. Opsonic Phagocytosis in Chronic 
Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. Am J Respir 
Crit Care Med. 2018;198(6):739-750. doi:10.1164/rccm.201705-0903OC. 
39. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. 
Smoking Alters Alveolar Macrophage Recognition and Phagocytic Ability. 
Am J Respir Cell Mol Biol. 2007;37(6):748-755. doi:10.1165/rcmb.2007-
0025OC. 
40. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar 
macrophages from subjects with chronic obstructive pulmonary disease are 
deficient in their ability to phagocytose apoptotic airway epithelial cells. 
Immunol Cell Biol. 2003;81(4):289-296. doi:10.1046/j.1440-1711.2003.t01-
1-01170.x. 
41. Russell REK, Culpitt SV, DeMatos C, et al. Release and activity of matrix 
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar 
macrophages from patients with chronic obstructive pulmonary disease. Am 
J Respir Cell Mol Biol. 2002;26(5):602-609. doi:10.1165/ajrcmb.26.5.4685. 
42. Molet S, Belleguic C, Lena H, et al. Increase in macrophage elastase 
(MMP-12) in lungs from patients with chronic obstructive pulmonary 
disease. Inflamm Res. 2005;54(1):31-36. doi:10.1007/s00011-004-1319-4. 
43. Hiemstra PS. Altered macrophage function in chronic obstructive pulmonary 







44. Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of 
bacteria by both alveolar and monocyte-derived macrophages in chronic 
obstructive pulmonary disease subjects. Respirology. 2012;17(5):802-807. 
doi:10.1111/j.1440-1843.2012.02135.x. 
45. Stolberg VR, McCubbrey AL, Freeman CM, et al. Glucocorticoid-
Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in 
Mice by Reducing Alveolar Macrophage Bactericidal Function. J Immunol. 
2015;195(1):174-184. doi:10.4049/jimmunol.1402217. 
46. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance 
of apoptotic cells (efferocytosis) with implications for chronic obstructive 
pulmonary disease. The Journal of Immunology. 2006;176(12):7657-7665. 
47. Xiao H, Qin X, Ping D, Zuo K. Inhibition of Rho and Rac 
geranylgeranylation by atorvastatin is critical for preservation of endothelial 
junction integrity. Lafrenie R, ed. PLoS ONE. 2013;8(3):e59233. 
doi:10.1371/journal.pone.0059233. 
48. Croasdell A, Thatcher TH, Kottmann RM, et al. Resolvins attenuate 
inflammation and promote resolution in cigarette smoke-exposed human 
macrophages. American Journal of Physiology - Lung Cellular and 
Molecular Physiology. 2015;309(8):L888-L901. 
doi:10.1152/ajplung.00125.2015. 
49. Harvey CJ, Thimmulappa RK, Sethi S, et al. Targeting Nrf2 Signaling 
Improves Bacterial Clearance by Alveolar Macrophages in Patients with 
COPD and in a Mouse Model. Science Translational Medicine. 
2011;3(78):78ra32-78ra32. doi:10.1126/scitranslmed.3002042. 
50. Shaykhiev R, Krause A, Salit J, et al. Smoking-dependent reprogramming 
of alveolar macrophage polarization: implication for pathogenesis of chronic 
obstructive pulmonary disease. J Immunol. 2009;183(4):2867-2883. 
doi:10.4049/jimmunol.0900473. 
51. Chung EY, Liu J, Homma Y, et al. Interleukin-10 expression in 
macrophages during phagocytosis of apoptotic cells is mediated by 
homeodomain proteins Pbx1 and Prep-1. Immunity. 2007;27(6):952-964. 
doi:10.1016/j.immuni.2007.11.014. 
52. Li C, Wang Y, Li Y, et al. HIF1α-dependent glycolysis promotes 
macrophage functional activities in protecting against bacterial and fungal 
infection. Sci Rep. 2018;8(1):3603. doi:10.1038/s41598-018-22039-9. 
53. Morioka S, Perry JSA, Raymond MH, et al. Efferocytosis induces a novel 
SLC program to promote glucose uptake and lactate release. Nature. 
2018;563(7733):714-718. doi:10.1038/s41586-018-0735-5. 
54. Wang T, Liu H, Lian G, Zhang S-Y, Wang X, Jiang C. HIF1α-Induced 






Macrophages. Mediators Inflamm. 2017;2017(11):9029327–10. 
doi:10.1155/2017/9029327. 
55. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for 
myeloid cell-mediated inflammation. Cell. 2003;112(5):645-657. 
56. Diskin C, Pålsson-McDermott EM. Metabolic Modulation in Macrophage 
Effector Function. Front Immunol. 2018;9:270. 
doi:10.3389/fimmu.2018.00270. 
57. Finkelstein R, Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG. 
Morphometry of small airways in smokers and its relationship to 
emphysema type and hyperresponsiveness. Am J Respir Crit Care Med. 
1995;152(1):267-276. doi:10.1164/ajrccm.152.1.7599834. 
58. Ravi AK, Plumb J, Gaskell R, et al. COPD monocytes demonstrate 
impaired migratory ability. Respir Res. 2017;18(1):90. doi:10.1186/s12931-
017-0569-y. 
59. Yang S-R, Chida AS, Bauter MR, et al. Cigarette smoke induces 
proinflammatory cytokine release by activation of NF-kappaB and post 
translational modifications of histone deacetylase in macrophages. 
American Journal of Physiology - Lung Cellular and Molecular Physiology. 
2006;291(1):L46-L57. doi:10.1152/ajplung.00241.2005. 
60. Hodge S, Matthews G, Mukaro V, et al. Cigarette smoke-induced changes 
to alveolar macrophage phenotype and function are improved by treatment 
with procysteine. Am J Respir Cell Mol Biol. 2011;44(5):673-681. 
doi:10.1165/rcmb.2009-0459OC. 
61. Pons AR, Noguera A, Blanquer D, Sauleda J, Pons J, Agustí AGN. 
Phenotypic characterisation of alveolar macrophages and peripheral blood 
monocytes in COPD. European Respiratory Journal. 2005;25(4):647-652. 
doi:10.1183/09031936.05.00062304. 
62. Kunz LIZ, Lapperre TS, Snoeck-Stroband JB, et al. Smoking status and 
anti-inflammatory macrophages in bronchoalveolar lavage and induced 
sputum in COPD. Respir Res. 2011;12(1):34. doi:10.1186/1465-9921-12-
34. 
63. Bazzan E, Turato G, Tinè M, et al. Dual polarization of human alveolar 
macrophages progressively increases with smoking and COPD severity. 
Respir Res. 2017;18(1):40. doi:10.1186/s12931-017-0522-0. 
64. Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis 
reveals a spectrum model of human macrophage activation. Immunity. 
2014;40(2):274-288. doi:10.1016/j.immuni.2014.01.006. 
65. Bewley MA, Preston JA, Mohasin M, et al. Impaired Mitochondrial 






Macrophages. Am J Respir Crit Care Med. 2017;196(7):845-855. 
doi:10.1164/rccm.201608-1714OC. 
66. Waterborg CEJ, Beermann S, Broeren MGA, et al. Protective Role of the 
MER Tyrosine Kinase via Efferocytosis in Rheumatoid Arthritis Models. 
Front Immunol. 2018;9:577. doi:10.3389/fimmu.2018.00742. 
67. Pollitt AY, Insall RH. WASP and SCAR/WAVE proteins: the drivers of actin 
assembly. J Cell Sci. 2009;122(Pt 15):2575-2578. doi:10.1242/jcs.023879. 
68. Schlam D, Bagshaw RD, Freeman SA, et al. Phosphoinositide 3-kinase 
enables phagocytosis of large particles by terminating actin assembly 
through Rac/Cdc42 GTPase-activating proteins. Nat Commun. 
2015;6(1):8623. doi:10.1038/ncomms9623. 
69. Kirkham PA, Spooner G, Rahman I, Rossi AG. Macrophage phagocytosis 
of apoptotic neutrophils is compromised by matrix proteins modified by 
cigarette smoke and lipid peroxidation products. Biochem Biophys Res 
Commun. 2004;318(1):32-37. doi:10.1016/j.bbrc.2004.04.003. 
70. Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD 
heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. 
doi:10.1186/1465-9921-11-122. 
71. Bewley MA, Belchamber KBR, Chana KK, et al. Differential Effects of p38, 
MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and 
Efferocytosis by Macrophages in COPD. Maus UA, ed. PLoS ONE. 
2016;11(9):e0163139. doi:10.1371/journal.pone.0163139. 
72. Dewhurst JA, Lea S, Hardaker E, Dungwa JV, Ravi AK, Singh D. 
Characterisation of lung macrophage subpopulations in COPD patients and 
controls. Sci Rep. 2017;7(1):7143. doi:10.1038/s41598-017-07101-2. 
73. Li Z, Jiao Y, Fan EK, et al. Aging-Impaired Filamentous Actin 
Polymerization Signaling Reduces Alveolar Macrophage Phagocytosis of 
Bacteria. J Immunol. 2017;199(9):3176-3186. 
doi:10.4049/jimmunol.1700140. 
74. Dranka BP, Hill BG, Darley-Usmar VM. Mitochondrial reserve capacity in 
endothelial cells: The impact of nitric oxide and reactive oxygen species. 
Free Radic Biol Med. 2010;48(7):905-914. 
doi:10.1016/j.freeradbiomed.2010.01.015. 
75. Hill BG, Dranka BP, Zou L, Chatham JC, Darley-Usmar VM. Importance of 
the bioenergetic reserve capacity in response to cardiomyocyte stress 
induced by 4-hydroxynonenal. Biochem J. 2009;424(1):99-107. 
doi:10.1042/BJ20090934. 
76. Freemerman AJ, Johnson AR, Sacks GN, et al. Metabolic reprogramming 






metabolism drives a proinflammatory phenotype. J Biol Chem. 
2014;289(11):7884-7896. doi:10.1074/jbc.M113.522037. 
77. Mills EL, Ryan DG, Prag HA, et al. Itaconate is an anti-inflammatory 
metabolite that activates Nrf2 via alkylation of KEAP1. Nature. 
2018;556(7699):113-117. doi:10.1038/nature25986. 
78. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory 
signal that induces IL-1β through HIF-1α. Nature. 2013;496(7444):238-242. 
doi:10.1038/nature11986. 
79. Nagy C, Haschemi A. Time and Demand are Two Critical Dimensions of 
Immunometabolism: The Process of Macrophage Activation and the 
Pentose Phosphate Pathway. Front Immunol. 2015;6. 
doi:10.3389/fimmu.2015.00164. 
80. Vats D, Mukundan L, Odegaard JI, et al. Oxidative metabolism and PGC-1β 
attenuate macrophage-mediated inflammation. Cell Metabolism. 
2006;4(1):13-24. doi:10.1016/j.cmet.2006.05.011. 
81. Feingold KR, Shigenaga JK, Kazemi MR, et al. Mechanisms of triglyceride 
accumulation in activated macrophages. J Leukoc Biol. 2012;92(4):829-
839. doi:10.1189/jlb.1111537. 
82. Mills EL, Kelly B, Logan A, et al. Repurposing mitochondria from ATP 
production to ROS generation drives a pro-inflammatory phenotype in 
macrophages that depends on succinate oxidation by complex II. Cell. 
2016;167(2):457–470.e13. doi:10.1016/j.cell.2016.08.064. 
83. Namgaladze D, Brüne B. Fatty acid oxidation is dispensable for human 
macrophage IL-4-induced polarization. Biochimica et Biophysica Acta 
(BBA) - Molecular and Cell Biology of Lipids. 2014;1841(9):1329-1335. 
doi:10.1016/j.bbalip.2014.06.007. 
84. Moon J-S, Nakahira K, Chung K-P, et al. NOX4-dependent fatty acid 
oxidation promotes NLRP3 inflammasome activation in macrophages. 
Nature Medicine 2016 22:9. 2016;22(9):1002-1012. doi:10.1038/nm.4153. 
85. Van den Bossche J, Baardman J, Otto NA, et al. Mitochondrial Dysfunction 
Prevents Repolarization of Inflammatory Macrophages. Cell reports. 
2016;17(3):684-696. doi:10.1016/j.celrep.2016.09.008. 
86. Fukuzumi M, Shinomiya H, Shimizu Y, Ohishi K, Utsumi S. Endotoxin-
induced enhancement of glucose influx into murine peritoneal macrophages 
via GLUT1. Infect Immun. 1996;64(1):108-112. 
87. Feng J, Han J, Pearce SF, et al. Induction of CD36 expression by oxidized 
LDL and IL-4 by a common signaling pathway dependent on protein kinase 






88. Covarrubias AJ, Aksoylar HI, Yu. Akt-mTORC1 signaling regulates Acly to 
integrate metabolic input to control of macrophage activation. Elife. 2016 
Feb 19;5. pii: e11612. doi: 10.7554/eLife.11612. 
89. Kim WJ, Lim JH, Lee JS, Lee S-D, Kim JH, Oh Y-M. Comprehensive 
Analysis of Transcriptome Sequencing Data in the Lung Tissues of COPD 
Subjects. Int J Genomics. 2015;2015:206937-206939. 
doi:10.1155/2015/206937. 
90. Michaeloudes C, Kuo C-H, Haji G, et al. Metabolic re-patterning in COPD 
airway smooth muscle cells. Eur Respir J. 2017;50(5):1700202. 
doi:10.1183/13993003.00202-2017. 
91. Green HJ, Burnett ME, D'Arsigny CL, O'Donnell DE, Ouyang J, Webb KA. 
Altered metabolic and transporter characteristics of vastus lateralis in 
chronic obstructive pulmonary disease. J Appl Physiol. 2008;105(3):879-
886. doi:10.1152/japplphysiol.90458.2008. 
92. Hoffmann RF, Zarrintan S, Brandenburg SM, et al. Prolonged cigarette 
smoke exposure alters mitochondrial structure and function in airway 
epithelial cells. Respir Res. 2013;14(1):97. doi:10.1186/1465-9921-14-97. 
93. Wiegman CH, Michaeloudes C, Haji G, et al. Oxidative stress-induced 
mitochondrial dysfunction drives inflammation and airway smooth muscle 
remodeling in patients with chronic obstructive pulmonary disease. J Allergy 
Clin Immunol. 2015;136(3):769-780. doi:10.1016/j.jaci.2015.01.046. 
94. Ahmad T, Sundar IK, Lerner CA, et al. Impaired mitophagy leads to 
cigarette smoke stress-induced cellular senescence: implications for 
chronic obstructive pulmonary disease. FASEB J. 2015;29(7):2912-2929. 
doi:10.1096/fj.14-268276. 
95. Gleeson LE, O’Leary SM, Ryan D, McLaughlin AM, Sheedy FJ, Keane J. 
Cigarette Smoking Impairs the Bioenergetic Immune Response to 
Mycobacterium tuberculosis Infection. Am J Respir Cell Mol Biol. 
2018;59(5):572-579. doi:10.1165/rcmb.2018-0162OC. 
96. Baker EH, Clark N, Brennan AL, et al. Hyperglycemia and cystic fibrosis 
alter respiratory fluid glucose concentrations estimated by breath 
condensate analysis. Journal of Applied Physiology. 2007;102(5):1969-
1975. doi:10.1152/japplphysiol.01425.2006. 
97. Chronic obstructive pulmonary disease: measuring disease progression. 
Thorax. 2008;63(Suppl 7):A39. 
98. Mallia P, Webber J, Gill SK, et al. Role of airway glucose in bacterial 
infections in patients with chronic obstructive pulmonary disease. Journal of 







99. Garcia D, Shaw RJ. AMPK: Mechanisms of Cellular Energy Sensing and 
Restoration of Metabolic Balance. Mol Cell. 2017;66(6):789-800. 
doi:10.1016/j.molcel.2017.05.032. 
100. Murai S, Ando A, Ebara S, Hirayama M, Satomi Y, Hara T. Inhibition of 
malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in 
cancer cells in glucose-restricted conditions. Oncogenesis 2017 6:5. 
2017;6(5):e329-e329. doi:10.1038/oncsis.2017.34. 
101. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. 
Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350-
351. doi:10.1038/37022. 
102. Kelly B, O'Neill LAJ. Metabolic reprogramming in macrophages and 
dendritic cells in innate immunity. Cell Res. 2015;25(7):771-784. 
doi:10.1038/cr.2015.68. 
103. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling 
pathways by reactive oxygen species. Biochimica et Biophysica Acta (BBA) 
- Molecular Cell Research. 2016;1863(12):2977-2992. 
doi:10.1016/j.bbamcr.2016.09.012. 
104. Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu Z-G. ROS play 
a critical role in the differentiation of alternatively activated macrophages 
and the occurrence of tumor-associated macrophages. Cell Res. 
2013;23(7):898-914. doi:10.1038/cr.2013.75. 
105. Kraus D, Peschel A. Staphylococcus aureus evasion of innate antimicrobial 
defense. http://dxdoiorg/102217/1746091334437. 2008;3(4):437-451. 
doi:10.2217/17460913.3.4.437. 
106. Judit Bartalis, W Geoffrey Chan A, Jan B Wooten. A New Look at Radicals 
in Cigarette Smoke. Anal. Chem.2007, 79,13, 5103-5106. 
doi:10.1021/ac070561. 
107. Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S. Pulmonary Oxidative 
Stress, Inflammation and Cancer: Respirable Particulate Matter, Fibrous 
Dusts and Ozone as Major Causes of Lung Carcinogenesis through 
Reactive Oxygen Species Mechanisms. International Journal of 
Environmental Research and Public Health 2009, Vol 6, Pages 445-462. 
2013;10(9):3886-3907. doi:10.3390/ijerph10093886. 
108. Rushmore TH, Pickett CB. Transcriptional regulation of the rat glutathione 
S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive 
element controlling inducible expression by phenolic antioxidants. J Biol 
Chem. 1990;265(24):14648-14653. 
109. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. 
Activation by oxidative stress and identification of the DNA consensus 







110. McMahon M, Itoh K, Yamamoto M, et al. The Cap “n” Collar Basic Leucine 
Zipper Transcription Factor Nrf2 (NF-E2 p45-related Factor 2) Controls 
Both Constitutive and Inducible Expression of Intestinal Detoxification and 
Glutathione Biosynthetic Enzymes. Cancer Res. 2001;61(8):3299-3307. 
doi:10.1080/01635589209514201. 
111. Kobayashi EH, Suzuki T, Funayama R, et al. Nrf2 suppresses macrophage 
inflammatory response by blocking proinflammatory cytokine transcription. 
Nat Commun. 2016;7(1):11624. doi:10.1038/ncomms11624. 
112. Heiss EH, Schachner D, Zimmermann K, Dirsch VM. Glucose availability is 
a decisive factor for Nrf2-mediated gene expression. Redox Biol. 
2013;1(1):359-365. doi:10.1016/j.redox.2013.06.001. 
113. Baardman J, Verberk SGS, Prange KHM, et al. A Defective Pentose 
Phosphate Pathway Reduces Inflammatory Macrophage Responses during 
Hypercholesterolemia. Cell reports. 2018;25(8):2044-2052.e2045. 
doi:10.1016/j.celrep.2018.10.092. 
114. Holmström KM, Baird L, Zhang Y, et al. Nrf2 impacts cellular bioenergetics 
by controlling substrate availability for mitochondrial respiration. Biol Open. 
2013;2(8):761-770. doi:10.1242/bio.20134853. 
115. Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and 
glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 
2012;22(1):66-79. doi:10.1016/j.ccr.2012.05.016. 
116. Dinkova-Kostova AT, Abramov AY. The emerging role of Nrf2 in 
mitochondrial function. Free Radic Biol Med. 2015;88(Pt B):179-188. 
doi:10.1016/j.freeradbiomed.2015.04.036. 
117. Motohashi H, Yamamoto M. Nrf2–Keap1 defines a physiologically important 
stress response mechanism. Trends in Molecular Medicine. 
2004;10(11):549-557. doi:10.1016/j.molmed.2004.09.003. 
118. Lee O-H, Jain AK, Papusha V, Jaiswal AK. An auto-regulatory loop 
between stress sensors INrf2 and Nrf2 controls their cellular abundance. J 
Biol Chem. 2007;282(50):36412-36420. doi:10.1074/jbc.M706517200. 
119. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 
enhances susceptibility to cigarette smoke-induced emphysema in mice. J 
Clin Invest. 2004;114(9):1248-1259. doi:10.1172/JCI21146. 
120. Suzuki M, Betsuyaku T, Ito Y, et al. Down-Regulated NF-E2–Related Factor 
2 in Pulmonary Macrophages of Aged Smokers and Patients with Chronic 
Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2008;39(6):673-
682. doi:10.1165/rcmb.2007-0424OC. 
121. Goven D, Boutten A, Leçon-Malas V, et al. Altered Nrf2/Keap1-Bach1 







122. Kansanen E, Kuosmanen SM, Leinonen H, Levonen A-L. The Keap1-Nrf2 
pathway: Mechanisms of activation and dysregulation in cancer. Redox 
Biol. 2013;1(1):45-49. doi:10.1016/j.redox.2012.10.001. 
123. Korytina GF, Akhmadishina LZ, Aznabaeva YG, et al. Associations of the 
NRF2/KEAP1 pathway and antioxidant defense gene polymorphisms with 
chronic obstructive pulmonary disease. Gene. 2019;692:102-112. 
doi:10.1016/j.gene.2018.12.061. 
124. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of 
anticarcinogenic protective enzymes from broccoli: isolation and elucidation 
of structure. PNAS. 1992;89(6):2399-2403. doi:10.1073/pnas.89.6.2399. 
125. Hu R, Xu C, Shen G, et al. Gene expression profiles induced by cancer 
chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice 
and C57BL/6J/Nrf2 (−/−) mice. Cancer Letters. 2006;243(2):170-192. 
doi:10.1016/j.canlet.2005.11.050. 
126. Jeong W-S, Keum Y-S, Chen C, et al. Differential Expression and Stability 
of Endogenous Nuclear Factor E2-related Factor 2 (Nrf2) by Natural 
Chemopreventive Compounds in HepG2 Human Hepatoma Cells. BMB 
Reports. 2005;38(2):167-176. doi:10.5483/BMBRep.2005.38.2.167. 
127. Pham N-A, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. 
The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell 
cycle arrest, and oxidative stress in human pancreatic cancer cells and 
inhibits tumor growth in severe combined immunodeficient mice. Mol 
Cancer Ther. 2004;3(10):1239-1248. 
128. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for 
Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by 
chemopreventive agents and oxidative stress. Mol Cell Biol. 
2003;23(22):8137-8151. doi:10.1128/mcb.23.22.8137-8151.2003. 
129. Dinkova-Kostova AT, Fahey JW, Kostov RV, Kensler TW. KEAP1 and 
Done? Targeting the NRF2 Pathway with Sulforaphane. Trends Food Sci 
Technol. 2017;69(Pt B):257-269. doi:10.1016/j.tifs.2017.02.002. 
130. Lewinska A, Adamczyk-Grochala J, Deregowska A, Wnuk M. Sulforaphane-
Induced Cell Cycle Arrest and Senescence are accompanied by DNA 
Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells. 
Theranostics. 2017;7(14):3461-3477. doi:10.7150/thno.20657. 
131. Baier SR, Zbasnik R, Schlegel V, Zempleni J. Off-target effects of 
sulforaphane include the derepression of long terminal repeats through 
histone acetylation events. J Nutr Biochem. 2014;25(6):665-668. 
doi:10.1016/j.jnutbio.2014.02.007. 
132. Durham A, Jazrawi E, Rhodes JA, et al. The anti-inflammatory effects of 
sulforaphane are not mediated by the Nrf2 pathway. European Respiratory 






133. Boehm J, Davis R, Murar CE, et al. Discovery of a crystalline sulforaphane 
analog with good solid-state stability and engagement of the Nrf2 pathway 
in vitro and in vivo. Bioorg Med Chem. 2019;27(4):579-588. 
doi:10.1016/j.bmc.2018.12.026. 
134. Fahey JW, Holtzclaw WD, Wehage SL, Wade KL, Stephenson KK, Talalay 
P. Sulforaphane Bioavailability from Glucoraphanin-Rich Broccoli: Control 
by Active Endogenous Myrosinase. Mukhopadhyay P, ed. PLoS ONE. 
2015;10(11):e0140963. doi:10.1371/journal.pone.0140963. 
135. Davies TG, Wixted WE, Coyle JE, et al. Monoacidic Inhibitors of the Kelch-
like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 
(KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified 
by Fragment-Based Discovery. J Med Chem. 2016;59(8):3991-4006. 
doi:10.1021/acs.jmedchem.6b00228. 
136. Singh A, Happel C, Manna SK, et al. Transcription factor NRF2 regulates 
miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013;123(7):2921-
2934. doi:10.1172/JCI66353. 
137. Moinova HR, Mulcahy RT. Up-regulation of the human gamma-
glutamylcysteine synthetase regulatory subunit gene involves binding of 
Nrf-2 to an electrophile responsive element. Biochem Biophys Res 
Commun. 1999;261(3):661-668. doi:10.1006/bbrc.1999.1109. 
138. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary 
disease. J Clin Invest. 2012;122(8):2749-2755. doi:10.1172/JCI60324. 
139. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-
inducible factor. Cell Cycle. 2005;4(2):256-258. 
140. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung 
inflammation in COPD. European Respiratory Journal. 2006;28(1):219-242. 
doi:10.1183/09031936.06.00053805. 
141. Ribas V, García-Ruiz C, Fernández-Checa JC. Glutathione and 
mitochondria. Front Pharmacol. 2014;5(223ra20):151. 
doi:10.3389/fphar.2014.00151. 
142. Georgakopoulos ND, Frison M, Alvarez MS, Bertrand H, Wells G, 
Campanella M. Reversible Keap1 inhibitors are preferential 
pharmacological tools to modulate cellular mitophagy. Sci Rep. 
2017;7(1):10303. doi:10.1038/s41598-017-07679-7. 
143. Linke M, Fritsch SD, Sukhbaatar N, Hengstschläger M, Weichhart T. 
mTORC1 and mTORC2 as regulators of cell metabolism in immunity. 
Ellmeier W, Nagy L, eds. FEBS Lett. 2017;591(19):3089-3103. 
doi:10.1002/1873-3468.12711. 
144. Suzuki M, Betsuyaku T, Ito Y, Nagai K, Nasuhara Y. Downregulated NF-E2-






Patients. Am J Respir Cell Mol Biol. 2008 Dec;39(6):673-82. doi: 
10.1165/rcmb.2007-0424OC. 
145. Zheng F-J, Ye H-B, Wu M-S, Lian Y-F, Qian C-N, Zeng Y-X. Repressing 
malic enzyme 1 redirects glucose metabolism, unbalances the redox state, 
and attenuates migratory and invasive abilities in nasopharyngeal 
carcinoma cell lines. Chin J Cancer. 2012;31(11):519-531. 
doi:10.5732/cjc.012.10088. 
146.        Dhakshinamoorthy S1, Jain AK, Bloom DA, Jaiswal AK. Bach1 competes 
with Nrf2 leading to negative regulation of the antioxidant response element 
(ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and 
induction in response to antioxidants. J Biol Chem. 2005 
Apr29;280(17):16891-900.	doi: 10.1074/jbc.M500166200 
147.       Ling Liu,Supriya Shah, Jing Fan, Junyoung O Park,Kathryn E 
Wellen,Joshua D Rabinowitz Malic enzyme tracers reveal hypoxia-induced 
switch in adipocyte NADPH pathway usage. Nat Chem Biol. 2016 May; 












8.1 Appendix 1: Percoll Preparations 
 
Human peripheral blood leucocyte preparation: 
Percoll concentration For 10 mls ( ie 3 
gradients) 
 
 90% Percoll  1 x PBS 
73% 8.1ml 1.9ml 
61% 6.8ml 3.2ml 
49% 5.5ml 4.5ml 
 
8.2 Appendix 2: Western Blot 
SDS-PAGE gels:  To generate 1.5mm gel plates  
Stacking gel 1 gel 
Water 3ml 
40% Acrylamide 620µl 
0.5M Tris pH6.8 1260µl 
20% SDS 25µl 
20% APS 50µl 
TEMED 5µl 
 










0.5M Tris pH6.8 3.8ml 
20% SDS 75µl 
20% APS 150µl 
TEMED 6µl 
 
Buffers for Immunoblot: 
10X Running Buffer  
 
Glycine   
190g  
Tris Base  30.3g  
20% SDS  50ml  
dH2O  to 1 litre  
1x Running buffer was made by adding 100ml of 10x running buffer and 900ml of 
dH2O 
10X Transfer Buffer  
 
Glycine  145g  
Tris Base  29g  
dH2O  to 800ml  
1X Transfer Buffer made  by adding 100ml of 10X transfer buffer, 200ml methanol 
and 700ml dH2O  
10X TBS-Tween  
 
Tris-HCl 1M pH 8.0 M  100ml  
NaCl  97.3g  
Water  to 1000ml  
Tween-20  5ml 
 







8.3 Appendix 3 Seahorse Compounds 
For the Glycolysis stress test: 
Use Glycolysis Stress Test Seahorse Media (prepared as per 2.14) 
Vial 1= Glucose, 3000µl of media was added to the vial and vortexed well. 
Vial 2=  Oligomycin, 720µl of media was added to the vial.  
Vial 3- 2DG, 3000µl of media was added to the vial and vortexed well. 
Compounds were added to ports A,B and C of the Seahorse Cartridge as detailed 
below: 
 
For the Mitochondrial Stress Test:  
Use Mitochondrial Stress Test Seahorse Media (prepared as per 2.14) 
Vial 1= Oligomycin,630µl of media was added to the vial. Then, 225µl of this stock 
was added to 1.275mls of Mitochondrial Stress Test Media. 
Vial 2= FCCP, 720µl of media was added to the vial. Then 300µl of this stock was 
added to 1.2mls of Mitochondrial Stress Test Media. 
Vial 3= Rotenone& Antimycin A, 540µl of media was added to the vial. Then 300µl of 
this stock was added to 1.2mls of Mitochondrial Stress Test Media. 
Final concertation of Compounds were added to ports A,B and C of the Seahorse 




























8.4 Appendix 4: Report from Edinburgh Clinical Research Facility 
Genetics Core for Total RNA sequencing data E161715 RNA-Seq : 
 Summary of Sequencing Protocol  
1)Quality Control: Total RNA samples were assessed on the Agilent Bioanalyser 
(Agilent Technologies, #G2939AA) with the RNA 6000 Nano Kit (#5067-1512) for 
quality and integrity of total RNA, and then quantified using the Qubit 2.0 
Fluorometer (Thermo Fisher Scientific Inc, #Q32866) and the Qubit RNA HS assay 
kit (#Q32855).  
2)Library Preparation: Libraries were prepared from total-RNA samples using the 
NEBNext Ultra 2 Directional RNA library prep kit for Illumina (#E7760S) with the 
NEBNext rRNA Depletion kit (#E6310) according to the provided protocol.  
150ng of total-RNA was added to the ribosomal RNA (rRNA) depletion reaction 
using the NEBNext rRNA depletion kit (Human/mouse/rat) (#E6310). This step used 
specific probes that bind to the rRNA in order to cleave it. rRNA-depleted RNA was 
then DNase treated and purified using Agencourt RNAClean XP beads (Beckman 
Coulter Inc, #66514). RNA was then fragmented using random primers before 
undergoing first strand and second strand synthesis to create cDNA.  
cDNA was end-repaired before ligation of sequencing adapters, and adapter-ligated 
libraries were enriched by 12 cycles of PCR using the NEBNext Multiplex oligos for 
Illumina (#E7500). Final libraries (including inserts and sequencing 
adapters/indexes) had an average peak size of 400bp.  
3)Library QC: Libraries were quantified by fluorometry using the Qubit dsDNA HS 
assay and assessed for quality and fragment size using the Agilent Bioanalyser with 
the DNA HS Kit (#5067-4626).  
4)Sequencing: Sequencing was performed using the NextSeq 500/550 High-Output 
v2 (150 cycle) Kit (# FC- 404-2002) on the NextSeq 550 platform (Illumina Inc, #SY-
415-1002). Libraries were combined in two equimolar pools based on the library 
quantification results and run across 2 High-Output Flow Cell v2.5.  
5) Summary of Analysis Pipeline: Basecall data produced by the NextSeq 550 is 
automatically uploaded to BaseSpace, a cloud- based data management and 






to allow analysis using a number of apps accessible directly through BaseSpace, or 
to download so that alternative analysis pipelines can be used.  
6) Summary: A 2x75bp sequencing run on the Nextseq 550 using a high output flow 
cell is expected to generate up to 400M paired-end (PE) reads (50-60Gb) with a data 
quality of >80% higher than Q30, based on a cluster density of 170-230K/mm2. 
When multiplexing 6 samples on a flow cell we would therefore expect to see up to 
66M PE reads per sample. Run performance is shown in table 1 below.  
Table 1: Sequencing metrics by flow cell.  
Coverage of all libraries was variable in part due to the difference in output between 
the two flow cells. However, all libraries bar one (C264) produced >66M PE reads 
(Min: 58.5M, Max 118.6M, Mean: 93.1M). The number of clusters PF per library is 
shown in Table 2 below.  
Table 2: Number of Clusters PF  
Sample ID  Run ID  
 
Number of Clusters PF  
C4096  190319_NB551016_0391_AH3F2CBGXB  
 
79,153,661  
C4096 + Comp 7  190319_NB551016_0391_AH3F2CBGXB  118,614,227  
C136  190319_NB551016_0391_AH3F2CBGXB  113,272,491  
C136 + Comp 7  190319_NB551016_0391_AH3F2CBGXB  104,469,628  
C2096  190319_NB551016_0391_AH3F2CBGXB  
 
91,329,344  
C2096 + Comp 7  190319_NB551016_0391_AH3F2CBGXB  
 
88,610,520  





PF (%)  
Estimated 










190320_NB551016_0393_AH3FKCBGCB  231  
89.0  
 






C255  190320_NB551016_0393_AH3FKCBGCB  
69,781,633  
 
C255 + Comp 7  190320_NB551016_0393_AH3FKCBGCB  95,990,755  
22894  190320_NB551016_0393_AH3FKCBGCB  
 
73,108,227  
22894 +7  190320_NB551016_0393_AH3FKCBGCB  106,176,077  
C264  190320_NB551016_0393_AH3FKCBGCB  
 
58,515,396  
C264+7  190320_NB551016_0393_AH3FKCBGCB  118,385,584 
 
8.5 Appendix 5: cDNA generation and TaqMan analysis  
Reverse transcription PCR master mix (Promega UK)  
Reagent Volume per sample: 
5 x AMV buffer  8µl 
10nM dNTPs 16µl 
RNasin 1.2µl 
Random primers 1.2µl 
AMV-RT 1.2µl 
Final Volume = 27.6 µl 
 
Primer Probes: 
Malic Enzyme 1 IDT Hs.PT.58.38957126 












GOLD 1 Mild FEV1≥ 80% predicted
GOLD 2 Moderate 50% ≤ FEV1 < 80% predicted
GOLD 3 Severe 30% ≤ FEV1 < 50% predicted
GOLD 4 Very Severe FEV1 <30% predicted
Classification of airflow limitation severity in COPD (based on post bronchodilator FEV1) in 






8.7 Appendix 7: COPD Assessment Test 
 
 
0 1 2 3 4 5X
Your name: Today’s date:
How is your COPD?Take the COPDAssessmentTest™ (CAT)
This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive
Pulmonary Disease) is having on your wellbeing and daily life.Your answers, and test score, can be used by you and
your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.
For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response
for each question.




COPDAssessmentTest and CAT logo is a trademark of the GlaxoSmithKline group of companies.
© 2009 GlaxoSmithKline. All rights reserved.
I never cough 0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
I cough all the time
I have no phlegm (mucus)
inmychest at all
My chest is completely
full of phlegm (mucus)
My chest does not
feel tight at all
My chest feels
very tight
When I walk up a hill or
one flight of stairs I am
not breathless
When I walk up a hill or
one flight of stairs I am
very breathless
I am not limited doing
any activities at home
I am very limited doing
activities at home
I am confident leaving






I don’t sleep soundly
because ofmy lung
condition
I have lots of energy I have no energy at all
COPD As essment Test and the CAT logo is  trade mark f the GlaxoSmithKline group of companies.
© 2 09 GlaxoSmithKline group of companies. All rights reserved.
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